Role of HDAC4 in the process of oncogenesis in human cells by Paluvai, Harikrishnareddy
 
                                                     
 
 
University of Udine 













Ph.D. Student                            Supervisor  
Harikrishnareddy Paluvai                                             Prof. Claudio Brancolini 
                                                                                                   Co-supervisor 
                                                                                    Dott. Eros Di Giorgio, PhD 
 
                                                                                 
Academic year 2019/2020 
Abstract 
The resetting of epigenetics is a common features of cancer cells.  In contrast, how epigenetic 
regulators trigger oncogenic transformation is a mystery. Previous studies reported that the 
hyper-activation of an epigenetic regulator HDAC4 transforms murine cells. However, the 
transformation process of human cells is much more complex and are relatively resistant to 
oncogenesis. In the present thesis we addressed the oncogenic potential of HDAC4 in human 
primary fibroblasts (BJ). The over-expression of an hyper-active mutant of HDAC4 in human 
fibroblasts triggers a permanent cell cycle arrest typical a feature of oncogene induced 
senescence. The contemporary inactivation of p53 and pRb/p16 pathways achieved by the 
transduction of the cells with SV40 LT allows the transformation of HDAC4-TM cells.  
Transcriptomic analysis of HDAC4-TM and RAS transformed cells evidenced that both the 
oncogenes require the repression of the interferon-response to transform the human cells. 
Further we have compared our signature with other two oncogenes like RAS and c-MYC which 
favour in vitro transformation in BJ-hTERT SV40 LT/ST. The tumorigenic properties driven 
by the three oncogenes rely on the activation of some common molecular pathways, but not on 
the activation and repression of the same genes. Importantly, commonly dysregulated genes, 
both up-regulated and down-regulated during in vitro transformation contribute to a worst 
survival rate in some cancer types. To gain insight on the cellular pathways supervised by 
HDAC4 and responsible for the transformation of human cells we investigated the genomic 
instability of leiomyosarcoma cells knocked out of HDAC4. In this cancer cell removal of 
HDAC4 results in the induction of cellular senescence through the augmentation of the DNA 









Aim of study 
This PhD projects aims to investigate the contribution of class IIa HDACs to senescence and 
escape of senescence in human cells. A genetic depletion of HDAC4 in tumor cells and 
expression of hyperactive mutant of HDAC4 in human fibroblasts triggered senescence and 
induced DNA damage. Our goal is to understand, relationship between DNA damage response 
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HDAC: Histone deacetylases 
HAT: Histone acetyltransferases 
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The replicative senescence was discovered by Hayflick and Moorhead in 1961, who observed 
that normal human fibroblasts could divide a limited number of times in vitro and enter in a 
stage of irreversible growth arrest. This phenotype was different from quiescence for being 
irreversible and contributing a powerful anti-tumorigenic mechanism (Braig et al., 2005; 
Collado et al., 2005; Hayflick & Moorhead et al., 1961). Apoptosis and senescence are the two 
main barriers that prevent the emergence of transformed cells. There are two major events 
which can promote the permanent replicative arrest: the first involves the existence of a 
molecular clock (telomere shortening) which keeps track of cell divisions and eventually stop 
them (Hayflick & Moorhead et al.,1961); the second is often mentioned as premature cellular 
senescence and can be achieved also in the absence of telomere dysfunction (Hanahan & 
Weinberg, et al.,2011). 
In addition to a permanent cell cycle arrest, senescent cells are characterised by the presence 
of low DNA replication capacity, high senescence-associated β-galactosidase (Saβ-gal) 
activity, increased cell size and flattened morphology, chromatin and nuclear rearrangements 
and increased expression of hallmark regulatory proteins, such as p53, p21 and p16 (Burton & 
Krizhanovsky, 2014; Campisi & d’Adda di Fagagna, 2007; Ivanov et al., 2013). Furthermore, 
senescent cells acquire other markers which intrinsically influence cell behaviour by producing 
some cytokines, chemokines and matrix remodelling proteins together called as senescence-
associated secretory phenotype (SASP) (Acosta et al., 2014; Campisi & d’Adda di Fagagna, 
2007; Kuilman & Peeper, 2009; Nelson et al., 2012). A detailed list of cellular senescence 
markers are reported in below table 1. 
In mammals, cellular senescence acts as a double edge sword, where it triggers cells to undergo 
permanent growth arrest condition and prevent cancer arising, while on other hand it causes 
age related diseases like atherosclerosis, diabetes and aging (Mattson & Arumugam, 2018). 
These two processes are characterized by excessive and aberrant accumulation of cellular 
damage and cell dysfunctions that negatively impact on cell proliferation. During aging process 
most of the tissues loose regenerative capacity (Chang, 2016; Sousa-Victor et al., 2014)  
Senescence is also involved in some biological processes like embryogenesis, tissue repair and 
in wound healing (Muñoz-Espín et al., 2013; Storer et al., 2013). Developmental senescence is 
transient, and its involves immune-mediated clearance (Muñoz-Espín et al., 2013; Storer et al., 
2013). The induction of senescence during embryogenesis is p21 dependent and genetic 
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ablations of p21 results in escape of senescence by developing abnormalities (Muñoz-Espín et 
al., 2013; Storer et al., 2013). 
 
Figure 1: Cellular Senescence: Physiological role of senescence in daily life activities. The main role of senescence 
in young/adult organisms is to provide anticancer mechanism and promote wound healing. On other hand it 
contributes to age related diseases (Calcinotto et al., 2019). It is important to understand that the induction of 
senescence in vitro is different from in vivo. It is known that senescent cells in vitro remain permanent growth 
arrested without any proliferation, while senescence in vivo is quite complex. For example, nevi are considered 
as an in vivo senescent cell which eventually undergo permanent growth arrest and induce senescence for years 
in the organism (Michaloglou et al., 2005) on the other hand senescent cells can be rapidly engulfed by phagocytic 




Table 1:  Specific Molecular markers used to identify senescent cell both in vitro and in vivo. 
1.1 Types of senescence 
In our daily life we observe some biological events, that rely on senescence namely wound 
healing and embryonic development. However, the contribution of senescence to wound 
healing is less described. Many human cells undergo senescence in response to DNA damage 
regardless of the genomic location. Until now there are few inducers of senescence which were 
successful in vitro and in vivo models   
1.1.1 Replicative senescence (RS) 
Until now the best explanation for replicative senescence is the shortening of telomeres which 
are found at the ends of chromosome. This happens because polymerases that copy the DNA 
template couldn’t copy until the end of chromosomes. As a result telomere regions gradually 
shorten with each cell division and  this creates a replication stress which results in induction 
of the cell cycle arrest called as replicative senescence (Linskens, Harley, West, Campisi, & 
Hayflick, 1995). Consistent with observations of Hayflick limit, many researchers have 
observed that human and murine fibroblast tend to undergo senescence during cell culture as 
they progressively loose the telomerase enzyme and face the end-replication problem. The loss 
of telomeric sequences elicits a DNA damage, leading to phosphorylation of Ser-139 of histone 
H2A.X molecules (γ-H2A.X) adjacent to the site of DNA damage thereby preventing genomic 
instability. It is thought that this phosphorylation of histone H2AX facilitates the focal 
assembly of checkpoint and DNA repair factors including 53BP1, MDC1/NFBD1 and NBS1, 
and promotes the activation by phosphorylation of the transducer kinases Chk1 and Chk2, 
which converge the signal on p53.  
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It was known already that telomere dysfunction induces growth arrest via activation of 
ATM/ATR (Karlseder, Broccoli, Yumin, Hardy, & De Lange, 1999; Rouse & Jackson, 2002)   
and eventually p53 and (in human but not mouse fibroblasts) p16 (Karlseder, 2002). However, 
ectopic expression of telomerase reverse transcriptase (abbreviated as TERT, or hTERT) in 
humans’ cells can bypass Replicative senescence thereby lengthening the telomere in DNA 
strands. Some tumour cells can escape this senescence barrier by expressing the telomerase 
enzyme, which can replenish the telomeric DNA de novo (Herbig, Ferreira, Condel, Carey, & 
Sedivy, 2006). In other cases, alternative lengthening of telomeres can be appreciated (De Vitis, 
Berardinelli, & Sgura, 2018). 
1.1.2 Oncogene Induced Senescence (OIS) 
Until last few decades what we know about oncogenes such as  H-RASV12 is that they are able 
to transform the mammalian and rodent cell lines, but on other hand it was lately discovered 
by a Spanish researcher Manuel Serrano in 1997 that oncogenes are able to induce senescence 
when they are introduced in primary human/murine cells. One common feature shared by 
replicative senescence and OIS is the triggering of DNA damage response. Unlike replicative 
senescence, oncogene induced senescence is not dependent on telomeric DNA loss, as ectopic 
expression of hTERT cannot bypass oncogene Induced senescence (Wei, Wei, & Sedivy, 
1999). However, the combined functional inactivation of p53 and p16 tumour suppressors is 
enough to bypass oncogene induced senescence (Serrano, Lin, McCurrach, Beach, & Lowe, 
1997). However, in these conditions DNA damages are not solved (Di Micco et al., 2006). 
Examples of oncogenes that induces senescence are RAS, AKT, PI3K and MYC (Schmitt et 
al., 2002; Serrano et al., 1997; Zindy et al., 1998). 
1.1.3 Oxidative stress Induced senescence (SIPS) 
Recent evidence suggests that reactive oxygen species (ROS) contribute to the pathophysiology 
of ageing. In addition to replicative senescence, cellular senescence can be triggered by various 
stressors called as Stress Induced premature senescence (SIPS). SIPS is characterized by a 
permanent cell cycle arrest comparable to cellular senescence. When human healthy cells are 
treated with Hydrogen peroxide, the cells that survive to the treatment  begin to show some 
biomarkers of senescence such as appearance of DNA damage, acquisition of an enlarged 
flattened morphology, increased beta-galactosidase activity, loss of proliferative markers and 
increased production of ROS (Davalli, Mitic, Caporali, Lauriola, & D’Arca, 2016). Some ROS 
producers like Mitomycin c display senescence features in dermal fibroblasts (Alili, Diekmann, 
Giesen, Holtkötter, & Brenneisen, 2014). Oxidative damage accumulates in a variety of 
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macromolecules like lipids, DNA, or proteins and results in a progressive decline in the 
function of cellular processes, finally resulting in the aging phenotype (Davalli et al., 2016). 
1.1.4 Drug-induced accelerated senescence (DIAS) 
It is known that many chemotherapeutic drugs like Doxorubicin and cisplatin, are efficient in 
inducing senescence in vitro and in vivo through the induction of irreparable DNA damage 
(Alili et al., 2014; Muñoz-Espín et al., 2013) and display several markers of senescence. 
1.1.5 Epigenetically induced senescence 
Our human genome is tightly packed in nucleosomes and wrapped around histones. Any 
alterations at chromatin level could trigger senescence or apoptosis. It was demonstrated that 
treating human fibroblasts cells with HDACs inhibitors, known to cause G1 cell cycle arrest, 
triggers senescence (Kadosh & Struhl, 1998). It is not well understood how HDACs Inhibitors 
induces senescence. In 2004 Munro confirmed that HDAC Inhibitors induce senescence in 
human cells in a p16 dependent manner while MEF cells show a p53 dependency (Munro, 
Barr, Ireland, Morrison, & Parkinson, 2004). Similarly, demethylating agents like (5-aza-
deoxycytidine) are known to induce senescence. Last, but not least it was shown that 
downregulation of p300/CBP acetyltransferase, triggers cell cycle arrest in melanocytes 
(Bandyopadhyay et al., 2007). It was also reported that Sirtuins (SIRT1,6) , (Class III HDACs) 
display anti-aging properties (Guarente, 2007; Ota et al., 2007). Inhibition of Sirtuins either by 
siRNA or inhibitors mediate cellular senescence in human endothelial cells (Lee, & Min, 2019; 
Ota et al., 2007). Another protein which could influence senescence state is Polycomb proteins 
G (PcG). PcG maintain the facultative heterochromatin state and regulate many developmental 
and differentiation processes. Polycomb proteins, exists as two forms Polycomb repressive 
complex 1 and 2 (PRC1 and PRC2) which belong to Polycomb protein G family. PRC2 
contains EZH2, a histone lysine methyltransferase that catalyzes the histone 3 trimethylation 
of lysine 27 (H3K27me3) by Su(var)3-9, and Enhancer-of zeste and Trithorax (SET) domain. 
It is well known that downregulation of EZH2 triggers a DNA damage response with global 
reduction of H3K27me3 and promotes senescence. Recent studies suggested that DNA damage 
response is an early event in respect to heterochromatinization (Anna Fortuny et al., 2018). 
Furthermore, chromatin compaction appears to play an important regulatory role in DNA 
damage signalling. One of the earliest responses of DNA damage infliction is the recruitment 
of DNA damage signalling kinases, which initiates a complex cascade of events leading to cell 
cycle checkpoint activation. Among the many targets of these kinases, the histone variant 
H2A.X gets rapidly phosphorylated in large chromatin domains surrounding DSBs, giving rise 
to γH2A.X foci (Rogakou, Pilch, Orr, Ivanova, & Bonner, 1998) which serve as a platform for 
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recruiting downstream checkpoint and repair factors. While this is a general response to DNA 
damage, several studies in yeast and mammalian cells originally showed that silenced 
chromatin domains were refractory to H2A.X phosphorylation (Cowell et al., 2007; J. A. Kim, 
Kruhlak, Dotiwala, Nussenzweig, & Haber, 2007) and hampered DNA damage checkpoint 
signalling (Cowell et al., 2007; Fortuny & Polo, 2018).  Altogether these studies demonstrate 
that heterochromatin is permissive for DNA damage signalling and that heterochromatin 
features including histone marks and chromatin compaction exert a positive role in response to 
DNA damage by contributing to checkpoint activation. But still a clear picture about the 
heterochromatinization in senescent cells is still missing. 
1.1.6 Paracrine senescence 
Senescent cells secrete a wide variety of cytokines, chemokines and metalloproteases 
commonly referred as SASP. Key factors of SASP proteins are Interleukin-6 (IL-6), 
interleukin-8 (IL-8), interleukin-1α and 1β and chemokines like CXCL-2, CXCL-3, and 
CXCL-5 which are released by senescent cells into the extracellular matrix (Coppé et al., 2010).  
These SASP proteins induce senescence in neighbouring cells via paracrine manner thereby 
allowing cells and tissues to enter senescence phase.  
1.2 Hallmarks of Senescence 
Currently there are several markers available to distinguish a senescent cell from a non-
senescent cell (proliferating cell). Traditionally senescent cells are detected by the presence of 
low DNA replication capacity which can be detected by BrdU incorporation. The irreversible 
proliferation arrest is required to distinguish senescent from quiescent cells. The former are 
characterized also by some morphological and biological alterations that allow the 




Figure 2: Hallmarks of cellular senescence. Morphological alterat loss of Lamin B1, accumulation of cytoplasmic 
DNA, followed by increased lysosomal content and ROS production (Hernandez-Segura, Nehme, & Demaria, 
2018). 
1.2.1 Morphological changes 
Senescent cells are usually characterized by large flattened enlarged morphology (Serrano et 
al., 1997) vacuolized and, occasionally, multinucleated (Wajapeyee, Serra, Zhu, Mahalingam, 
& Green, 2008). However, the molecular mechanism behind this is partially unknown. 
Moreover, differences exist regarding the morphology of senescent cells: for example, human 
fibroblasts transduced with RAS display flattened cell morphology, while senescence induced 
by BRAFV600E display spindle shaped morphology (Wajapeyee et al., 2008). 
1.2.2 DNA Damage Response 
Persistent DNA damage signals are considered a major contributor to cellular senescence and 
organismal aging.It is well known that cells undergoing senescence triggers a DNA damage 
response and more precisely a DNA Double strand break response (DSBR). The DSBs created 
during senescence are unrepairable and which eventually leads to permanent cell cycle arrest 
(Campisi & d’Adda di Fagagna, 2007). Sophisticated DDR network that responds to DSBs 
include the recruitment of certain proteins (e.g., 53BP1 and Rad17), particular modifications 
like histone phosphorylation (e.g., γH2AX), or both (e.g., p-ATM), and the subsequent events 
(e.g., the activation of p53-p21 and/or p16-Rb signaling) to counteract DNA damage effects 
(Costes et al., 2007). Activated ATM orchestrates the DNA repair process by phosphorylating 
multiple proteins, such as H2AX and 53BP1, to form characteristic DNA foci (Campisi J et al., 
2007). ATM also phosphorylates the substrates CHK2 and p53 to initiate cell-cycle arrest. This 
method of DNA repair is called the homologous recombination (HR) repair pathway (Lavin 
MF et al., 2007) . Alternatively, DSBs activate non-homologous end joining (NHEJ) repair 
pathway which mediated by DNA-PKcs (Chung JH et al., 2018) . Upon detecting DNA damage, 
the cell follows two routes: activation of DDR-dominant cell cycle checkpoints and cell cycle 
arrest to facilitate repair, or if damaged beyond repair, induction of apoptosis.  In some cellular 
models like replicative senescence the DNA damage response is triggered as a consequence of 





Figure 3: H2AX is commonly used as a marker of senescence in response to DNA damage (DSB). Here the human 
lung fibroblasts IMR90 cells (right side) are exposed to UV and Immunofluorescence is performed by using 
Phospho H2AX (ser139) mouse mAb (red) and a DNA damage sensor 53BP1 is stained in green. (A.carnero et 
al., 2013). 
Another protein which is involved in DNA damage response is p53 binding protein 1 (53BP1). 
53BP1 protein is recruited to the sites of DNA double strand breaks and forms microscopically 
visible foci (Ward, Minn, Deursen, & Chen, 2003). 53BP1 has been extensively characterized 
in the context of its contribution to the non-homologous enjoining (NHEJ) DNA double-strand 
break (DSB) repair pathway (Chapman, Taylor, & Boulton, 2012). Any defect in 53BP1 
impairs DNA damage checkpoint and show defects in DNA repair . In addition to these 
numerous small foci, 53BP1 has also been involved in different large NBs (Nuclear Bodies) as 
telomere dysfunction-induced foci (TIFs) (Takai, Smogorzewska, & de Lange, 2003), DNA 
segments with chromatin alterations reinforcing senescence (DNA-SCARS) (Rodier et al., 
2011) and finally 53BP1 nuclear bodies (53BP1 NBs). During DNA damage, cells accumulate 
53BP1 NBs and disappear during mitosis and further transmitted to daughter cells, these DNA 
lesions are sequestered into large chromatin domains enriched in 53BP1 and other markers 
associated with DDR (Harrigan et al., 2011). 
1.2.3 SAHF 
During senescence, chromatin is reorganised and thus favours a global heterochromatinization 
also called as Senescence associated Heterochromatin foci (SAHF). SAHF are specialized 
domains of facultative heterochromatin that silence some proliferating -promoting genes (such 
as E2F target genes) in senescent cells (Narita et al., 2003). Usually SAHF appears during 
senescence that is induced by various stimuli such as activation of oncogenes, replication stress 
induced by loss of telomerase enzyme in primary cells or chemotherapeutics drugs such as 
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etoposide. SAHF seems to act as a tumour suppressive mechanism, as any disruption of SAHF 
lead to cell transformation (Narita et al., 2006). SAHF formation and senescence are not 
directly linked and it is not clear whether SAHF drives cellular senescence or not. Indeed, 
several studies have shown that senescence can occur even in the absence of SAHF formation. 
Some experimental studies show that SAHF formation is cell line dependant (Kosar et al., 
2011), for example SAHF formation is observed in replicative senescence of IMR90 and WI 
38 but less in BJ fibroblasts (Narita et al., 2003).  On the opposite, some cells like murine NIH-
3T3 fibroblasts display SAHF like structure in the absence of any stress (Kennedy et al., 2010); 
moreover, MCF10A transduced with RAS display SAHF-like structures in absence of cell-
cycle arrest (Sherman, Meng, Stampfer, Gabai, & Yaglom, 2011). 
 
Figure 4: SAHF appearance in RAS induced senescence. Confocal images representing SAHF formation in OIS, 
on the left a picture repressive marks (H3K9me3 and H3K27me3) dispersed but always close to the nucleus 
envelope. Xi represents inactive X chromosome. On the right there is a picture represents Ras-induced senescent 
cell. It is possible to see that the chromatin is reorganised forming now a red core (H3K9me3) surrounded by a 
green ring (H3K27me3) (Narita et al., 2013). 
1.2.4 Changes in Nuclear architecture 
Nuclear Lamina is a protein structure that surrounds the nuclear membrane on its nucleoplasm 
side (Y Gruenbaum et al 2003). It is made by intermediate cytoskeletal filaments of Lamin (A-
C) and lamina associated proteins. It is widely accepted that alterations in nuclear lamina are 
linked to the onset of senescence. In particular, Lamin B1 down-regulation universally marks 
senescent cells (Freund, Laberge, Demaria, & Campisi, 2012) as a consequence of 
transcriptionally and post-transcriptionally (autophagy) mechanisms (Dou et al., 2015). 
Moreover, mutations in Lamin A gene have been linked to premature aging diseases. For 
example, point mutation in Lamin A gene that give rise to a splicing isoform called progerin 
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leads to a premature aging disorder called Hutchinson–Gilford Progeria Syndrome (HGPS). 
Like HGPS patients, cells derived from elderly people display nuclear lamina alterations. The 
alterations of nuclear lamina influence the chromatin architecture . In fact, knock down or 
knock out of Lamin B1 induces premature senescence and leads to SAHF formation in few 
human cell lines (Dreesen et al., 2013). However, on the opposite it is reported that also the 
over-expression of LMNB1 triggers senescence of human fibroblasts. It is hypothesized that 
the re-arrangement of chromatin territories imposed by the alteration of nuclear lamina is at the 
basis of a new kind of senescence imposed by epigenetic clues. However, some analysis were 
confirmed by ChIP or DamID showed that, interaction between nuclear lamin B1 with 
chromatin is abolished during OIS but H3K9me2/3 is enriched in proliferating cells (Lenain et 
al., 2017). On contrary, some regions carrying H3K27me3 were retained at nuclear periphery 
upon OIS thereby keeping senescent cells in transcriptionally repressed chromatin state (Lenain 
et al., 2017). Another example of strong chromatin and nuclear lamin interactions is seen in 
HGPS. Several studies on HGPS cells revealed that tethering of heterochromatin to the nuclear 
lamina is abolished (Goldman et al., 2004). HGPS cells do not display SAHF and display 
reduced level of heterochromatin protein H3K9me3 (Shumaker et al., 2006). In agreement with 
the loss of peripheral heterochromatin markers, H3K27me3 in the regions losing lamin A/C 
binding is also diminished in HGPS cells (McCord et al., 2013). What might be the reasons for 
such variation in nuclear reorganization when nuclear lamin is disrupted is unknown. 
 
Figure 5: Schematic representation of heterochromatinization generated upon loss of NL-chromatin tethering. (a) 
Conventional nuclear architecture in most mammalian cell types. (b) Nuclear architecture in Drosophila S2 cells 
lacking both A- and B-type lamins. (c) Nuclear architecture upon OIS or RS. (d) “Inverted” nuclear architecture 
in rod photoreceptors where active regions are interacting with facultative heterochromatin. 
1.2.5 SASP 
Cells which undergo senescence secrete a wide variety of inflammatory cytokines such as IL-
6, IL-8, IL-1β, IL-1α, chemokines, proteases and growth factors which positively impacts non 
senescent cells in a paracrine signalling. SASP has dual roles: it stimulates neighbouring cells 
to undergo senescence but it also promotes the clearance from immune cells, and on other hand 
it promotes tumor progression (Coppé et al., 2010). SASP is required to sustain senescence but 
is not necessary to trigger it. In fact, inactivation of p53 bypasses senescence and restarts cell 
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proliferation but SASP production remains unchanged and active (Coppé et al., 2010). Further 
studies establish that the powerhouse of SASP is NFkB and C/EBP and cytokines regulation 
occurs at transcriptional and post transcriptional level. Many of cytokines mRNA were 
upregulated during senescence and inhibition of NFkB pathway delayed senescence as well as 
DNA damage response in some cellular models (Tilstra et al., 2012). The major trigger of 
SASP is the DNA damage response which activate NFkB pathway. In fact absence of DDR in 
some senescence models where p21 and p16 is overexpressed completely abolished SASP 
production. Release of cytokines from senescent cells is heterogenous and it influenced by the 
way of inducing senescence and cell lines used too. For example, expression of BRAFv600E 
in BJ fibroblasts to induce senescence, released a cytokine IGFBP7 and the same oncogene in 
Lung fibroblast IMR90 released IL-6 and IL-8 (Sherman et al., 2011).  
The conditioning with the medium taken from senescent cells is strong enough to induce 
senescence in proliferating cells (Hubackova, Krejcikova, Bartek, & Hodny, 2012) ; however 
the pathways triggered by SASP-induced senescent are still unexplored. Further clarifications 
are needed also to understand why p53 abrogates SASP. 
 
 
Figure 6: Senescent cell secrete some SASP proteins which mediates many cell-extrinsic functions of senescent 
cell, later they stimulate NK cells to clear the senescent cell (McHugh & Gil, 2018). 
1.2.6 Senescence Associated-β-Galactosidase (SA- β Gal) 
SA- β Gal was first described by the Judith Campisi group in 1995 and become one of the most 
popular markers of senescence. The advantage of using this marker is that it detects only 
senescent cells but not quiescent cells both in vitro and in vivo models. The enzymatic activity 
of SA-β-GAL derives from lysosomal β-galactosidase which is encoded by the GLB1 gene 
(Dimri et al., 1995). In normal, proliferating cells, lysosomal activity of galactosidase is 
detected at a pH of 4, and however in senescent cells the pH activity is increased to 6. The 
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increased pH activity of senescent cells is due to expansion of lysosomal activity in senescent 
cells. The drawback of this assay is that it stains the cells under confluency by providing a false 









1.3 Role of Senescence In vivo 
1.3.1 Replicative senescence 
Several studies have suggested that during aging process, senescent cells are accumulated. 
Senescent cells from skin of elderly people show an increase in SA-β-gal activity (Dimri et al., 
1995) and these cells significantly decreased telomere length (Cristofalo, Lorenzini, Allen, 
Torres, & Tresini, 2004). Later these studies were supported with introduction of other 
senescence markers like DNA damage, SAHF and SASP. Dermal fibroblasts from aged 
baboons showed a decreased in telomere length and increased DNA damage response when 
compared to young ones. DNA damage markers were known to colocalize with telomeres, and 
this is correlated with increase of p16INK4A levels (Herbig et al., 2006), suggesting that telomere 
dysfunction can create DNA damage signals leading to the onset of senescence also in vivo .  
Telomeres plays an important role in replicative senescence as cells undergo replication stress 
as they gradually loose telomeric DNA. However, telomeric dysfunctions also contribute to 
age related pathology such as Atherosclerosis and Osteoarthritis. These patients showed an 
increased expression of SA-β-gal activity (Price et al., 2002). Since these studies were 
performed by using single senescent markers, some more additional marker should be used to 
confirm the above studies. In a mouse model of liver fibrosis, senescent cells were identified 
by positivity for SA-β-gal, increased expression of p16INK4A, p53, p21CIP1. These senescent 
cells derive from activated hepatocellular stem cells and limit the progression of fibrosis (Price 
et al., 2002). In addition, two scientific reports have supported Hayflick that replicative 
senescence limits tumor progression (Cosme-Blanco et al., 2007). Both studies reported that 
mice lacking telomerase enzyme (mTR) showed a decreased tumor progression in the context 
of either one or two copies of mutant p53R172P replacing endogenous p53 (Cosme-Blanco et al., 
2007) or Eμ-MYC/BCL2-driven lymphomagenesis. 
1.3.2 Oncogene Induced Senescence In VIVO 
Melanocytic Nevi are considered as one of the best examples of senescence in vivo. 
Melanocytic Nevi undergo a permanent cell cycle arrest that prevents them from progressing 
to melanoma. Although nevi can persist in the skin for years, some eventually progress and 
give rise to melanomas. One of the most frequently mutation found in melanoma is BRAFE600. 
(Davies et al., 2002) and the same oncogenic mutation is present in the majority of nevi 
(Pollock et al., 2003). Although the presence of oncogenic mutation in BRAF allele in nevi, 
these cells undergo M0 mitogenic senescence. Michaloglou et al has confirmed that BRAF 
V600E mutation in nevi have displayed increased p16 and SA-β-gal expression. Furthermore, 
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nevi had showed positivity to other senescence markers such as increased number of SAHF 
formation and typically these nevi did not display shortened telomeres. This strongly suggests 
that nevi undergo OIS in vivo. These findings have been confirmed by Bennett and co-workers 
(Gray-Schopfer et al., 2006). Taken together, this evidence shows that nevi didn’t undergo a 
telomere-dependent senescence when oncogenic BRAF V600E mutant is present (Michaloglou 
et al., 2005). In support to this, an experimental model has been designed by Michaloglou et al 
where primary melanocytes cultured in vitro underwent senescence when BRAFV600E is 
expressed. These cells initially show burst in cell proliferation followed by morphologic 
changes such as flattened enlarged shape, appearance of multinucleation and increased levels 
of SA-β-gal (Michaloglou et al., 2005). 
The studies on senescent nevi are consistent with previous observations that a mutant BRAF 
V600E in melanocytic lineage induced the formation of nevus-like lesions in zebrafish and in 
transgenic mouse models. Furthermore, inactivation of p53 together with oncogenic BRAF, 
accelerated the formation of invasive melanomas. Another study conducted by Dankort et al 
and Dhomen et al in 2009, demonstrated that conditional expression of mutant BRAF in the 
melanocytic compartment results in the development of nevus like lesions and which remain 
growth arrested for several months and years by displaying markers of senescence (David 
Dankort et al., 2009, Dhomen et al., in 2009) . However, depletion of p16INK4A did not affect 
the nevus formation. In contrast, loss of Pten, together with expression of BRAF resulted in 
melanoma, which is like metastatic melanoma of humans. These elegant models have shown 
that oncogenic mutation of BRAF induces nevus formation and any mutation such as loss of 
Pten and p53 results in melanoma progression (David Dankort et al., 2009). 
1.3.3 Senescence during Embryogenesis 
Early findings by Hayflick suggest us that normal human cells can proliferate for a certain 
limited number of times before entering replicative senescence. It was considered in the past 
that senescence is limited only to adults’ cells, but in 2013 Munoz et al discovered the role of 
senescence during embryogenesis focusing on inner ear and retraction of mesonephric tubules 
in murine species. The induction of senescence during embryogenesis was not clear, to 
understand better the role of senescence in embryo, p53, p21, p16 depleted mice were used. 
The knockout mice for p53 and p16 showed a positivity for SA-β-Gal staining during 
embryogenesis and on the contrary knock out mice for p21 showed low positivity for SA-β-
Gal staining and the embryo was not developed well when compared to controls. Therefore, 
up-regulation of p53 and p16 pathways doesn’t contribute to any role in senescence during 
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embryo development. Studies conducted by Munoz et al and Storer et al, provide an evidence 
that developmental senescence is mainly induced by the presence of p21 through a 
TGFβ/SMAD and PI3K/FOXO dependant, and p53-independent pathways (Muñoz-Espín et 
al., 2013; Storer et al., 2013). These studies showed that inhibition of senescence during 
embryogenesis resulted in abnormal developmental function even in the presence of apoptotic 
mechanism. 
 
Figure 8: Cellular senescence maintains proper homeostasis during embryogenesis. Examples of senescent 
structures stained for a marker of senescence after embryo at the indicated stages. ES, endolymphatic sac; AER, 
apical ectodermal ridge (Muñoz-Espín et al., 2013). 
1.4 Epigenetic changes during Cellular senescence and aging 
Epigenetics is a big network consists of three major events  
 1.DNA modifications 
 2.Histone modifications like histone deacetylation and acetylation or histone methylation 
 3.Recruitment of higher-order chromatin structures or remodelers.  
Epigenetic changes are the major cause of cellular senescence and aging. Any alternations in 
Epigenetics would affect the transcription profiles. Alterations in Epigenetics can be induced 
by endogenous (e.g., intracellular signalling pathways) as well as exogenous stimuli deriving 
from daily life activities, food consumption and environmental exposure (like smoking, 
exposing to toxic chemicals, UV radiations). 
Studies conducted by many groups showed that chromatin of aged people is characterized by 
a remodelling of chromatin as a consequence of altered histones. 
Indeed, histone post-translational modifications and chromatin remodelling are very important 
in the recruitment and activation of DNA damage repair pathways and, therefore, protecting 
the genomic integrity of a cell. When there is a DNA damage response there is activation and 
phosphorylation of serine 139 of histone H2A variant (γ-H2AX), trimethylation of H3K9 and 
H3K27, methylation of H3K79me,acetylation of H3K9) and H3K14. These later are involved 
in DNA damage sensing and relaxing the chromatin. 
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On the opposite, dephosphorylation of H2AX, acetylation of HATs and deacetylation by 
HDACs on histone H3 and H4 are important to close the chromatin or restore the chromatin 
after DNA repair. The H3K27me3 and H3K9me3 form facultative and constitutive 
heterochromatin and promote gene silencing in senescent cell (Tamar Segal et al., 2018). 
However, this is not true that in all the cases SAHF should be appeared in senescent cells, for 
example fibroblasts derived from Progeria patients show no sign of SAHF. But indeed, the 
chromatin is also disorganised in those fibroblasts. About 70% of fibroblasts derived from 
HGPS patients display aberrant nuclear morphology and low levels of the heterochromatin 
protein HP1α, which acts as adaptor between the nuclear lamina and the chromatin.  
Epigenetic changes are not restricted to facultative heterochromatin regions that form the 
SAHF. The SAHF could be also present in telomeres and pericentromeres (R. Zhang, Chen, & 
Adams, 2007). During senescence, pericentric satellite DNA undergo a dramatic 
decondensation which is quite, independent from SAHF formation (De Cecco et al., 2013). 
This nuclear chromatin condensation is termed Senescence-associated distention of satellites 
(SADS) and  which appears to be formed in senescent cells but not in proliferating cells and 
cancer cells (Swanson, Manning, Zhang, & Lawrence, 2013). SAHF formation is limited only 
to few senescent cells, while SADS formation is observed among all senescent cell types and 
senescence-inducing stimuli like RS, OIS, and in HGPS fibroblasts. Recently, SADS formation 
has been identified in vivo and suspected to promote tissue aging (Kosar et al., 2011). 
However, the exact mechanism of SADS formation during cellular senescence remains 
unknown. One possible explanation could be that pericentric satellite transcripts is an early 
event during senescence induction that promotes genomic instability to activate cell cycle 
arrest. Satellite distention could also be only a consequence of the detachment of 
pericentromeric chromatin from LMNB1 (Swanson et al., 2013). 
2 Oncogene Induced Senescence 
Oncogenes are well known to initiate and promote tumorigenesis. For example, activation of 
RAS oncogene contributed to 25% of human cancers (Fernández-Medarde & Santos, 2011). 
Although oncogenes have a direct effect on cell proliferation which is important for initiation 
of tumour progression in many human cancers, later in 1997, it was shown by Serrano and his 
colleagues that ectopic expression of activated oncogenes like H-RASG12V create a stress 
conditions where human fibroblasts undergo a permanent cell cycle arrest called as Oncogene 




Figure 9: Schematic representation of OIS. Normal cells in the presence of oncogene unudergo senescence with 
a decreased DNA synthesis.  
OIS is independent from telomere as ectopic expression of hTERT didn’t allow them to bypass 
senescence. The growth arrested cells resemble to replicative senescent ones  by displaying 
markers of senescence like increase of DNA damage response, loss of Lamin B1, increased 
formation of SAHF, and expression of classic SA-β-gal and flattened enlarged morphology. 
OIS could be triggered by some other oncogenes, such as BRAF600E, AKT, C-MYC, E2F1, 
TGF-BETA and cyclin E.  
For example, multiple evidences indicated that increased PI3K/AKT signalling also induces 
cellular senescence in normal human fibroblasts. Loss of PTEN, the major negative regulator 
of the PI3K/AKT pathway, induced senescence in mouse embryonic fibroblasts (Astle et al., 
2012). PTEN deletion also induces loss of mouse hematopoietic stem cells by induction of the 
senescence effectors p53, p21 and p19Arf (Yilmaz et al., 2006). Expression of constitutively 
active AKT induces senescence in human endothelial cells (Miyauchi et al., 2004) mouse 
embryonic fibroblasts and mouse primary keratinocytes. The mechanisms underlying induction 
of senescence by AKT are poorly defined, although the accumulation of reactive oxygen 
species has been implicated as playing a role. A better understanding of the mechanisms of 
PI3K/AKT-induced senescence will be crucial for understanding the role of dysregulated 
PI3K/AKT signalling in cancer. 









Oncogenes Inducing senescence Pathway 
TGFb Promotes Smad signaling 
H-rasV12, K-rasG12V, N-rasG12D Ras signaling 
BRAF V600E Promotes Ras signaling 
c-Myc Effector of Ras signaling — transcription and 
chromatin remodeling factor 
Akt PI3K/Akt signaling 
β-Catenin Promotes Wnt signaling 
PTEN (TSG) Downregulates PI3K/Akt/mTOR signaling 
Cyclin E Activated cyclin-dependent kinase-2: promotes G1 to 
S phase 
STAT5 Promotes JAK–STAT signaling 
MEK Promotes Ras signaling 
NOTCH TGF β signalling  
 
Table 2: List of oncogenes induces senescence  
However, to induce OIS, in both in vitro and in vivo models, their expression levels are 
important, as studies revealed that senescence was induced by oncogenic Ras only  when 
certain level of Ras is expressed. Activation of tumour suppressors proteins is a part of response 
triggered by senescence.  
2.1 Factors influencing OIS 
Activation of Tumour suppressors during OIS 
In murine cells, the abrogation of either p53 and p16 pathways is strong enough to bypass 
Replicative senescence (RS). On the opposite, human fibroblast requires the contemporary 
ablation of p53 and p16 tumor suppressors to re-entre cell-cycle. 
The blockage in the cell-cycle imposed by tumor suppressors is required to prevent the 
extension of DNA damage and to avoid its spreading. It culminates in the repression of E2F 
target genes and in the up-regulation of CDKi. 
DNA damage response 
RAS induced senescence is associated with a DNA damage response that is due to unlimited 
replicative potential eventually leading to withdraw from cell cycle progression. However, 
inactivation of DNA damage response would allow cells to bypass senescence and favour cell 
transformation (Di Micco et al., 2006). Senescence induced by oncogenes was suppressed 
when ATM kinase is inhibited which senses DNA double strand breaks. Inhibition of ATM 
kinase increased tumour formation and invasion in mice. A study showed that Ubiquitin 
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degradation of ATM by E3 ligases like WSB1(WD repeat and SOCS box-containing protein 
1) promoted cell transformation and bypassed OIS (J. J. Kim et al., 2017). An analysis on 
human precancerous lesions showed that DNA damage response and induction of senescence 
occurred concurrently. ATM and ATR (ataxia telangiectasia and Rad3-related) kinases 
together can activate GATA4, which is more expressed in cells undergoing senescence. 
GATA4 presence can activate NF-κB to initiate production of proinflammatory cytokines and 
helps in facilitating senescence, indicating its role downstream of DNA damage. 
Unlike RAS, AKT promotes rapid proliferative arrest in the absence of a replicative phase and 
show no sign of DNA damage response. Yet the senescence induced by AKT show activation 
of p53 and is characterised by mTORC1-dependent thereby increasing p53 translation and 
inactivation of MDM2 (Astle et al., 2012) and activation of Interferon response and release of 
cytosolic DNA. The link between DNA damage and Interferon response are interconnected. 
Interferons are secreted in response to activation of pathogen-associated molecular patterns and 
acts as anti-viral response. Recent reports demonstrate that IFN-stimulated genes are triggered 
due to DNA damage response by etoposide, anticancer drugs or irradiation (Moschella et al., 
2013). 
DNA damage in the nucleus leads to accumulation of micronuclei (cytosolic DNA) which 
triggers cGAS and produce cGAMP. The product released by cGAS i.e. cGAMP binds and 
activates Stimulator of IFN Gene (STING). STING then recruit and activate TANK-binding 
kinase 1 (TBK1) and IκB kinase to activate IFN regulatory factor 3 (IRF3) and NF-κB, 
respectively in a phosphorylation dependant manner to turn on the production of type I 
interferons and cytokines (Li et al., 2015). Moreover, production of type 1 interferons response 
due to DNA damage trigger cellular senescence and depletion of the IFN α/β receptor 1 
(IFNAR1) rescues the senescence phenotypes in Terc−/− mice. Type I IFNs are also 
prosenescence and antiproliferative, as they induce DNA damage and elevate the p53 level . 
The cytosolic DNA mostly contains single-stranded DNA (ssDNA) (Härtlova et al., 
2015; Shen et al., 2015; Erdal et al., 2017) and very few of double-stranded DNA (dsDNA) 
( Shen et al., 2015). ssDNA in general induces very little type I IFNs compared with dsDNA 
(Ishii et al., 2006) because cGAS doesn’t bind ssDNA. Some studies shown that mouse 
embryonic fibroblasts (MEFs) from cGas−/− mice displayed reduced signs of senescence and 
underwent rapid immortalization when compared with MEFs from WT mice. Depletion of 
cGAS in different mouse or human cells abolished SASP production and interferon production 
when exposed to DNA damaging agents like including etoposide and ionizing irradiation. 
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Therefore, the cGAS–STING pathway provides a critical paracrine signal that is necessary for 
sustaining cellular senescence. 
Activation of Autophagy during OIS 
Senescent cells are typically metabolically active forever, by displaying enlarged morphology. 
Originally, autophagy was thought to suppress cellular stress created during senescence and 
direct them for lysosomal degradation, but on other hand it was shown that autophagy promoted 
cellular senescence and in aging fibroblasts there is an increase of autophagic vacuoles 
(Capparelli et al., 2012). Autophagy and senescence are closely related, but there are many 
questions to be answered regarding the relationships between senescence and autophagy at a 
molecular level. 
Autophagy is a regulatory process where majority of the cells undergo lysosomal degradation, 
in response for harsh conditions like starvation involved in energy homeostasis.  
During senescence, autophagy related genes were upregulated like ATG5 and ATG7 and their 
depletion via knock out or knock down resulted in escape of senescence, like BRAF OIS is 
bypassed by ATG5 knock down. However, during senescent phase, a negative regulator of 
autophagy ie mTOR is switched off and induces senescence in cancer cells (Nam et al., 2013). 
The ectopic expression of ULK3 induced senescence through autophagy and its inhibition 
delayed OIS and markers of senescence such as SASP. Additional studies of autophagy in 
cancer showed that some of autophagic genes are deleted or decreased like in melanoma where 
the expression of ATG5 and LC3B is decreased (Liu et al., 2014) and in some cancers ATG6 
ie Beclin is deleted. However, the relationship between autophagy and senescence is not clear. 
Autophagy is induced during senescence and its suppression of autophagic genes ATG5 and 
ATG7 allowed cells to escape senescence and prolonged inhibition of autophagy via knock out 
or knock down of ATG5 and ATG7 induced cellular senescence, because increased of ROS 
production and defective mitochondria (Kang et al., 2011). 
2.2 OIS as a barrier for cancer progression 
Many groups have described the presence senescence markers in neoplastic lesions such as 
melanocytic nevi, lung adenomas, and hyperplastic prostate tissue (Braig et al., 
2005; Michaloglou et al., 2005) indicating that senescence caused by oncogenic activation led 
to  irreversible growth arrest by limiting uncontrolled cell proliferation and acting as barrier for 
tumour progression. Furthermore, evidence suggested that senescence is observed in 
premalignant samples but not in malignant samples (Michaloglou C et al., 2005;Collado M et 
al., 2005; Braig M et al., 2005). Genetic manipulations showed that activation of an oncogene 
is enough to induce senescence, whereas in mouse model’s depletion of tumour suppressors 
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protein and activation of oncogene lead to aggressive tumours. These studies strongly suggest 
that senescence act as a barrier to protect from neoplastic transformation of cells in vivo.  
Taking nevi, as an example several researchers tried to prove OIS acts as a barrier for tumour 
progression. Nevi are benign melanocytic tumours that generally lack proliferative activity. 
They commonly harbour BRAF mutation with a single amino acid change (V600E) accounting 
for most of the cases (H. Davies et al., 2002; P.M. Pollock et al., 2003). These nevi undergo 
permanent cell cycle arrest, by expressing higher levels of p16 which is a hallmark of OIS 
(Michaloglou et al., 2005). In addition, there is no sign of loss of telomeres suggesting that nevi 
have undergone OIS. All these results show that OIS in nevi acts as a barrier to melanoma 
development (W.J. Mooi et al 2006). Any further mutations in BRAF lead melanoma. 
A Link between OIS and Cancer 
Early studies showed that during oncogene induced senescence, the senescence is induced by 
hyper replicative stress, later it is mediated by DNA double strand breaks which ultimately 
leads to cell cycle arrest. However, inhibition of cell cycle checkpoints in the presence of 
oncogenes promoted tumor progression. This provides us an information that in the presence 
of tumour suppressor genes, oncogenes induce senescence while absence resumes cell 
proliferation. More importantly, overcoming barrier of senescence would require inactivation 
of DNA damage pathways and some senescence independent pathways. Once the cell escapes 
this barrier, oncogenes promote tumor progression by acquiring additional mutations. During 
senescence some proteins like SASP are secreted and released into extra cellular matrix and 
presence of these proteins have a significant role in senescence and tumorigenesis.  
 
 





Molecular mechanisms to bypass Senescence 
Cancer is a complex genetic disease that arises by accumulating specific genetic lesions 
affecting oncogenes and tumor suppressor genes. These lesions hijack the 
transcriptional/epigenetic machineries to reprogram the transcriptional profile of the cells with 
the final goal of sustaining a robust proliferation, invasion and suppressing cell death. Normal 
human/murine cells proliferate for a limited period and they enter a stage of growth arrest called 
as Replicative senescence as they lose telomeric DNA which are found at the end of 
chromosome. To overcome this permanent growth-arrest barrier in vitro, researchers made 
several efforts to immortalize the primary cells by different methods such as ectopic expression 
of telomerase reverse transcriptase (abbreviated as TERT, or hTERT), viral oncogenes 
(Chang S et al., 1982; Rudland P et al., 1989) carcinogenic agents (Stampfer M et al., 1985; 
Russo J et al., 1993) and radiation (Wazer D et al., 1999). 
Tumorigenesis is described as a step-by-step wise process during which the tumor cells must 
overcome many crises like erosion of the telomeres that are often shortened at every DNA 
duplication cycle due to the template requirement for DNA polymerase, escaping of DNA 
damage response due to the replication stress created during cell division ,the restrain in blood 
supply, the increase in energy consumption , the resistance to pro-apoptotic stimuli and the 
infiltration of immune system cells (Hanahan & Weinberg, 2011). 
Here I list some few genetic events that a normal cell should agree to be tumorigenic. 
3.1 Immortalization 
One of the hallmarks of tumor cells is the immortalized phenotype (Hanahan and Weinberg 
2000). Since immortalization is a major consequence of surviving crisis, telomeres may serve 
to limit cell lifespan and to provide a defence against unrestrained proliferation. (Klingelhutz 
A et al.,1999). Telomerase is a ribonucleoprotein that maintains the telomeres at the end of 
chromosomes and helps the cells to escape senescence barrier as a result of telomere 
shortening. Ectopic expression of hTERT restores functional activity of telomerase in normal 
human cells like fibroblasts and stabilization of telomeres leads to direct immortalization of 
cells in cultures (Vaziri H  et al.,1998;Bodnar AG et al.,1998;Klingelhutz A et al.,1999;Harada 
H et al 2003). However, this is not true in few cell types like keratinocytes and epithelial cells, 
where expression of hTERT is not sufficient to immortalize the cells and the full 
immortalization is achieved by the contemporary inactivation of the retinoblastoma 
(RB)/p16INK4A pathway. A better understanding of the immortalization process was achieved 
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by studying Simian Virus 40 (SV 40) Large T or Small T (Hanahan and Weinberg 2000), 
Adenovirus E1A and human papillomavirus E6 and E7. These viral oncoproteins target and 
inactivate p53 and pRB pathways, thereby allowing pre-senescent cells to escape senescence 
barrier like oncogene induced senescence or replicative senescence. Apart from viral 
oncogenes, tumor suppressor pathways are silenced through abnormal DNA methylation of a 
CpG islands on the promoters on those genes and there are also some genetic evidences such 
as overexpression of murine double minute 2 protein (HDM2), that degrade p53 protein  and 
loss of heterozygosity of the p53 locus (JM Stommel et al.,2004). p16INK4A is often 
methylated in several cancers and overexpression of cyclin D1 often cause inactivation of pRB 
which resulted in immortalization of epithelial cells. This immortalization is independent from 
telomerase activity, where the length of telomeres is maintained by Alternative Lengthening of 
Telomeres (ALT). About 10-15% of human cancers show ALT activity to prevent erosion of 
telomeres. 
3.2 Malignant Transformation 
Cancer cells are known to be immortal cells, as they overexpress hTERT or maintain telomere 
by ALT. Ectopic expression of hTERT in normal cells make them immortal but fail to support 
anchorage independent growth, contact inhibition and tumorigenesis. In order to be 
tumorigenic, some additional events are required like inactivation of tumour suppressor genes, 
activation of oncogenes and in vivo the ablation of immune system (Hanahan et al., 2011). 
Since human studies in vivo are ethically unacceptable, the use of human cells in in vitro 
conditions represents the historically most used experimental approach (Hahn et al.,1999). 
Isogenic models proved to be very useful. 
Transformation is a step wise process during which several genetic and epigenetic alterations 
cooperate to acquire the malignancy state. To understand the process of transformation, Hahn 
and Weinberg described a stepwise tumorigenic model system in which defined genetic 
changes had been introduced into normal human/murine fibroblasts in order to generate cancer 
cells (Hahn et al., 2002). Despite the multiple levels of tumour complexity, this genetic model 
approach has helped us to understand the basic principles involved in cancer development. It 
helps us to identify the minimal fundamental changes required in different cell types during the 
transformation.  
Actually, at least three hits are required to achieve transformation of human cells, while in 
rodents two hits are enough. Cells must be immortalized; they must express an oncogene and 
24 
 
turn off p53 and/or p16 tumor suppressors.  As a consequence of these manipulation, the tumor 
cells originated acquire the capability to proliferate in absence of exogenous growth factors 
Some other genetic combinations have been successfully implemented in transforming human 
cells, like expression of mutant form of CDK4 i.e. CDK4R24C which inactivates p53 and   with 
combination of oncogenic RAS, in epidermal keratinocytes led malignant transformation of 
keratinocytes, and formed tumours in immunosuppressed mice (Lazarov et al., 2002).  
Recent evidence suggest that telomerase enzyme activity is not required for initial 
tumorigenesis under certain conditions. Seger et al demonstrated that co-expression of E1A 
together with RAS in BJ fibroblasts supported anchorage independent growth in vitro. 
However, these cells are not tumorigenic in vivo. In order to be tumorigenic Seger et al 
overexpressed MDM2 protein that stably degrade p53 protein. Lysates from these cells show 
lack of telomerase activity. However, these cells undergo crisis either after extended passaging 
in vitro (40–50 population doublings (PDs) or after expansion into culture. Cells which survive 
this period of crisis show telomerase activity (Seger et al., 2002). Overall, the use of genetic 
elements to transform human cells in vitro did not correspond to pathways altered in human 
cancer but these studies helped us to understand pathways affected in cancer should also 
recapitulate in vitro tumorigenesis. For example, to understand molecular pathways involved 
in Oral-Oesophageal carcinoma, Goessel et al developed a genetic model, where primary oral 
epithelial cells are immortalized in vitro with absence of viral oncoproteins, by overexpression 
of cyclin D1 and subsequent inactivation of p53. This immortalization is dependent on ALT 
mechanism but not on telomerase activation. Further expression of epithelial growth factor 
receptor (EGFR) together with c-myc transformed epithelial cells. This model truly copies the 
pathways altered in human cancer like ALT mechanism.  
4 Histone Deacetylases (HDACs) 
Histone acetylation and deacetylation is one of the post-translational modification of 
transcriptional regulation, which regulates the epigenetic state of the chromatin structure. 
Histone acetylation and deacetylation is reversible and tightly regulated (Martin, Kettmann, & 
Dequiedt, 2007). The main epigenetic regulators are the histone acetyltransferases (HATs) and 
the histone deacetylases (HDACs), histone methyltransferase and demethylases which have 
opposite functions. Usually, HDACs are found in corepressor complexes thereby removing 
acetyl groups from histones which results in compact chromatin structure (Delcuve, Khan, & 
Davie, 2012). More differential is the output of histone methylation that in some cases correlate 
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with transcription activation (eg H3K4me3), while in other cases mediate gene silencing (eg 
H3K9me3).  
Until now, 18 HDACs have been identified in mammals. They are divided into four classes 
based on their sequence homology. The class I, II and IV are Zn2+-dependent proteins 
(Gregoretti, Lee, & Goodson, 2004) while, the class III is NAD+- dependent. The other 
differences between these classes is their cellular localization and enzymatic activity (reviewed 
by Martin et al, 2007).  
Class I consists of Histone Deacetylases 1, 2, 3 and 8 which show a high degree of sequence 
similarity with the yeast transcriptional regulator Rpd3. They are ubiquitously expressed and 
they are located into the nucleus (Martin et al., 2007). 
Class II consists of HDAC 4, 5, 6, 7, 9 and 10 which are homologous to yeast Hda1 in 
Saccharomyces cerevisiae.  Class II are Zn2+- dependent, highly expressed in muscles, bones, 
neurons, in the endothelium and in thymocytes. Their expression differs from tissue to tissue. 
Based on structure and function they are divided into two groups, such as Class IIa and 
ClassIIb. Class IIa consists of HDAC 4, 5, 7 and 9 which often travel in and out of the nucleus 
and are enzymatically inactive but able to repress some transcription factors which will be 
discussed later. The Class IIb (HDAC 6 and 10) are enzymatically active on some proteins such 
as tubulin (Fischle et al., 2002) and are mainly cytoplasmic. 
Class III HDACs also called as Sirtuins contains SIRT1, 2, 3, 4, 5, 6, and 7 which are 
completely different from other classes of HDACs as they are NAD+- dependent enzymes. 
Sirtuins are present in nuclear, cytoplasmic and mitochondrial compartments(Haigis & 
Guarente, 2006).  
The other Class of HDACs is Class IV(HDAC11) which has some properties of class I and of 




Figure 11: Histone deacetylase family subdivided into different subfamilies according to homologies to yeast 
prototypes (Clocchiatti A. et al., 2011). 
HDACs have been emerged as epigenetic regulators involved in cell growth, differentiation, 
and apoptotic programs (Bolden et al., 2006 ). Aberrant expression of HDACs are linked to 
tumour malignancy. Several literatures have demonstrated that HDACs are involved in many 
human cancers like breast cancer, hematological malignancies, ovarian cancer, endometrial 
carcinomas (Weichert W et al., 2008).  High level expression of HDACs is associated with 
poor survival rate of patients.  For example, high expression of HDAC 1, 2, and 3 cause a poor 
prognosis in ovarian cancer and gastric cancer patients (Weichert et al., 2008; Sudo et al., 2011) 
whereas high level expression of HDAC8 is seen in neuroblastoma which correlates with poor 
survival and advanced stage (Oehme et al.,2009; Rettig et al.,2015). HDACs are also 
dysregulated in multiple myeloma (MM). Overexpression of HDAC1, is correlated with 
inferior patient outcomes (Mithraprabhu et al., 2014) and some HDACs like HDAC4 suppress 
p21 expression and promote tumor survival which is clearly appreciable in colon, gliobostama 
and ovarian cancer. 
It is also well known that HDAC inhibitors in vitro induce apoptosis and  induce cell cycle 
arrest in colon cancer cell lines and other cancer cell lines (Heerdt et al., 1994 ; Mariadason et 
al.,1997 ; Archer etal.,1998 ; Litvak et al., 1998 ; Mariadason et al., 2000 , 2001b ; Gurvich et 
27 
 
al., 2004 ; Wilson et al., 2006 ). Based on these studies, several HDAC inhibitors came into 
light targeting amino terminus and catalytic domain. Few of them are in clinical trials for the 
treatment of cancer (Rasheed et al., 2007). Recently few HDAC inhibitors like SAHA are being 
approved for the treatment of cutaneous T cell lymphoma. 
Structure of Class IIa HDACs 
Class IIa HDACs function as transcriptional repressor but they do not recognise DNA, while 
they interact with some transcription factors and they are recruited on specific genomic regions. 
There are many important differences between Class I and Class IIa HDACs which will be 
explained later. Class IIa HDACs are large enzymes (120-135 kDa) in comparison to the other zinc- 
dependent HDACs apart from HDAC6. Since the early 2000s, it took a lot of effort to understand 
the biological functions of Class IIa HDACs (Parra, 2015). Knock out of HDAC1, 2 in mouse 
models  results in embryonic and perinatal lethality, (Montgomery et al., 2007) whereas knock 
out of HDAC4 is viable but the mice die soon after the birth because of skeletal abnormalities, 
premature ossification and breath problems (vega 2004) .On other hand HDAC4 regulates 
skeletal muscle differentiation by showing repression activity on myogenic transcription factor, 
MEF2 (McKinsey et al., 2000 ; Miska et al., 2001).  Mice lacking HDAC5 or HDAC9 are vital 
but are characterized by an exacerbated cardiac hypertrophy triggered by hormonal stress-
related signals (Chang et al, 2004). Moreover, HDAC9 knock-out mice are exaggeratedly 
sensitive to the denervation responses in skeletal muscle (Mejat et al, 2005). HDAC7 -/- mice 
results in embryonic lethality due to severe defects in blood vessels; these are caused by a loss 
in cell-cell adhesion between endothelial cells (Chang et al., 2006). 
The main difference between class IIa and class I, is the presence of an extended  amino 
terminus (N-terminal domain) which is absent in the class I (Yang & Gre, 2005) and mediates 
the binding with co-factors and co-regulators, like CtBP, HP-1 and TFs, like MEF2, Runx2.  
 
 
Figure 12: Schematic representation of class IIa HDACs (HDAC4). Different interactors associate with the N-
terminal domain of class IIa HDACs such as CtBP, MEF2 or HP1, whereas the C-terminal domain recruits 
HDAC3-NCoR/SMRT complex to promote Lys deacetylation (Di Giorgio E. et al, 2015).  
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On the N-terminus domain, there is a nuclear localisation signal (NLS) which play a crucial 
role in importing Class IIa HDACs into the nucleus and there is Nuclear export signal at C 
terminus which help to export the protein into cytoplasm. These proteins often move in and out 
of the nucleus and cytoplasm in a phosphorylation dependant manner, phosphorylation occurs 
on serine residues present in amino terminus domain. When dephosphorylated, they remain in 
nucleus, where class IIa HDACs associate with Class I ie HDAC3 and N-CoR/SMRT, forming 
an enzymatically active protein complex which influences the epigenetic state of a transcription 
factor.  
Class IIa HDACs is enzymatically inactive and they show their function mainly in the nucleus 
and where they repress some transcription factors. However, cytoplasmic accumulation of 
Class IIa HDACs also repress few transcription factors like like HIF-1, STAT-1,MEKK2 
(Clocchiatti et al., 2013) and DNAJB6/8 complex (Hageman et al, 2010). Still it is mysterious 
how these HDACs have catalytic activity in the cytoplasm. For example, Class IIa HDACs are 
nuclear in undifferentiated cells and remain cytoplasm in differentiated cells (McKinsey et al., 
2001; Backs and Olson et al., 2006; Mihaylova et al., 2011).  
The shuttling of Class IIa HDACs to the nucleus is supported by the presence of the NLS which 
bind to importin-α,  Class IIa are exported into cytoplasm by presence of a NES to bind to 
CRM1. Both NLS and NES regulate the function of Class IIa HDACs.  This rapid kinetics and 
the high reversibility of the phenomenon led scientists to speculate that the "shuttling" was 
mediated through phosphorylation and dephosphorylation, as this PTM (post translational 
modifications) is extremely quick and easily reversible by phosphatases. The goodness of this 
theory was confirmed in 2000 when multiple experimental evidences joined the nuclear export 
with the action of CaMKII (McKinsey et al, 2001). Later on, the nuclear import was associated 
to the activity of the phosphatase PP1 and PP2A (Martin et al 2007; Paroni et al 2008; 
Kozhemyakina et al 2009).  CaMKII was the first known kinase that export Class IIa from the 
nucleus but now there are other kinases which do the same job as CAMkII. The other 
supervisors which have opposite action (dephosphorylation and nuclear import) were 
discovered much later associated to the activity of the phosphatases PP1 and PP2A. The control 
of phosphorylation of at least three serine residues in HDAC4: S 246, 467, 632; HDAC5: S 
259,497,661 HDAC9: S 220, 451, 611 and four serine residues in HDAC7 S155, 181, 321, 446 
facilitate the binding with 14-3-3 chaperones (Grozinger and Schreiber et al 2000) 
The binding with the 14-3-3 chaperon  proteins could mask NLS thereby preventing the 
interaction with importin-α to impede the class IIa HDACs localisation into the nucleus 
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(Grozinger & Schreiber, 2000) or unmask the NES and promote the direct interaction with 
CRM1 (Mc Kinsey et al, 2001). Alternatively, these interactions with 14-3-3 binding site could 
promote an additional conformational change and the consequent exposition of the NES in the 
carboxy terminal region that favours nuclear export of Class IIa (Clocchiatti, Florean, & 
Brancolini, 2011). The mutation of the serine residues into alanine prevent the export from 
nucleus thereby promoting a super-repressive form of the class IIa HDACs (Clocchiatti et al., 
2015) (C. L. Zhang et al., 2002). Here are three possible ways, to import Class IIa in the nucleus 
i) either by inhibition of the serine/threonine kinases implicated in the phosphorylation of the 
14-3-3 sites, ii) the Ser to Ala mutation of these sites, or iii) the activation of phosphatases. All 
these favour nuclear accumulation of class IIa HDACs and confirm nuclear export of HDACs 
is dependent on phosphorylation and on 14-3-3 proteins (Grozinger and Schreiber et al 2000; 
Wang et al 2000; Nishino et al  2008; Paroni et al  2008). 
The other regulators of the class IIa HDACs are phosphatases and kinases. The serine/threonine 
kinases involved in the HDACs shuttling are the calcium/calmodulin-dependent protein kinase 
family (CaMK). CaMK I and CaMK IV phosphorylate all Class IIa while CaMKII 
phosphorylate only HDAC4 and export them out of nucleus (T. a McKinsey, Zhang, Lu, & 
Olson, 2000). The calcium-mediated export of class IIa HDACs is involved in many biological 
processes such as myogenesis, hypertrophy and neuronal survival (Bolger and Yao et al 2005; 
Shalizi et al 2006; Metrich et al 2010). In 2005 Bolger and Yao observed that nuclear export 
of HDAC4 via CaMKII into cytoplasm showed a pro-survival role in granule cells exposed to 
depolarizing low potassium concentrations (Bolger and Yao, 2005). Later in 2006 it was 
discovered that this pro-survival effect is due to activation of MEF2 when HDAC4 is exported 
into cytoplasm (Shalizi et al, 2006). 
Moreover PKD (Protein kinase D) a kinase activated by PKC, MARK1 (Microtubule Affinity 
Regulating Kinase) and MARK2 are important regulators of the Class IIa HDACs localisation 
(Hanks, 2003). Indeed, two studies reported that PKD1 and PKD3 phosphorylates HDAC5 and 
HDAC7 on 14-3-3 binding sites (Parra, Kasler, McKinsey, Olson, & Verdin, 2005). As a result, 
they are exported into cytoplasm inducing chromatin relaxation and activation of MEF2. In 
order to block nuclear export of HDAC5 a double knock out of PKD1,3 is required. PKD, 
MARK1 and MARK2, which belong to the same CaMK superfamily, are additional kinases 
involved in the regulation of class IIa HDACs shuttling (Hanks SK et al., 2003, McKinsey TA 
et al.,2007). MARK1 and MARK2 are constitutively active enzymes, which phosphorylate the 
first serine residue of the 14-3-3 binding site localized in the amino-terminal domain (Dequiedt 
F. et al, 2006). Regulation of class IIa HDACs is obtained also by further kinases such as the 
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Salt inducible kinase 1 and Mirk/dyrk1B kinases that consequently affect myogenic 
differentiation (Berdeaux R. et al, 2007; Deng X. et al, 2005). Phosphorylation is not the only 
post-translational modification which regulates HDACs. As a matter of fact, HDACs are also 
subjected to proteolytic cleavage (Paroni et al., 2004), sumoylation (Gregoire & Yang, 2006) 
and ubiquitination (Cernotta, Clocchiatti, Florean, & Brancolini, 2011). The kinase’s impact 
on HDACs localization can be rapidly and efficiently counteracted by phosphatases: the 
removal of the phosphate groups, catalyzed by PP1 or PP2A, stimulates class IIa HDACs 
nuclear accumulation and the treatment with some phosphatase inhibitors, such as the calyculin 
A and the okadaic acid, causes their cytoplasmic accumulation. (Paroni G. et al, 2008). 
Even though Class IIa are grouped in the family of histone deacetylases they dont have a 
deacetylase activity as a consequence of a point mutation in the Zn binding site conserved in 
vertebrates. However, they can repress some transcription factors by recruiting class I HDACs 
and supre-repressive complexes. All the class IIa HDACs are characterised by the presence of 
a highly conserved HDAC domain at the C-terminus but which is “inactive” or at least inactive 
on acetyl-lysine (Di Giorgio & Brancolini, 2016). The HDAC domain which is present at C-
terminus is important for the binding with HDAC3. As a matter of fact just the SMRT/N-CoR-
HDAC3 complexes which are present on the HDAC domain can give an association with 
HDAC activity of these proteins (Fischle et al., 2002). It has been proposed that class IIa 
HDACs may not be real enzymes but rather they act as adaptors of repressor complexes (Parra, 
2015). HDACs are able to bind acetylated lysine because of a Tyr with Histidine  in their 
catalytic site but anyway class IIa HDACs have negligible intrinsic deacetylase activity 
(Bradner et al., 2010). 
Binding partners of Class IIa HDACs 
MEF2 TFs  
To negatively affect the transcription, class IIa HDACs need to bind some macromolecular 
complexes inside the nucleus (Clocchiatti A. et al, 2011). As Class IIa HDACs are unable to 
bind DNA they need some transcription factors to interact with DNA. Different interactors 
associate with the N-terminal domain of class IIa HDACs, such as MEF2 (Myocyte Enhancer 
Factor-2), SRF (Serum Response Factor), RUNX2 (Runt Related Transcription Factor 2), CtBP 
(C-Terminal Binding Protein 1), or HP1 (Heterochromatin Protein 1). Until now the best 
binding partners with class IIa HDACs are members of the MEF2 transcription factors family, 
which regulate differentiation, cell growth and survival (Arnold MA. et al, 2007; Li L. et al, 
2018). MEF2 proteins are members of the MADS-box (Minichromosome maintenance genes 
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agamous deficient and serum response factor) family of transcription factors (TFs). MEF2 is 
expressed as a single gene in Caenorhabditis elegans, Drosophila, and Saccharomyces 
cerevisiae, while in vertebrates (humans) there are four members of MEF2 as MEF2A, B, C 
and D, which are located on 15q26, 19q12, 5q14 and 1q12-q23, respectively (Potthoff MJ. and 
Olson EN., 2007). 
MEF2 family proteins in all the species share similar N-terminus that contains a highly 
conserved MADS-box domain and an adjacent MEF2 domain. These domains mediate the 
homo- and heterodimerization of MEF2 proteins, the binding to a conserved A-T rich DNA 
consensus sequence, YTA(A/T)4TAR, and the interactions with transcriptional co-factors and 
co-regulators (Black & Olson, 1998)(T. A. McKinsey, Zhang, & Olson, 2002). The N terminus 
domain is well conserved among the MEF2 members, on the contrary the carboxyl-terminal 
regions of MEF2 factors are more divergent and acts as transcription activation domains 
(TADs), contain the NLS and undergoes splicing events (Potthoff & Olson, 2007) (Lu, 
McKinsey, Nicol, & Olson, 2000). 
MEF2 proteins play a crucial role in the differentiation, morphogenesis, and maintenance of 
several vertebrate tissues. KO mice of Mef2a and Mef2c show neonatal and embryonic lethality 
whereas KO mice of Mef2B/ Mef2D were viable. This shows that how these proteins are 
important during embryogenesis and differentiation (Pon & Marra, 2016). 
There are some other evidences that MEF2 is involved in the cell cycle progression by 
activating CDKN1A transcription. The CDK inhibitor p21 (CDKN1A) is a well-known 
negative regulator of cell proliferation, under the control of multiple signals. It was 
demonstrated that MEF2D downregulation was coupled with the reduction of CDKN1A levels, 
an increase in DNA synthesis and augmented cell proliferation. mRNA levels of MEF2 target 
genes and of CDKN1A were reduced in cells with impaired MEF2D expression (Di Giorgio, 
Gagliostro, Clocchiatti, & Brancolini, 2015). In particular, MEF2D binds the CDKN1A 
promoter at +2.1 kb from the TSS and ChIP experiments proved that HDAC7 bound 
preferentially the same region of the MEF2-binding site (Clocchiatti et al., 2015). The action 
on P21 expression made by HDAC7 and MEF2 confirm the strong cooperation between them. 
Class IIa HDACs contain a conserved region among the HDACs fundamental for the MEF2 
binding and these sequence correspond to the glutamine rich-region (Lu et al., 2000). HDAC7 
lack of this region but the presence of two leucine permit the interaction with MEF2 (Dressel 
et al., 2001) 
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Class IIa HDACs in Cancer 
Class IIa HDACs are frequently upregulated in cancer. The first demonstration of HDAC4 
proliferative effects comes into the light after making a knock-out mouse for HDAC4 -/-. 
HDAC4-/- mice die because of premature and ectopic endochondral ossification, which 
determines their suffocation (Vega et al 2004). This phenotype is somewhat similar to over-
expression of MEF2C and RUNX2 (Vega et al 2004; Arnold et al 2007). On the contrary, 
HDAC4 over-expression slows-down the process of ossification and prevents chondrocytes 
hypertrophy (Vega et al 2004). 
In 2003 Kao and colleagues demonstrated that reduced expression of HDAC4 in HeLa cells by 
siRNA, lead them to a decrease in cell viability. Later it was reported that, HDAC4 and p53 
co-localized upon DNA damage response (Basile V et al 2005). By using immunoprecipitation 
assay, they found that HDAC4 interacts with p53 (Kao GD et al 2003). However, some studies 
reported an opposite effect concerning with reduced levels of HDAC4 decreased cell viability.  
For example, in urothelial cancer cells, inhibition of HDAC4 expression delayed cell 
proliferation but not decreased cell growth (Kaletsch A, et al 2018). A study conducted by 
Cadot and colleagues investigated the effects of HDAC4 on cell cycle progression by making 
a knock-out / knock-down of HDAC4 in normal and tumor cells. The knockdown of HDAC4 
in HeLa cells negatively impacted the cell cycle progression leading to mitotic arrest and 
apoptosis. During apoptosis, HDAC4 (Paroni et al 2004) and HDAC7 (Scott FL et al 2008) are 
cleaved by caspases.  
In some cancers like gastric cancer, HDAC4 typically acts as an oncogene (Kang et al 2014). 
HDAC4 mediates the repression of p21 and silencing of HDAC4 resulted in decrease of cell 
proliferation in gastric cancer cell lines by increasing p21 levels and arresting the cells in G1. 
HDAC4 silencing in those gastric cancer cell lines also increased autophagy and apoptosis rate; 
suggesting that most HDAC4-mediated effects are due to p21 de-regulation (Kang et al, 2014). 
Repression of p21 by HDAC4 is dependent on SP1 transcription factor, which were recruited 
to Sp1/Sp3 binding site of the p21WAF1/CIP1 promotor (Mottet D et al 2009). As HDAC4 is 
enzymatically inactive, some additional binding partners are needed to mediate the repression 
of p21WAF1/CIP1 expression. One of the binding partners with Class IIa HDACs are Class I which 
are present at the catalytic site and probably may be recruited to the site (Fischle W et al 2002). 
Later it was proved that HDAC4 associates with the HDAC3-NCoR/SMRT complex to 
mediate the suppression of p21WAF1/CIP1 expression in colon cancer cells. Another study 
conducted by Geng et al in non-small cell lung cancer showed that when cells exposed to 
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irradiation (IR), HDAC4 translocate from cytoplasm to nucleus. Treating the cells with pan-
HDAC inhibitors (panobinostat) reversed the location of HDAC4 in response to IR (Geng L et 
al 2006). It is interesting to address one question, in the presence of DNA damage response 
whether inhibiting HDAC4 leads to cytoplasmic accumulation.? To answer this a selective 
class IIa HDAC inhibitors are required. Panobinostat exported HDAC4 even in the presence of 
irradiation (IR), this could be due inhibition of HDAC3. A study reported that NLS independent 
nuclear import of HDAC4. The N terminus part of MEF2 interact with HDAC4(aa 1-208) and 
deletion of MEF2 binding site in HDAC4 domain abrogated interaction with MEF2 (Chan et 
al 2003).  
Studies from Stronach et al. showed that there is a link between the HDAC4 and resistance of 
platinum-based DNA damaging drugs. They have screened 16 tumor biopsies of ovarian 
cancer, before and after the development of resistance to platinum-based drugs. Curiously 44% 
of platinum resistant tumour biopsies showed a huge upregulation of HDAC4 (Stronach EA et 
al 2011). This resistance could be due to acetylation status of STAT1. Silencing of HDAC4 in 
platinum-resistant cell lines increased acetylation of STAT1 (Stronach EA et al 2011) and cells 
were sensitive to the treatment of cisplatin.  
Presence of high-level expression of HDAC7 in lung cancer correlates with a poor survival rate 
in patients. This is because of deacetylation of STAT3 by HDAC7 results in inhibition of 
STAT3 activity. However, knock down of HDAC7 in endothelial cells effected the migration 
properties by decreasing angiogenesis (Mottet D et al 2007). In pancreatic tumours, there is a 
high expression of HDAC7 in the cytoplasm (Ouaïssi M et al 2008).  Presence of high-levelsof 
HDAC7 and HDAC9 contributes to a poor prognosis in acute lymphoblastic leukaemia (ALL) 
(Moreno DA et al 2010). HDAC7 regulates cell proliferation in tumour cell by upregulating 
strong oncogene MYC and downregulating tumour suppressor proteins like p21 and p27. On 
other hand in B-cell malignancies there is a low expression of HDAC7. Overexpression of 
HDAC7 in these cells leads to downregulation of c-Myc and promotes apoptosis (Barneda-
Zahonero B et al 2015). Silencing of HDAC7 led to withdraw from cell cycle and triggered 
senescence (Zhu C et al 2011).  
Another protein that is frequently upregulated in cancer is HDAC9.  In breast cancer cell lines 
presence of high level of HDAC9 decrease apoptosis and increase cell proliferation. A recent 
study from Di Giorgio et al 2019, demonstrated that presence of high level of HDAC9 in high 
grade leiomyosarcoma contribute to a worse survival rate in patients. Simultaneously, knock 
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out of HDAC9 in those cell lines resulted in triggering apoptosis by extrinsic pathways. This 
is because HDAC9 repress FAS gene, an initiator of apoptosis (Di Giorgio et al 2019).   
A spliced isoform of HDAC9 i.e. MITR (lacking c-terminus) is expressed in lung, skeletal 
muscle and in adult and fetal brain, although they are considerably more abundant in fetal tissue 
(Petrie K. et al 2003). Further inspections in hematopoietic cell lines show that HDAC9 
isoforms are differentially expressed in the B cell lineage and cell lines derived from B cell 
tumors. HDAC9 is generally expressed in pre-B cell acute lymphoblastic leukemia cell lines, 
B cell lymphoma cell lines and in the plasma cell line U-266. HDAC9 is also expressed in 
some T cells and in particular in T cell leukemia cell line MOLT-3 express MITR.  
However, all these studies show that Class IIa HDACs are involved in oncogenesis process. 
Therefore, further novel compounds/inhibitors should be generated targeting specific domains 


















Material and Methods 
Cell cultures and reagents 
The human foreskin fibroblasts BJ/TERT cells received from CRO AVIANO were cultured in 
Earle's salts minimal essential medium (EMEM) and human leio-myosarcoma cell lines SK-
LMS-1 were cultivated in Dulbecco modified Eagle medium (DMEM) (Euroclone, Milan, 
Italy) and completed with 10% FBS, L‐glutamine (2 mM), penicillin (100 U·mL−1), and 
streptomycin (100 μg·mL−1) (Lonza, Basel, Switzerland). In addition EMEM is supplemented 
with nonessential amino acids (HyClone, Little Chalfont, UK ). All the cells were grown at 
normoxic conditions at 37 °C with 5% of CO2. Cells expressing the inducible form of Estrogen 
receptor were grown in a medium without phenol red and the serum is stripped with charcoal. 
All transgenes which are pre-transformed and transformed were cultured in EMEM. 
BrdU (Bromodeoxyuridine) assay 
Cells were grown for 3h with 100μM BrdU and then fixed with 3% paraformaldehyde and 
permeabilized with 0.1% Triton X-100. Incubation with HCl (1N) for 10 min on ice permits to 
break open the DNA structure of the labelled cells. This is followed by HCl treatment (2N) for 
10 min at RT and then the cells are incubated at 37°C for 20 min. After acid washes, borate 
buffer (0.2M) is added to buffer the cells before the incubation of the mouse anti-BrdU antibody 
(Sigma-Aldrich). Secondary antibodies (AlexaFluor 488 or 533) were used for the detection. 
Nuclei were stained with Hoechst 33258 (Sigma-Aldrich). 
Invasion and random motility assays 
To understand the transformation process in vitro we have performed Invasion assay and Soft 
agar Assay. For soft agar assay, equal volumes of 1.2% agar and DMEM were mixed to 
generate 0.6% base agar. A total of 0.5*105/ml sarcoma cells were seeded in 0.3% top agar and 
incubated at 37°C. The cells were grown for 21 days changing the culture medium twice per 
week. Foci were evidenced with MTT staining and counted by using ImageJ.  
For invasion assay, each well of the invasion chamber (CLS3428, Corning) was coated with 
200μl of Matrigel matrix coating solution (Cultrex, Trevigen). Next, a cell suspension of 
0.5*105/ml cells in 0.1% FBS-DMEM was added. As chemoattractant, 20% FBS-DMEM was 
added in each lower chamber. As a control 0.1% FBS-DMEM was used to evaluate random 
invasion. After 16h cells were fixed and stained with Hoechst. 5 random field were counted. 
Random motility was analysed by time-lapse video microscopy, as previously described 




Cloning and Plasmid construction, transfections, retroviral infections 
The stable expression of pWZL/HDAC4‐WT and mutants, pWZL‐Neo/E1A (1–143) and 
pBABE‐Puro/myristoylated AKT1 (myr‐AKT1) expressing plasmids were generated by 
cloning. pWZL-HDAC4-TMΔMEF2 was generated in two steps. The N-terminus (aa 1 to 166 
and aa 184 to 221) was generated by PCR and cloned into pcDNA3.1 (EcoRI/ BamHI and 
BamHI/SalI). Finally, fragment 1-221 was subcloned into pWZL-HDAC4-TM-GFP restricted 
by using Eco-SalI Di Giorgio et al 2013). pCW‐Puro/HDAC4 and H‐RAS/G12V plasmids 
were generated by subcloning with a PCR amplification and digested with restriction enzymes 
and cloned into DOX‐inducible pCW‐Cas9 plasmid (#50661 Addgene, Cambridge MA, USA). 
pMXPIE‐Puro HDAC4‐WT/TM, H‐RAS/G12V were obtained by subcloning with a PCR 
method the ORF into the 4 hydroxy‐tamoxifen (4‐OHT)‐ inducible pMXPIE plasmid 
(Toledo et al 2008).Apple 53bp1 truncated (69531) plasmid was purchased from Addgene and 
subcloned into pWZL hygro vector by digesting with restriction enzyme (BamHI/SalI). pBabe 
puro H2B GFP (26790) was purchased from Addgene. pLKO plasmids (15 and 27) expressing 
shRNAs directed against hMEF2D were obtained from Sigma-Aldrich. For lentivirus‐based 
knock‐down, HEK‐293T cells were used and transfected with 1.8 μg of VSV‐G, 5 μg of Δ8.9 
and 8 μg of pLKO plasmids. After 12 hours of transfections, virus is collected later 24 hours at 
37 °C and diluted with new medium ad infected the cells. Later, the cells are selected for 
puromycin resistance. Retroviral infections were performed at 32 °C and virus is collected after 
48 hours and used to infect the cells (Di Giorgio et al 2013).  
Immunoblotting 
The protein sample preparation required a first SDS denaturating cell lysis in presence 
of protease and phosphatase inhibitors and of β-mercaptoethanol to reduce the intra and inter-
molecular disulfide bonds. Protein samples were sonicated and heated in boiling water for 5 
min before the electrophoresis. Proteins were then transferred to a 0.2μm pore-sized 
nitrocellulose membrane (Protran, Amersham) by an electroblotting device. Blocking of non-
specific binding was achieved through incubation with non-fat dry milk in tris-buffered 
saline (TBS) with the 0.1% of Tween 20. Blots were incubated with primary antibodies (1h at 
RT or overnight at 4°C). After washes, blots were incubated with peroxidase-conjugated goat 
anti-rabbit or goat anti-mouse (Sigma-Aldrich) for 1h at RT. Secondary antibodies (Sigma-
Aldrich) were developed with Super Signal West Dura (Pierce Waltham). For primary antibody 
stripping, blots were incubated for 30 min at 60°C in stripping solution (62.5mM Tris-HCl pH 




RNA extraction and quantitative qRT‐PCR 
Cell were lysed and homogenized directly on the culture dish by using TRI-REAGENT 
(Sigma-Aldrich). 1.0μg of the total isolated RNA was retro-transcribed by using 100 units of 
M-MLV (Moloney Murine Leukemia Virus) Reverse transcriptase (Life Technologies). qRT-
PCRs were performed using the Bio-Rad CFX96 real-time PCR detection system and SYBR 
green (KAPA Biosystems) technology. Data were analysed by comparative threshold cycle 
using the expression levels of two housekeeping genes, HPRT (hypoxanthine phosphoribosyl 
transferase) and GAPDH as normalizer genes. All reactions were done in triplicates. 
Antibodies 
Antibodies used were against HDAC4 is produced in the laboratory (Paroni et al 2004) 
(MEF2D (BD Bioscience), H3K27ac (ab4729; Abcam, Cambridge, MA, USA). H3K27me3 
(ab195477, Abcam) γH2AX (9718, Cell Signalling, Leiden, The Netherlands), TP53 (DO‐7; 
Dako, Santa Clara, CA, USA), LT SV40 (sc‐147, Santa Cruz), Lamin B1 (ab16048, Abcam), 
p21 (CP74, Sigma), RACK1 (sc‐17754, Santa Cruz, Dallas, TX, USA), GFP (Paroni et al 
2004). 
Immunofluorescence and in vivo time lapse assay 
Cells were seeded at 0.8*105/ml and then they are fixed with 3% paraformaldehyde and 
permeabilized with 0.1% Triton X-100. Secondary antibodies used were Alexa Fluor 
conjugated 488, 546 and 633 (Molecular Probes). Actin was labeled with Phalloidin-AF546 
(Molecular Probes). Nuclei were stained with Hoechst 33258 (Sigma). Imaged were performed 
with a Leica confocal scanner SP equipped with a 488 λ Ar laser and a 543 to 633 λ HeNe 
laser. For in vivo time lapse assay, cells expressing H2B GFP and apple 53BP1 truncated were 
seeded on a time lapse petridish and further processed for time lapse assay.  
CRISPR/Cas9 technology 
CRISPR/Cas9 technology was applied to generate HDAC4 knock out clones in SKLMS-1. 
Two sgRNA (CACCGCCGATGCCCGAGTTGCAGGT,  CACCGTAGGGAATGCCGGGGCTGTT) were 
lentivirally delivered and positive clones were selected. After selections, clones were 
screened by PCR and immunoblot. Sanger sequencing was applied for the final validation 
SA‐β‐gal assay 
For SA‐β‐gal assay, cells were fixed in a solution of 2% formaldehyde/0.2% glutaraldehyde 
and stained with staining solution: 40 mM citric acid/Na phosphate buffer, 
5 mM K4[Fe(CN)6]3H2O, 5 mM K3[Fe(CN)6], 150 mM sodium chloride, 2 mM magnesium 
chloride and 1 mg·mL−1 X‐gal (Debacq‐Chainiaux et al., 2009). Staining was performed for 
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16 h at 37 °C and cells were imaged under bright‐field microscope (Leica). To quantify SA‐β‐
gal activity, the percentage of positively stained blue cells versus total cells were counted (300–
400 cells in total were counted per each round). 
Matrigel plug assay 
A total of 1600 cells were seeded in a Matrigel solution which composes of  20 μL 0.1% FBS‐
EMEM, 60 μL Matrigel. The cells are seeded on coverslips in 35‐mm tissue culture plates. 
After 30 min of incubation at 37 °C, cells were supplied with EMEM of 20% FBS. After 4‐
days of incubation, coverslips were fixed and processed for Immunofluorescence analysis. 
Transcriptome profiling and data analysis 
Total RNA was isolated using Direct‐zol RNA mini prep (Zymo Research). Preparation and 
hybridization of cRNA samples were performed at Cogentech (Milan, 
Italy, https://www.cogentech.it/). Labeled cRNAs were hybridized on Affymetrix GeneChip 
Human Clariom S arrays. Differentially expressed genes (DEGs) were selected based on 1.5 
cut‐off in the fold changes. Analysis was performed as previously described (Di Giorgio et al 
2013; Picco et al 2014). Gene set enrichment analysis (GSEA) (Subramanian et al 2005) and 
the MSigDB database (http://software.broadinstitute.org/gsea/index.jsp) (Liberzon et al 2015) 
were used to investigate statistical association between genes modulated by HDAC4‐TM or 
RAS and genes perturbed by other conditions. 
Data retrieval and analysis 
The transcriptional profiles of the three isogenic transformation models were obtained by re-
analyzing the datasets GSE17941 (Hirsch et al 2010), GSE72530 (Malysheva et al 2016) and 
GSE120040 (Paluvai et al 2018) deposited as raw files in GEO (Gene Expression Omnibus). 
The CEL files were processed with affy package in R (Gauthier et al 2004). Multiple callings 
coming from redundant probes were reduced to a single signal per gene by using Unigene ID 
centered CDFs (Chip Description Files) retrieved from the Molecular and Behavioral 
Neuroscience Institute Microarray Lab (URL:http://brainarray.mbni.med.umich.edu/ 
Brainarray/ Database/ CustomCDF/genomic_curated_CDF.asp) (Dai et al 2005). RMA 
algorithm was used for normalization (Irizarry et al 2003). In the three datasets selected, the 
hybridization was done on three different Affymetrix chips (platforms HG-U133A_2, HuGene-
1_0-st-v1 and Clariom.S). For the identification of differentially expressed genes (DEGs), the 
limma package (Ritchie et al 2015) was used. The calling of significance was based on a 1.5 
fold change/FDR<0.05 criteria. In each dataset, the transformation model represented by pre-
transformed BJ cells expressing RAS G12V (GSE17941) or c-MYC (GSE72530) or HDAC4 
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(GSE120040) was compared to the pre-transformation model which is represented by BJ 
fibroblasts expressing hTERT, LT and ST SV40 genes.  
Enrichment analysis 
The “HALLMARK” collection of 50 gene sets deposited in the Molecular Signatures Database 
(MSigDB) (subject) was interrogated with the three DEG lists generated (query). The MSigDB 
analysis tool (Broad Institute (http://www.broadinstitute.org/gsea/msigdb/index.jsp) algorithm 
was used to score the overlap between queries and subjects. The identified hits were ranked by 
the enrichment score and the p-value (FDR < 0.05) (Daly et al 2003, Subramanian et al 2005). 
Generation of the signatures of transformation 
The signature of the induced genes includes three genes that were significantly upregulated in 
the three selected models of transformation. The signature of the repressed genes includes 13 
genes commonly down-regulated in the three models of transformation. This signature was 
further sub-divided in sub-signatures A and B, where A includes 6 genes that do not belong to 
the HALLMARK gene sets “inflammation” and “interferon response” and B includes the other 
7 genes.   
Analysis of survival 
mRNA expression data coming from RNAseq studies and normalized by the expectation-
maximization (RSEM) method and patients’ clinical data about 32 cancer studies were 
retrieved from TCGA, using the R package cgdsr (Ritchie et al 2015). Hits corresponding to 
patients with incomplete expression or survival data were discarded. The Kaplan-Meier 
survival analysis was performed by using the survival package in R (Jacobsen A et al 2015). 
Estimation of the contribution/perturbation of the immune infiltration to the survival 
analysis  
The infiltration of immune cells in the tumor biopsies was evaluated by using MCP counter 
method (Becht et al 2016). Briefly, immunological signatures were retrieved by using the R 
package MCPcounter. The previously described dataset of 11424 samples was interrogated 
with these signatures and each sample was associated to the median value of expression of each 
signature. According to these values, patients were segregated in two groups and the Kaplan-
Meier method was applied to calculate the survival rate. To evaluate the 
contribution/disturbance of the inflammatory infiltrate to the prediction of survival based on 
the transformation signatures, patients were divided in 4 groups accordingly to the expression 
levels of genes belonging to the MCPcounter signatures and to the transformation signatures: 
high–high (high levels of both), high–low (high MCP/low transformation), low–low (low 
levels of both) or low–high (low MCP-high transformation). The ‘survfit’ function and the 
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“survdiff” function were used to generate the Kaplan-Meier curves and to calculate the 
significance. 
Statistics 
For experimental data Student t-test was employed. Mann-Whitney test was applied when 
normality could not be assumed. p<0.05 was chosen as statistical limit of significance. For 
comparisons between samples >2 Anova test was applied, coupled to Krustal-Wallis and 
Dunn's Multiple Comparison Test. We marked with * p<0.05, ** p<0.01, *** p<0.001. Unless 
otherwise indicated, all the data in the figures were represented as arithmetic means + the 
























6.1 Senescence Induced by HDAC4 
Expression of nuclear mutant of HDAC4 in BJ-hTERT fibroblasts triggers senescence 
To investigate the role of HDAC4 in human fibroblasts, we used foreskin derived BJ 
fibroblasts, which are immortalized with hTERT. Presence of hTERT in the cells allow them 
to bypass replicative senescence. A set of conserved serine residues, once phosphorylated act 
as docking sites for 14-3-3 binding sites and mediate export of HDAC4 from the nucleus into 
the cytoplasm, thereby limiting repressive potential of deacetylase. Since HDAC4 often travels 
in and out of the nucleus in a phosphorylation-dependent manner, a nuclear mutant of HDAC4 
(HDAC4-TM) was generated (Di Giorgio et al 2013) which is defective in 14-3-3 binding 
sites. Dephosphorylation of 14-3-3 binding sites or Ser/Ala mutations or the activation of 
phosphatases allow strong nuclear accumulation of HDAC4 protein. 
Expression of HDAC4-TM in NIH 3T3 cells induces cell transformation and is capable to form 
tumors when injected in nude mice (Di Giorgio et al 2013). However, nuclear accumulation of 
HDAC4 shows a strong repressive activity on MEF2 transcription factor, and additional 
nuclear mutants were tested i) which lack MEF2 binding site (HDAC4‐TMΔMEF2), ii) and a 
mutant which has a mutation on nuclear export signal (HDAC4‐L1062A), which reside in the 
nucleus similarly  to the HDAC4-TM (Di Giorgio et al 2013) show less transcriptional 
repressive activity on MEF2 (Figure 13A). 
BJ-hTERT fibroblasts were infected retrovirally with all the mutants of HDAC4 and as positive 
control also with RAS and AKT. Expression of strong oncogenes like RAS, MYC and AKT in 
normal human fibroblasts induces senescence and this is described in the part of introduction 
(Oncogene induced Senescence). After positive selection of retroviral infections, HDAC4-TM 
triggers senescence which is similar to RAS and AKT. Presence of senescence was confirmed 
by SA‐β‐gal staining, a marker of senescence (Figure 13B). While other two nuclear mutants 
HDAC4-TMΔMEF2 and HDAC4L1062A show moderate staining to SA‐β‐gal, HDAC4 WT 
is largely cytoplasmic and didn’t contribute to senescence like negative control GFP. One 
reason could be HDAC4 TM is able to bind for a longer time to the chromatin in respect both 
to the wild-type form and to a nuclear resident form of HDAC4 mutated in the nes (L1062A, 




Figure 13: Expression of HDAC4-TM in BJ- hTERT fibroblasts triggers senescence. (A) Schematic representation 
of HDAC4 mutants used in this study. Phosphorylated serine residues, binding sites for 14‐3‐3 proteins are 
indicated. (B) AKT,RAS two well known oncgenes were used. Quantitative analysis of SA-β-gal positive cells. 
Data is expressed as means SD, n = 3. Student t-test: *P < 0.05, **P < 0.01, ***P < 0.005. (C) Immunoblot was 
performed after 48 hours of treatment with tamoxifen. RACK1 was used as a loading control. (D) Analysis of cell 
proliferation assay at DAY 2 and DAY 8, as scored after BrdU staining at the indicated times. Data are expressed 
as means ± SD, n = 4. Student t‐test: **P < 0.01, ***P < 0.005. (E) Cells were treated for 2 hours with Etoposide 
(10um) and fixed and stained with H2A.X antibody: two phenotypes were observed (i) nuclei in HDAC4-TM  and 
RAS-expressing cells were larger than in control and HDAC4-WT cells; (ii) nuclei of TM cells showed fewer but 
bigger H2AX-positive foci than RAS cells. (F) A DNA damage analysis was performed at day 2 and day 8. 
HDAC4-TM showed early induction of DNA damage at day 2, while RAS expressing cells, showed a DNA 
damage response after 8 days of induction (G) BJ-hTERT fibroblasts expressing HDAC4-TM showed huge 
activation of p53 when compared with RAS at day8 . (H) Quantitative analysis SA- β‐gal staining for cells 
expressing dominant negative of p53. 
As HDAC4-TM cells undergo senescence, an inducible system is required. We have generated 
all the transgenes fused to Estrogen receptor alpha (Figure 13C).  Presence of tamoxifen 
induces the expression of transgenes. After adding tamoxifen to the cells, we analysed cell 
proliferation assay at different time periods (day2 and day8). HDAC4-TM blocked DNA 
synthesis at day2 and showed low DNA replication capacity (which is detected by BrdU 
incorporation) and stained positive for SA‐β‐gal, while HRAS on day2 is in proliferative phase 
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and showed negative staining for SA‐β‐gal and positivity for BrdU incorporation. As reported 
by others, longer induction of HRAS causes cell-cycle arrest and senescence (Figure 13D). 
To exclude any contribution of tamoxifen to senescence, we generated a TET-ON doxycycline 
inducible system. In the presence of doxycycline HDAC4-TM triggered a permanent growth 
arrest similar to RAS and AKT which was confirmed by staining of SA‐β‐gal (Data not shown 
here, included in the paper Paluvai et al 2018). 
The major difference between RAS and HDAC4-TM is early induction of cell cycle arrest, 
which is clearly seen in HDAC4-TM. As RAS expressing cells show a boost in cell 
proliferation during initial days and later undergo senescence due to replication stress created 
by RAS. Therefore, two different time periods (day2 and day8) were chosen to analyse the 
DNA damage response triggered by two oncogenes (Figure 13F-G). After 2 days of induction 
with tamoxifen, HDAC4‐TM‐expressing cells showed an accumulation of DNA damage, while 
RAS expressing cells, showed a DNA damage response after 8 days of induction with 
tamoxifen (Figure 13E). Our single cell analysis showed that γH2AX‐positive foci formed by 
HDAC4-TM are bigger than RAS, while nuclei of HDAC4-TM and RAS are quite bigger than 
control and HDAC4 WT cells (Paluvai et al 2018). 
During cellular senescence, there is a constant activation of DNA damage response which 
ultimately activates p53. Cells expressing nuclear mutant of HDAC4 show stabilization of p53 
in response to DNA damage. After 2 days of induction with tamoxifen, an Immunoblot was 
perfomred on the cells expressing HDAC4-TM and cells expressing RAS at day 8. As shown 
in figure 13G there is a massive upregulation of p53 in HDAC4-TM cells at day 2, when 
compared to RAS expressing cells at day 8 (Figure 13G). 
To investigate the contribution of p53 in HDAC4-TM‐induced senescence, p53 responses were 
abrogated by expressing a dominant negative form of p53 (R175H) (Figure 13H) 
(Gualberto et al 1998). The dominant negative effect was clearly appreciable on p53‐target 
genes such as DEC1 and GADD45A (Paluvai et al 2018). Later, cells expressing BJ‐
hTERT/p53DN GFP together with HDAC4-TM and RAS were generated. Depletion of p53 in 
HDAC4-TM expressing cells resulted in bypass of senescence (Figure 12H) while RAS 
underwent senescence even in the presence of DN of p53. This suggests us that further hits are 
required to escape RAS but not HDAC4-TM induced senescence (Brookes et al 2002; Huot et 
al 2002). 
To sum up, HDAC4-TM induces senescence in BJ-hTERT fibroblasts and this senescence is 
dependent on p53 activation. Abrogation of p53 in BJ-hTERT HDAC4-TM cells resulted in 




Oncogenic mediated Transformation 
Oncogenes have two different roles in human cells, they can induce senescence and are able to 
transform the cells. In order to transform human cells multiple hits are required as in respect to 
murine cells they are more resistant to transformation process. Transformation of 
human/murine cell can be achieved by presence of viral oncogenes like SV40, E1A or exposing 
them to carcinogens. 
6.2 Transformation of BJ-hTERT fibroblasts by HDAC4-TM 
Class IIa HDACs are often dysregulated in human cancer and promote tumorigenesis in vivo. 
To prove the oncogenic properties of HDAC4 an in vitro transformation assay was performed. 
As HDAC4-TM cells escape senescence in the presence of DN environment of p53, an in vitro 
transformation assay was performed to observe transformation process in the absence of p53 
(Paluvai et al 2018). Presence of DN p53(p53 R175H)  in HDAC4-TM cells poorly supported 
oncogenic transformation, this suggest us that why human cells are resistant to oncogenesis 
and why further genetic alterations pathways are required to transform the cells. 
Next BJ-hTERT fibroblasts were pre-transformed by viral oncogene Simian Virus 40 (SV40). 
It was reported by many groups that SV40-Large-T-antigen pre-transforms human cells and 
immortalise them. A pool of cells were generated with a combination of BJ-hTERT/SV40-LT 
alone and with a combination of HDAC4-WT, HDAC4-TM and RAS (Figure 14A). Presence 
of Large T antigen in the cells allowed them to escape senescence and stained negative for SA-
β-gal assay a marker of senescence (Figure 14B-C). After growing the cells for 21 days with 
20% FBS, cells were stained with MTT to visualise the foci formation (Figure 14D). The 
diameter of each foci was measured (according to Cifone and Fidler.,1980 model) and 
classified them into three groups based on their diameter of foci formation like 0-50μm, 100-
150μm and >150μm (Figure 14E). HDAC4-TM and RAS showed colonies more frequently 
smaller than 50‐μm diameter and very rarely big colonies of diameter >150μm appeared 
(Figure 14E). More interestingly small colonies were also observed in HDAC4-WT (Figure 
14D). Based on our experimental data, HDAC4-TM and RAS transformed the cells but a mild 
transformation was supported by HDAC4-WT.  
To confirm that cells were malignant in the presence of HDAC4-TM we performed an Matrigel 
Invasion assay to score the random motility and invasiveness. As expected HDAC4-TM 
increased the random motility.  Both HDAC4-TM and RAS promoted invasiveness when 
compared with BJ-hTERT LT (Paluvai et al 2018). 
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Next, in order to achieve full transformation, we have introduced Small T antigen together with 
Large T antigen (Figure 14F). Expression of Large T antigen and small T drastically enhanced 
transformation. Next clones were generated with a combination of both T antigens together 
with HDAC4-WT, HDAC4-TM and RAS as a positive control. After growing for 21 days in 
soft agar, cells were stained with MTT to score the foci formation (Figure 14G).  
After staining with MTT, we have divided them into three groups similar to Large T expressing 
clones alone (Figure 14H). Quantitative analysis proved that the expression of the Small T 
antigen together with Large T antigen increased efficiency of number of foci and increased the 
size of foci dimensions (Figure 14H). The combinations of SV40 T antigens increased the 
efficiency of transformation when compared with the presence of Large T antigen only. We 
have noticed that HDAC4-TM increased the efficiency of invasiveness in soft agar which we 
could clearly see with their branching out in soft agar. HDAC4 WT also supported anchorage 
independent growth but at a less potent when compared with HDAC4-TM. This shows that 
HDAC4 favours cell transformation but nuclear mutant of HDAC4 achieves an enhanced 
transformation efficiency.  
To confirm the invasiveness properties elicited by HDAC4-TM and RAS we have performed 
Random motility and Invasion assay. This experiment supports that HDAC4-TM is invasive 
(Paluvai et al 2018). Later we performed Matrigel assay on cells expressing BJ-hTERT LT/ST 
and HDAC4-TM and RAS. For this experiment we seeded cells on Matrigel surface to provide 
3D growth. Only the cells which are invasive supported 3D growth and Immunofluorescence 
was performed by staining cytoskeleton with actin using phalladoin 546 (Figure 14I). Hence 
both HDAC4-TM and RAS supported the growth in Matrigel showing strong invasiveness 
behaviour. 
All our data suggest us that HDAC4 acts like an oncogene by inducing senescence in primary 
fibroblasts (BJ-hTERT) and capable to transform the cells. 
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Figure 14: Presence of SV40 LT/ST in cells leads to cellular transformation. (A) Immunoblot analysis of presence 
of Large T (LT) in BJ-hTERT cells. Actin was used as loading control. (B) BJ-hTERT LT cells were stained for 
SA-β-gal activity as a marker of senescence. Scale bar: 50 um. (C) Quantitative analysis of SA- β -gal positivity 
from experiments described in (B). Data are expressed as means SD, n = 3. Student t-test: *P < 0.05, **P < 0.01, 
***P < 0.005. (D) The colonies were stained and visualized with MMT. Scale bars are indicated as 50um and 
100um. (E) Quantitative analysis of soft agar foci formation by BJ-hTERT LT together with a combination of 
HDAC4-WT, TM, and RAS related to figure D. Data are expressed as means SD, n = 4. Student t-test: *P < 0.05, 
**P < 0.01, ***P < 0.005. (F) Immunoblot analysis of BJ-hTERT LT/ST expressing Hygro, HDAC4-WT, 
HDAC4-TM and RAS. HDAC4 was tagged with GFP and the recombinant proteins detected with an anti-GFP 
antibody. Actin was used as loading control. (G) The colonies of BJ-hTERT LT/ST together with HDAC4WT, 
HDAC4-TM and RAS were stained and visualized with MMT and divided into three categories based on size of 
foci formation. (H) Quantitative analysis of soft agar foci formation of BJ-hTERT LT/ST and with a combination 
of HDAC4-WT, TM, and RAS related to Fig B. Data are expressed as means SD, n = 4. Student t-test: *P < 0.05, 
**P < 0.01, ***P < 0.005. (I) Confocal images representing the cells grown under 3D condition in a Matrigel 
surface. BJ-hTERT LT/ST HDAC4-TM, RAS and Hygro were seeded on a Matrigel plug. Immunofluorescence 








Gene Expression profiling studies further helped in understanding the transformation 
process initiated by HDAC4-TM 
To understand the transformation process elicited by HDAC4-TM and RAS a transcriptomic 
analysis was performed. We have compared transcriptomes of BJ-hTERT LT/ST together with 
BJ-hTERT LT/ST HDAC4- TM and BJ-hTERT LT/ST RAS. DEGs were analysed relative to 
BJ-hTERT LT/ST cells. We have found that 920 genes were affected during transformation 
process induced by HDAC4-TM and 892 genes under RAS. In both HDAC4-TM and RAS, 
the number of repressed genes is higher than induced genes. Since HDAC4 is an Epigenetic 
repressor that favours transcriptional gene silencing, more attention is paid on repressed genes 
during transformation by both oncogenes. Nearly 156 genes were repressed by both oncogenes 
(HDAC4-TM and RAS) while RAS repressed 400 genes while HDAC4-TM repressed 450 
genes (Figure 15A). Interestingly most of the genes that are repressed (downregulated) during 
transformation process are Interferon genes and inflammatory response (Figure 15B) It is 
known that oncogenes inhibit the function of interferon response during transformation process 
by inhibiting STAT1 and STAT2 pathways. Next we have analysed genes downregulated by 
HDAC4-TM alone and found that Epithelial-mesenchymal transition, Hypoxia and 
Myogenesis are effectively downregulated (Figure 15D). The high number of genes regulating 
cell adhesion, cellular movements and morphological structure, as disclosed by the Gene 
Ontology analysis, could explain us the phenotype of colonies formed by HDAC4-TM in soft 
agar (Figure 15D). Finally, by looking at transcriptomic analysis of BJ-hTERT LT/ST 
HDAC4-TM cells we have concluded that the transformation process initiated by HDAC4- TM 







Figure 15: Transcriptomic analysis of BJ-hTERT LT/ST RAS and HDAC4-TM. (A) A venn diagram representing 
number of genes up and down regulated in BJ-hTERT LT/ST RAS and BJ-hTERT LT/ST HDAC4-TM cells with 
comparing to BJ-hTERT LT/ST HYGRO. (B) GSEA for 156 genes commonly downregulated by HDAC4-TM 
and RAS using hallmark and GO biological process gene sets. (C) GSEA for 400 genes specifically downregulated 
by RAS alone using hallmark and curated gene sets. (D) GSEA for 450 genes specifically downregulated by 
HDAC4-TM alone using hallmark and GO biological process gene sets. (E) GSEA plots showing significant 
enrichment for HDAC4‐regulated genes in a BJ transformation model (GSE43010), considering both HDAC4‐
positively regulated genes (left) and HDAC4‐repressed genes (right). 
 
Analysis of the transcriptional profiles in three different models of in vitro transformation 
In order to understand the cellular and molecular pathways during the transformation process 
a transcriptomic analysis of BJ-hTERT/ST/LT/HDAC4S246A, S467A, S632A(HDAC4-TM) 
(GSE120040) is compared with other two strong oncogenes like BJ-hTERT/ST/LT/MYC 
(GSE72530) and BJ-hTERT/ST/LT/HRASG12V (GSE17941) in respect to BJ-hTERT/ST/LT.  
Our transcriptomic analysis showed that the number of repressed genes are more than induced 
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genes in all three oncogenes. Overall,519 and 634 genes were respectively up-regulated and 
down-regulated by MYC, while 556 and 595 by RAS and finally, 551 and 979 by HDAC4 
(Figure 16A-B). 
A limited number of genes were commonly dysregulated during oncogenic transformation 
process and only 3 genes were commonly upregulated (Figure 16A) while 22 genes were 
commonly downregulated by three oncogenes (HDAC4-TM, RAS, MYC) (Figure 16B).  
Although the number of genes that were commonly shared by three oncogenes is limited, yet 
they could influence cell behavior and cell transformation by some common pathways. To 
understand this we have performed Gene Set Enrichment Analysis (GSEA) using the hallmark 
MSigDB gene sets and we found out that 14 different gene sets were commonly up-regulated 
by RAS, MYC and HDAC4 (Figure 16C) and for the down-regulated genes there were 23 gene 
sets (Figure 16D). Individual hallmarks for both upregulated and downregulated genes during 
transformation process were listed (Di Giorgio et al 2019, submitted to IJMS).  
The genes that were commonly upregulated during in vitro transformation are DOCK4, G0S2, 
SRPX and Interferon and Inflammatory are the gene set downregulated during in vitro 
transformation, as listed in below (table 2).  
For the commonly downregulated genes, we divided our signature into two categories A and 
B. The downregulated signature A includes genes (CDH11, DKK1, GREM1, MYLK, SPRY2) 
which does not belong to neither inflammatory and interferon gene sets listed in below table. 
While signature B represents genes related to inflammatory-immune responses (ARID5B, 




Figure 16:  Analysis of the transcriptional profiles in three different models of in vitro transformation. (A) Venn 
diagram showing the number of genes upregulated during in vitro transformation process in BJ/hTERT/LT/ST 
cells expressing RAS, MYC or HDAC4 as indicated. (B) Venn diagram showing the number of genes down 
regulated during in vitro transformation process in BJ/hTERT/LT/ST cells expressing RAS, MYC or HDAC4 as 
indicated. (C) Venn diagram showing the number of different hallmarks gene sets significantly upregulated by 
RAS, MYC and HDAC4. (D) Venn diagram showing the number of different hallmarks gene sets significantly 
down regulated by RAS, MYC and HDAC4. Venn diagrams were generated by using Bioinformatic software 
indicated below http://bioinformatics.psb.ugent.be/webtools/Venn/. 








A link between in vitro transformation and cancer 
Can in vitro models predict cancer? To address this, we have interrogated our up-regulated 
signatures (DOCK4, G0S2, SRPX) on survival data of 32 cancer types deposited in the Cancer 
Genome Atlas (TCGA). 
Genes upregulated during in vitro transformation contribute to a worst survival rate in patients 
For the up-regulated genes, we grouped patients into two groups: ones characterized by high 
expression of our signature (above the third quartile) and the ones with repressed signature 
(below the third quartile). As Figure 17A shows that presence of high mRNA levels of DOCK4, 
G0S2, SRPX gene in 6 different cancer types like colorectal adenocarcinoma, kidney 
chromophobe, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, 
testicular germ cell tumors and uveal melanoma contributed to worst survival rate. 
On other hand high levels of the signature of up-regulated genes positively influenced a better 
survival rate in adrenocortical carcinoma (ACC) (Figure 17B). In ACC, very frequently G0S2 
is hypermethylated and the presence of low levels of G0S2 mRNA expression characterize 
tumors with G0S2 hypermethylation. Although low levels of G0S2 contribute to 40% of ACC 
and independently predicts shorter disease-free and overall survival, the role of this gene in 
adrenocortical biology is still unknown. To confirm this data, we repeated survival analysis 
just by excluding G0S2 gene. In this case the positive correlation with ACC survival was 
abolished (Figure 17C).  
To verify whether G0S2 is the key gene in predicting patients’ survival, we repeated the 
analysis for DOCK4 and SRPX alone. High levels of DOCK4 expression showed a negative 
impact on survival in 5 different tumors (colorectal, kidney chromophobe, brain low grade 
glioma, stomach adenocarcinoma and uveal melanoma) and with a better prognosis in two 
cancer types (mesothelioma and skin cutaneous melanoma) (Eros Di Giorgio et al 2019). Same 
analysis was repeated for SRPX, this showed a dramatic effect on patient survival in 7 different 
cancer types (bladder, colorectal, head and neck squamous carcinoma, kidney renal clear cell 
and papillary carcinomas, thyroid carcinoma and uterus corpus endometrial carcinoma) while 
it predicted a better outcome in melanoma. This suggests us that 3 commonly up-regulated 





Figure 17: Presence of high mRNA levels of upregulated genes during in vitro transformation process influence 
patients’ survival. (A) Kaplan-Meier survival analysis related to the three up-regulated genes DOCK4, G0S2, 
SRPX. All cases were analyzed and clustered into two groups according to DOCK4, G0S2 and SRPX expression 
levels (high levels > the third quartile). Cases were: colorectal adenocarcinoma (all n=382, high expressing n= 
95), kidney chromophobe (all n=65, high expressing n=16), kidney renal clear cell carcinoma (all n=510, high 
expressing n=127), kidney renal papillary cell carcinoma (all n=283, high expressing n=70), testicular germ cell 
tumors (all n=149, high expressing n=37) and uveal melanoma (all n=80, high expressing n=20). (B) Kaplan-
Meier survival analysis related to G0S2 in adrenocortical carcinoma (ACC). High level expression (above the 
third quartile) of G0S2 in ACC were in n 19 cases. All cases were n=78. (C) Kaplan-Meier survival analysis 
related to DOCK4 and SRPX in ACC. High level expression (> the third quartile) of DOCK4 and SRPX were in n 





Genes repressed during in vitro transformation and patients’ survival 
Next, we analyzed the TCGA survival data represented in the table 2. Using our repressed 
signature A we divided patients into two groups according to the median value of expression 
of the signature. Only in two cancer types, high levels of our signature correlated with an 
increased survival rate, while in six cancer types high levels of the same signature correlates 
with reduced survival (data not shown). On other hand a quite opposite result was observed 
with the repressed signature B that groups inflammatory and interferon genes. Presence of low 
levels of signature B correlate with a worst prognosis, at least this is evident in few cases like 
kidney chromophobe carcinoma, kidney clear cell carcinoma, sarcoma, skin cutaneous 
melanoma and uterine carcinosarcoma (Figure 18A). On contrary, low levels of this signature 
predict a better outcome in patients with brain lower grade glioma and ovarian serous 
cystadenocarcinoma (Figure 18B).  
As a final analysis we have evaluated the presence of tumor infiltrating immune cells and the 
repressed inflammatory B signature on overall survival. To approach this, we have analyzed 3 
tumors (LGG, skin cutaneous melanoma and sarcoma) showing a significant correlation 
between immune cell infiltrates and overall survival (Figure 19). In LGG, the presence of high 
levels of immune cells (T cells) and signature B represent a poor prognosis (Figure 19B/C/G) 
while in sarcoma the presence of immune cells infiltrate positively correlates with increased 
survival rate even in the presence of low levels of signature B (Figure 19E-G). In contrast, in 
skin cutaneous melanoma low levels of expression of the B signature are enough to reduce the 
overall survival (Figure 19A/C/D/F/G). In melanoma the best prognosis is observed in the 
presence of high expression of the signature and the concomitant presence of immune cells, 





Figure 18: TCGA survival data on genes repressed during in vitro transformation. (A) Kaplan-Meier survival 
analysis related to the immune/inflammatory signature. All cases were analyzed and clustered into two groups 
according to median expression levels (high levels > the median). Cases were: kidney chromophobe (all n=65, 
high expressing n=32), kidney renal clear cell carcinoma (all n=510, high expressing n=255), sarcoma (all n=253, 
high expressing n=126), skin cutaneous melanoma (all n=443, high expressing n=221) and uterine carcinosarcoma 
(all n=57, high expressing n=28). (B) Kaplan-Meier survival analysis related to the immune/inflammatory 
signature. All cases were analyzed and clustered into two groups according to median expression levels (high 
levels > the median). Cases were: brain low grade gliomas (all n=514, high expressing n=257) and ovarian serous 







Figure 19: The contribution of tumor infiltrating immune/inflammatory cells to overall survival. Kaplan-Meier 
survival analysis related to the immune/inflammatory signature and the infiltration of different 
immune/inflammatory cells. Infiltrating immune/inflammatory cells were defined as described in materials and 
methods. Patients were grouped high/high (high levels of both infiltrating cells and immune signature), high/low 
(high levels of infiltrating cells and low levels of the immune signature), low/high (low levels of infiltrating cells 
and high levels of the immune signature) and as low/low (low levels of both infiltrating cells and immune 
signature). The four groups were generated according to median expression levels of the two signatures. Cases: 
(A) Sarcoma (all=253, high/high=75, high/low=51, low/high=51, low/low=76) and skin cutaneous melanoma 
(all=428, high/high=133, high/low=82, low/high=82, low/low=131). (B) Brain low grade glioma (all=512, 
high/high=155, high/low=102, low/high=101, low/low=154). (C) Brain low grade glioma (all=512, 
high/high=164, high/low=92, low/high=92, low/low=164) and skin cutaneous melanoma (all=428, 
high/high=148, high/low=66, low/high=67, low/low=147). (D) Skin cutaneous melanoma (all=428, 
high/high=143, high/low=72, low/high=72, low/low=141). (E) Sarcoma (all=253, high/high=70, high/low=56, 
low/high=56, low/low=71) and skin cutaneous melanoma (all=428, high/high=136, high/low=77, low/high=79, 
low/low=136). (F) Brain low grade glioma (all=512, high/high=164, high/low=93, low/high=92, low/low=163) 
and skin cutaneous melanoma (all=428, high/high=140, high/low=73, low/high=75, low/low=140). (G) Brain low 
grade glioma (all=512, high/high=153, high/low=104, low/high=103, low/low=152), sarcoma (all=253, 
high/high=74, high/low=52, low/high=52, low/low=75) and skin cutaneous melanoma (all=428, high/high=142, 
high/low=74, low/high=73, low/low=139). (H) kidney renal clear cell carcinoma (all=510, high/high=132, 
high/low=123, low/high=123, low/low=132), sarcoma (all=253, high/high=70, high/low=56, low/high=56, 
low/low=71) and skin cutaneous melanoma (all=428, high/high=126, high/low=89, low/high=89, low/low=124). 
 
6.3 Senescence Induced by HDAC4 knock out in cellular models 
HDAC4 is downregulated during Oncogene Induced senescence in a GSK3β dependant 
mechanism 
The relationships between HDAC4 and the induction of senescence is unclear. To investigate 
the contribution of class IIa HDACs to senescence and senescence escape, we generated an 
inducible model of senescence by expressing RAS and AKT in an inducible manner 
(doxycycline) in BJ-hTERT cells. In cells undergoing OIS, class IIa HDACs levels decrease 
except for HDCA9 (Figure 20A). The induction of senescence is accompanied by the 
phosphorylation of γH2A.X (a marker of DNA damage) and by the appearance of SA-β-gal 
positive cells (a marker of senescence). Class IIa HDACs activity were scored in different 
models of senescence and in tissues from aged mice; among the different conditions only 
HDAC4 was de-regulated (data not shown). We therefore decided to focus more attention on 
HDAC4 for further studies. The downregulation of HDAC4 is due to UPS degradation, since 
HDAC4 levels are restored by the proteasome inhibitor MG132 but not by inhibiting autophagy 
(Data not shown). The UPS mediated degradation of HDAC4 was proved in the past to be 
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GSK3β dependent (Cernotta et al, 2011). We confirmed that the degradation of HDAC4 during 
senescence is mediated by GSK3β by silencing GSK3β in BJ-hTERT RAS cells (doxycycline) 
at day 8 (when they reach senescence). The silencing of GSK3β in senescent cells do not 
positively impact on the senescence of these cells but it is enough to restore HDAC4 levels as 
confirmed by immunoblot (Figure 20B).  
 
Figure 20: HDAC4 are regulated during cellular senescence. (A) Immunoblot analysis of different class IIa 
HDACs during OIS at day2 and at day8 in BJ-hTERT fibroblastss and percentage of SA- β-gal is indicated in the 
below lane (B). Immunoblot analysis of siRNA GSK3β in the absence and presence of doxycycline. Presence of 
doxycycline triggers OIS, leading to degradation of HDAC4 by GSK3β dependant. siRNA of GSK3β in the 
presence of doxycycline, recovered the stability of HDAC4 which is lost during OIS and percenatge of SA- β-gal 
is indicated in the below lane  
Knock out of HDAC4 triggers senescence in SK-LMS-1 
To better investigate the role of HDAC4 in regulating senescence, we made a knock-out of 
HDAC4 in low grade sarcoma cells (SK-LMS-1). Depletion of HDAC4 in these cells altered 
cellular and nuclear morphology, triggered permanent cell cycle arrest and the cells stained 
positive for SA-β-gal assay a marker of senescence (Figure 21A-C) and showed an increase in 
DNA damage response as when compared with WT HDAC4 and confirmed by gH2A.X 
positivity (Figure 21D). Moreover, as these cells undergo senescence in the absence of 
HDAC4, they lost their tumorigenic properties. We have generated different KO clones by 




Figure 21:  Generation of knock-out cells by using CRISPR CAS9 technology. (A) Immunoblot analysis showing 
4 knock out clones of HDAC4 as generated by using CRISPR/Cas9 technology in SL-LMS-1 cells. (B) 
Microscopic pictures of indicated cells stained for a marker of senescence (SA-β-gal assay). (C) Quantitative 
analysis of SA- β -gal positivity described in Figure B. Data are expressed as means SD, n = 3. Student t-test: *P 
< 0.05, **P < 0.01, ***P < 0.005. (D) Quantitative analysis of cells positive for γH2A.X. Data are presented as  
percentages of cells. (E) Immunoblot analysis of an inducible Cas9 resistant HDAC4 knock-out clone. Absence 
of tamoxifen removes HDAC4 in SK-LMS-1 cell line, thereby cells undergo senescence by activation of ɣH2A.X 
in response to DNA damage, cells in the presence of tamoxifen recover HDAC4 protein and start to proliferate. 
 
As the cells in the absence of HDAC4 undergo senescence, we decided to generate a knock-
out clone that can express an inducible Cas9-resistent HDAC4. By using CRISPR/Cas9 
technology, we have generated an inducible cas9 knockout clone of SKLMS1 that is HDAC4 
-/- in absence of tamoxifen and in the presence of tamoxifen induces HDAC4 protein thereby 
allowing cells to proliferate (clone 66). The re-expression of HDAC4 rescues the senescent 
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phenotype as the levels of Lamin B1 are recovered as well as the magnitude of DNA damage 
is reduced (γH2A.X) (Figure 21E).   
Adoption of a DNA damage sensor in in vivo microscopy 
Absence of HDAC4 in SK-LMS-1 triggered a DNA damage response. To investigate the onset 
of this response and the relationships with the cell cycle we engineered SK-LMS-1 cells in 
order to monitor in vivo the appearance of lesions in the DNA and the progression through the 
cell cycle. We transduced SK-LMS-1 HDAC4-/- cells that re-express HDAC4 in an inducible 
manner (clone 66) with H2B-GFP (to track mitosis) and apple-53BP1 truncated protein as a 
double strand breaks reporter (53BP1 localizes to sites of double-strand breaks).  
To validate these probes, we treated SK-LMS-1-WT with etoposide (10um) for 2 hours and 
then we performed an immunofluorescence assay using antibody against 53BP1. Cells treated 
with etoposide display accumulation of 53BP1 spots (Figure 22A). In our immunofluorescence 
analysis we have observed that some cells display bigger foci and some display small foci of 
53BP1. Hence, we quantified the immunofluorescence results. Cells not treated with DNA 
damaging agents were divided into two groups based on foci dimension as small and large, as 
previously noted (Julian Spies et al.,2019). Figure 22B shows accumulation of 53BP1 in small 
and larger spots which should represent sites of DNA damage. This result also indicates that 
SK-LMS-1 suffer of an endogenous amount of DNA damage. 
Since removal of HDAC4 in SK-LM-1 causes the progressive accumulation of DNA damage 
and activation of γH2A.X, we used SK-LMS-1 inducible clone 66 HDAC4-/- to investigate 
DNA damage response and mitosis in in vivo by time-lapse microscopy. For this purpose we 
retrovirally infected clone 66 KO HDAC4 with H2B-GFP and apple-53BP1 truncated probes 




Figure 22: Development of a single cell DNA damage reporter and a mitosis sensor (Apple-53BP1 truncated and 
H2B-GFP). (A) Immunofluorescence analysis of SK-LMS-1 cells untreated and treated with etoposide showing 
accumulation of 53BP1 in foci (indicated by arrow) sites of DNA damage. Nuclei of the cells were stained with 
Hoechst 33342 and 53BP1 is stained with secondary antibody conjugated to Alexa546. (B) Dot plot representation 
of SK-LMS-1 WT treated with etoposide showing accumulation of small and large foci of 53BP1 in each cell. An 
average of 270 cells were counted. (C) Sk-LMS-1/HDAC4-/- cells were retrovirally infected with H2B-GFP and 
apple-53BP1. Immunofluorescence was performed to see the positivity of cells for the probes in the presence of 




SK-LMS-1 HDAC4-/- cells accumulate a DNA damage response in a time frame 
HDAC4-/- clone 66 expressing H2B-GFP and apple 53BP1 was subjected to in vivo time-lapse 
microscopy. Figure 23E shows that cells in the presence of HDAC4 (+4OHT) spontaneously 
accumulate DNA damage, frequently in the G2 phase of the cell cycle. Although apple-P53BP1 
does not allow the monitoring of DNA lesions during mitosis, the two daughter cells emerging 
in G1 show lower number of DNA lesions. This result suggests that in the presence of HDAC4 
spontaneous DNA lesions in SK-LMS-1 cells are possibly resolved in G2. Frequently these 
cells enter two times in mitosis under the time of analysis (72 hours). Each arrow on the 
heatmap indicates the mitosis taken by the cell.  
The heatmaps measuring the accumulation of 53BP1 nuclear bodies clearly evidence an 
increase in the DNA lesions of in the absence of HDAC4 (-4OHT). Although peaks of lesions 
accumulate in G2 they also spread throughout the cell cycle. Under this increased amount of 
DNA damage cells rarely enter a second mitosis during the time of the analysis (Figure 23E). 
In summary the increase of the DNA damage seems to be an early response to the removal of 
HDAC4.  
Next we analyzed in more detail the relationships between mitosis, HDAC4 and DNA damage. 
Figure 23A shows that in the presence of HDAC4 nuclear bodies of P53BP1 are well resolved 
before entering mitosis and, with the exception of two cases the mitotic length is quite constant 
average length 127 + 39.34 minutes on average. Similar number were observed with the second 
mitosis (139.09+53.37minutes). When the activity of HDAC4 was abrogated by the removal 
of 4OHT, the number of P53BP1 nuclear bodies accumulating in late G2 increased and in 
parallel the duration of mitosis increased (166.67+65,55 minutes).  
We also analyzed the relationships between P53BP1 nuclear bodies and the emerging of the 
two daughters’ cells in early G1 (Figure 23B). Also in early G1 the absence of HDAC4 
provokes an overall increase in the number of P53BP1 nuclear bodies in the daughter cells. 
Next we performed another to time-lapse to confirm the difference in the mitosis length in a 
larger number of cells. Figure 23C demonstrate that in the absence of HDAC4 SK-LMS-1 cells 
spend a longer time in mitosis. Monitoring the nuclear morphology in vivo using the GFP-H2B 
we also observed that the presence of CCF (Chromatin Cytoplasmic Fragments), of nuclear 
cycoplasmic bridges and of aberrant mitosis are all increased in the absence of HDAC4 (Fig. 
23D).  
In summary these results suggest that HDAC4 prevents the accumulation of lesion in the DNA 











Figure 23: A serial in vivo time-lapse microscopic imaging of SK-LMS-1 HDAC4-/- ko clone66 expressing H2B 
GFP and apple 53BP1 trunc probes in the presence/absence of 4OHT. (A) A dot plot representing accumulation 
of 53BP1 nuclear bodies in late G2. In the presence of 4OHT cells accumulated very few nuclear bodies of 53BP1 
when compared with absence of 4OHT. (B) A dot plot representing in the presence of 4OHT mother cell 
accumulate 2-4 nuclear bodies of 53BP1 (on average), during two conservative mitosis eventually leading 
offspring’s (blue spots) to accumulate few nuclear bodies of 53BP1, while in the absence of 4OHT mother cell 
accumulated huge DNA damage response which negatively impacted on mitosis and showed single mitosis. In 
the absence of 4OHT both mother and daughter cell accumulated huge nuclear bodies 53BP1 nuclear bodies. (C) 
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Cells in the absence of 4OHT showed a delay in cell proliferation and took time to duplicate when compared with 
in the presence of 4OHT. (D) Mitotic defects in the absence of 4OHT, show accumulation of micronuclei, 
cytoplasmic bridge and unproductive mitosis. 
HDAC4 silencing by siRNA triggers senescence in different cell lines 
In order to further exclude the off targets of CRISPR/Cas9 technology, we used small 
interfering RNA (siRNA) technology to silence HDAC4 protein in several cellular models like 
BJ-hTERT/LT/RAS transformed cells and WM115 (metastatic melanoma).  
Silencing of HDAC4 in these cell lines triggers a mild induction of senescence as scored by 
means of percentage of β-gal positivity. Silenced cells similarly to knocked-out cells are 




Figure 24: Knockdown of HDAC4 in few cellular models. (A) Immunoblot analysis showing siRNA interference 
HDAC4 in BJ-hTERT LT/RAS resulted in induction of senescence by activating p53 and accumulating 
phosphorylation of γH2A.X. (B) Immunoblot analysis showing siRNA of HDAC4 in metastatic melanoma 
induced senescence by triggering p53 and γH2A.X and decreasing Lamin B1 levels.  
To summarize knock out of HDAC4 or siRNA of HDAC4 triggers a DNA damage response 
thereby allowing the cells to enter a state a permanent irreversible growth arrest. Our time lapse 
analysis showed that absence of HDAC4 in the SK-LMS-1 cell lines showed a mitotic defect 
with unrepairable DNA damage. This DNA damage response could be due to some epigenetic 








Normal human cells/murine cells in response to strong oncogenic signals enter into a state of 
irreversible cell cycle growth arrest called Oncogene Induced senescence (OIS) 
(Serrano et al 1997). Activation of OIS depends on tumor suppressor proteins like pRB/p53 
pathways and their response to DNA damage (Serrano et al 1997). The escape from senescence 
barrier seems to be required step for oncogenesis. The epigenetic resetting represents a novel 
hallmark in the transformation process (Bradner et al 2017). At each step of tumor progression, 
from initiation to evolution, epigenetic plasticity is necessary to fuel new waves of transcription 
(Koschmann et al 2017). Among the epigenetic regulators, class IIa HDACs represent novel 
promising druggable targets in consideration of the increasing number of evidences of their 
oncogenic properties. Here we described for the first time the capability of HDAC4 to drive 
oncogenic transformation in human cells. Differently from the transformation of murine cells, 
human fibroblasts require a step-by-step oncogenic conversion that allow the escape from 
apoptotic and pro-senescent stimuli. The over-expression of a nuclear mutant of HDAC4 
(HDAC4-TM) in primary fibroblasts triggers premature senescence earlier than RAS and WT 
form of HDAC4 showed no sign of senescence. Although the levels of p16 have been shown 
to be an important determinant for RAS-induced senescence (Benanti and Galloway et al 
2004), HDAC4-TM induced senescence is strongly dependent on p53. 
The senescence induced by HDAC4-TM is rapid with early signs of DNA damage and with 
the activation of p53. Depletion of p53 in cells expressing HDAC4-TM results in escape of 
senescence, and further mutations leads to malignant transformation. On contrary, inactivation 
of p53 in RAS induced senescence is frequently reported to be not sufficient to escape the cell-
cycle arrest (Di Micco et al 2006).  
Some senescence features of HDAC4-TM are commonly shared with AKT (Astle et al 2012). 
Presence of AKT in the normal cells triggers rapid cell cycle arrest similarly to HDAC4-TM 
but seems to not evoke a DNA damage response (Astle et al 2012), differently from RAS and 
HDAC4-TM  
The contemporary inactivation of p53 and p16/Rb pathways achieved by the transduction of 
the cells with SV40 LT allows the transformation of HDAC4-TM cells. HDAC4 expressing 
cells achieve full transformation in the presence of small T and Large T, probably because 
through the inhibition of PP2A phosphatase (Hahn et al 2002). In this condition also the WT 
form of HDAC4 displays oncogenic properties 
Transcriptomic analysis of  HDAC4-TM and RAS transformed evidenced that both the 
oncogenes require the repression of Interferon-related genes, as previously reported 
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(Battcock et al 2006; Christian et al 2009; Noser et al 2007). It was previously reported that 
some of the Interferon genes act as tumour suppressor during oncogenic transformation process 
(Tanaka N et al 1994). Later further studies confirmed that absence of Interferon genes 
mediates cellular transformation; for example, IRF-/- MEF cells expressing oncogenes like 
RAS were readily transformed but not MEF WT type . Another study revealed that ectopic 
expression of IRF-1 reduced tumorigenic properties of oncogene induced transformation and 
tumour cells in vitro and in vivo (Takaoka A et al 2008). Other pathways altered by HDAC4 
during transformation are mostly related adaptation to hypoxia, adhesion, motility and 
differentiation processes. Further investigations of these signalling pathways are required to 
prove the direct involvement of HDAC4 in their regulation. 
Next we have compared our signature with other two oncogenes like RAS and c-MYC which 
favour in vitro transformation in BJ-hTERT SV40 LT/ST. Differently from what reported by 
others, we found out that most of the tumorigenic properties driven by the three oncogenes 
relies on the activation of some common molecular pathways (like inhibition of interferon 
response) but not on the activation and repression of the same genes.  
By checking the commonly regulated genes, we found out that very few genes upregulated 
during in vitro transformation and these genes contribute to a worst survival rate in some 
cancers. On opposite most of the genes that are downregulated during in vitro transformation 
are Interferon and Inflammatory genes. Switching off the Interferon and the inflammatory 
responses provide a double advantage to the transformed cells, both in a cell autonomous and 
non-autonomous manner. Repression of Interferon genes favor the transformation process, by 
limiting tumor suppressive actions (such as apoptosis/escaping senescence), and it can 
influence the tumor microenvironment and the immune response. In some in vivo experiments 
on murine models of cancer have reported that, the initial step of tumorigenesis provides an 
strong inflammatory environment which promote cancers in later events. All our results justify 
the inclusion of HDAC4 in the group of two historically well-known oncogenes for being 
similarly able to repress IFN genes during the transformation process. 
Epigenetic dysregulation is a hallmark of senescence and aging. Recent studies in diverse 
species and cell types have highlighted the pervasiveness of age-associated changes in 
transcription factor binding, histone marks, heterochromatin formation, and DNA methylation 
(Benayoun et al 2015; Zampieri et al 2015) that contribute to changes in gene expression. 
Indeed, gene expression has been shown to change drastically during aging by reorganising 
chromatin structure (Baumgart et al 2014). In particularly we focused on one aspect of 
epigenetic regulation of HDAC4 which was not known for its role in oncogenesis and aging. 
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Expression of HDAC4-TM in BJ-hTERT induces senescence while knock out of HDAC4 / 
knock down of HDAC4 in low grade leiomyosarcoma triggers DNA damage, eventually 
leading to senescence.  The absence of HDAC4 in SK-LMS-1 triggers a DNA damage response 
and may recruit some chromatin modifiers like acetylation which could affect DNA repair. 
This suggests that an accumulation of DNA damage and loss of HDAC4 repression may 
underlie age-associated epigenomic changes. Further studies are required to answer, the link 
between HDAC4 and DNA damage. The fruitful strategies could be developing a specific 
inhibitors or block HDAC function in combination with other standard treatments, like 
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Expression of the class IIa HDACs is frequently altered in different human
cancers. In mouse models these transcriptional repressors can trigger trans-
formation, acting as bona fide oncogenes. Whether class IIa HDACs also
exhibit transforming activities in human cells is currently unknown. We
infected primary human fibroblasts with retroviruses to investigate the
transforming activity of HDAC4 in cooperation with well-known onco-
genes. We have discovered that HDAC4 triple mutant (S246A, S467A,
S632A) (HDAC4-TM), a nuclear resident version of the deacetylase, trig-
gers TP53 stabilization and OIS (oncogene-induced senescence). Unlike
RAS, HDAC4-induced OIS was TP53-dependent and characterized by
rapid cell cycle arrest and accumulation of an unusual pattern of cH2AX-
positive foci. The inactivation of both TP53 and of the retinoblastoma
(pRb) tumor suppressors, as induced by the viral oncogenes large and
small T of SV40, triggers anchorage-independent growth in RAS, HDAC4-
TM and, to a lesser extent, in HDAC4-wild type (WT)-expressing cells.
Our results suggest an oncogenic function of class IIa HDACs in human
cells, and justify further efforts to discover and evaluate isoform-specific
inhibitors of these epigenetic regulators from a therapeutic perspective.
1. Introduction
The remodeling of transcriptional programs is a key
aspect of tumorigenic processes (Bradner et al., 2017).
Oncogenes and tumor suppressor genes can influence
transcription directly by acting as transcription factors
(TFs) or indirectly by supervising signaling pathways that
control the transcriptional machinery (Bradner et al.,
2017). Transcriptional remodeling requires epigenetic
changes and the involvement of chromatin modifiers
(Brien et al., 2016; Yang et al., 2012). Epigenetic plastic-
ity is emerging as an important hallmark of cancer. At
each step of tumor progression, from initiation to evolu-
tion, epigenetic plasticity is necessary to fuel new waves of
transcription (Koschmann et al., 2017).
Histone modifications contribute to chromatin
remodeling and to the epigenetic signature. Dysfunc-
tions in enzymes controlling these post-transcriptional
Abbreviations
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Dulbecco’s modified Eagle’s medium; DN, dominant negative; EMEM, Earle’s salts minimal essential medium; ENG, engrailed; ER,
estrogen receptor alpha; GSEA, gene set enrichment analysis; HDAC4-TM, HDAC4 triple mutant (S246A, S467A, S632A); HDAC, histone
deacetylase; HPRT, hypoxanthine phosphoribosyltransferase 1; IFN, interferon; LT, large T antigen; MEF2, myocyte enhancer factor; MTT, 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; myr-AKT1, myristoylated AKT1; OIS, oncogene-induced senescence; pRb,
retinoblastoma protein; PTM, post-transcriptional modification; SASP, senescence-associated secretory phenotype; ST, small T antigen;
TERT, telomerase catalytic subunit; TF, transcription factor; WT, wild type.
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modifications (PTMs) can affect the tumorigenic pro-
cess (Cheng et al., 2017a,b; Montero-Conde et al.,
2017). Both pro-tumorigenic and tumor-suppressive
activities have been reported for some epigenetic regu-
lators, which reflects the importance of the specific cel-
lular context (Beira et al., 2018; Chen et al., 2018;
Koschmann et al., 2017; Wang et al., 2017).
In addition to alterations in epigenetic regulators,
mutations in histones can trigger the tumorigenic pro-
cess. Oncogenic mutations in H3.3 genes encoding
K27M and G34R/V have been characterized in pedi-
atric high-grade gliomas (Fontebasso et al., 2014;
Khuong-Quang et al., 2012; Schwartzentruber et al.,
2012; Taylor et al., 2014).
Histone deacetylases (HDACs) are important erasers
of epigenetic marks. HDAC can be subdivided into five
subclasses (I, IIa, IIb, III and IV). Class IIa includes
four members (HDAC4/5/7/9) characterized by a
poor deacetylase activity, phosphorylation-dependent
nuclear/cytoplasmic shuttling and an extended amino-
terminal region devoted to TFs and co-repressor bind-
ing (Martin et al., 2007). The C-terminal deacetylase
domain is required to interact with the SMRT/N-CoR/
HDAC3 complex, which confers the KDAC activity
(Lahm et al., 2007). Important partners of class IIa
HDACs are members of the MEF2 (myocyte enhancer
factors) family of TFs (Clocchiatti et al., 2013a,b; Di
Giorgio and Brancolini, 2016). There is evidence from
several reports of the altered expression of class IIa in
human cancer (Barneda-Zahonero and Parra, 2012;
Clocchiatti et al., 2011). Furthermore, in vitro and
in vivo studies have proved the oncogenic role of
HDAC4 (Di Giorgio et al., 2013; Peruzzo et al., 2016),
HDAC7 (Di Giorgio et al., 2013; Lei et al., 2017; Rad
et al., 2010) and HDAC9 (Gil et al., 2016) in different
murine models. Since human cells behave differently
from rodent cells and, in general, require more genetic
alterations to acquire a neoplastic phenotype (Boehm
et al., 2005), whether these deacetylases can transform
human cells is currently unknown.
In vitro oncogenic transformation of normal cells
represents an invaluable model to prove tumor-
suppressive or oncogenic functions of a specific gene
(Funes et al., 2014). The robustness of the assay is cor-
roborated by the correlation between the in vitro trans-
forming activities of the tested genes and their
implications in human cancers (Boehm and Hahn,
2005; Boehm et al., 2005; Maya-Mendoza et al., 2015;
Seger et al., 2002). Moreover, these in vitro generated
transformed cells can provide alternatives to costly
mouse models, as well as genetically defined environ-
ments for testing anticancer therapies (Balani et al.,
2017). In this manuscript we investigated the ability of
HDAC4 to cooperate with well-known oncogenes to
transform human fibroblasts.
2. Materials and methods
2.1. Cell cultures and reagents
The BJ/TERT cells were cultured in Earle’s salts minimal
essential medium (EMEM) (Euroclone, Milan, Italy)
completed with nonessential amino acids (HyClone, Lit-
tle Chalfont, UK). Media were supplemented with 10%
FBS, L-glutamine (2 mM), penicillin (100 UmL1), and
streptomycin (100 lgmL1) (Lonza, Basel, Switzerland).
Cells expressing the inducible form of the transgenes
were grown in medium without phenol red. For S-phase
analysis, cells were grown for 3 h with 50 lM bromod-
eoxyuridine (BrdU, Sigma). Mouse anti-BrdU (Sigma,
St. Louis, MO, USA) was used as the primary antibody
in the immunofluorescent assays. Nuclei were stained
with Hoechst 33258 (Sigma).
2.2. Invasion and soft agar assays
For invasion assay, each well of the invasion chamber
(CLS3428, Corning, New York, NY, USA) was coated
with 200 lL of Matrigel matrix coating solution (Cul-
trex, Trevigen, Gaithersburg, MD USA). Next, a cell
suspension of 30 000 cells in 0.1% FBS-Dulbecco’s
modified Eagle’s medium (DMEM) was added. As
chemoattractant, 20% FBS-DMEM was added in each
lower chamber. As a control, 0.1% FBS-DMEM was
used to evaluate random invasion. For soft agar
assays, equal volumes of 1.2% agar and DMEM were
mixed to generate 0.6% base agar. A total of
0.8 9 105 cells were seeded in 0.3% top agar, followed
by incubation at 37 °C in humidified conditions. The
cells were grown for 21 days and visualized by MTT
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide] staining. Images were taken with a DN6000 Leica
microscope that allows the the number and the diameter
of the foci to be counted.
2.3. Plasmid construction, transfections,
retroviral infections
The pWZL/HDAC4-WT and mutants, pWZL-Neo/
E1A (1–143) and pBABE-Puro/myristoylated AKT1
(myr-AKT1)-expressing plasmids were previously
described (Astle et al., 2012; Deng et al., 2005; Di Gior-
gio et al., 2013). pCW-Puro/HDAC4 and H-RAS/
G12V plasmids were obtained by subcloning with a
PCR method, HDAC4 and H-RAS/G12V into the all-
in-one DOX-inducible pCW-Cas9 plasmid (#50661
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Addgene, Cambridge MA, USA). pMXPIE-Puro
HDAC4-WT/TM, H-RAS/G12V were obtained by sub-
cloning with a PCR method the ORF into the 4
hydroxy-tamoxifen (4-OHT)- inducible pMXPIE plas-
mid (Toledo et al., 2008). The plasmids used to silence
MEF2D and plasmids encoding for MEF2D-FLAG
and MEF2-Engrailed FLAG (MEF2-ENG) were previ-
ously described (Di Giorgio et al., 2015, 2017). For len-
tivirus-based knock-down, HEK-293T cells were
transfected with 1.8 lg of VSV-G, 5 lg of D8.9 and
8 lg of pLKO plasmids. After 36 h at 37 °C, virions
were collected and opportunely diluted in fresh medium.
Retroviral infections were performed as previously
described (Di Giorgio et al., 2017).
2.4. RNA extraction and quantitative qRT-PCR
Cells were lysed using Tri-Reagent (Molecular
Research Center, Cincinnati, OH USA). A total of
1 lg of total RNA was retrotranscribed using 100 U
of Moloney murine leukemia virus reverse transcrip-
tase (Invitrogen, Carlsbad, CA, USA). qRT-PCR anal-
yses were performed using Bio-Rad CFX96 and SYBR
green technology (Resnova, Roma, Italy). The data
were analyzed by a comparative threshold cycle using
the b2 microglobulin gene and hypoxanthine phospho-
ribosyltransferase 1 (HPRT) as normalizer genes. All
reactions were done in triplicate.
2.5. Antibodies
Antibodies used were against MEF2D (BD Bio-
science), H3K27ac (ab4729; Abcam, Cambridge, MA,
USA). H3K27me3 (ab195477, Abcam) HDAC4 (Par-
oni et al., 2004), cH2AX (9718, Cell Signalling, Lei-
den, The Netherlands), TP53 (DO-7; Dako, Santa
Clara, CA, USA), LT SV40 (sc-147, Santa Cruz),
Lamin B1 (ab16048, Abcam), p21 (CP74, Sigma),
RACK1 (sc-17754, Santa Cruz, Dallas, TX, USA),
GFP (Paroni et al., 2004).
2.6. Immunofluorescence and immunoblotting
Immunofluorescence and immunoblotting were per-
formed as previously described (Di Giorgio et al.,
2017). Briefly, cells were fixed with 3% paraformalde-
hyde and permeabilized with 0.1% Triton X-100. Sec-
ondary antibodies were conjugated to Alexa Fluor 488,
546 and 633 (Molecular Probes, Eugene, OR, USA).
Cells were imaged with a Leica confocal microscopy
(LSM) SP2 and SP8. After SDS/PAGE and
immunoblotting, cell lysates were incubated with pri-
mary antibodies. HPR-conjugated secondary antibodies
were from Sigma-Aldrich and blots were developed with
Super Signal West Dura (ThermoFisher Scientific,
Waltham, MA, USA).
2.7. SA-b-gal assay
For SA-b-gal assay, cells were fixed in a solution of 2%
formaldehyde/0.2% glutaraldehyde and stained with
staining solution: 40 mM citric acid/Na phosphate buf-
fer, 5 mM K4[Fe(CN)6]3H2O, 5 mM K3[Fe(CN)6],
150 mM sodium chloride, 2 mM magnesium chloride
and 1 mgmL1 X-gal (Debacq-Chainiaux et al., 2009).
Staining was performed for 16 h at 37 °C and cells were
imaged under bright-field microscope (Leica). To quan-
tify SA-b-gal activity, the percentage of positively
stained blue cells versus total cells were counted (300–
400 cells in total were counted per each round).
2.8. Matrigel plug assay
A total of 1600 cells were suspended in a Matrigel solu-
tion (20 lL 0.1% FBS-EMEM, 60 lL Matrigel) and
plated on coverslips in 35-mm tissue culture plates.
After 30 min of incubation at 37 °C, cells were fed with
EMEM–20% FBS. Following a 4-day incubation,
coverslips were fixed and processed for fluorescence
analysis.
2.9. Transcriptome profiling and data analysis
Total RNA was isolated using Direct-zol RNA mini prep
(Zymo Research). Preparation and hybridization of
cRNA samples were performed at Cogentech (Milan,
Italy, https://www.cogentech.it/). Labeled cRNAs were
hybridized on Affymetrix GeneChip Human Clariom S
arrays. Differentially expressed genes (DEGs) were
selected based on 1.5 cut-off in the fold changes. Analysis
was performed as previously described (Di Giorgio et al.,
2013; Picco et al., 2014). Gene set enrichment analysis
(GSEA) (Subramanian et al., 2005) and the MSigDB
database (http://software.broadinstitute.org/gsea/index.
jsp) (Liberzon et al., 2015) were used to investigate statis-
tical association between genes modulated by HDAC4-
TM or RAS and genes perturbed by other conditions.
2.10. Statistics
For experimental data, a Student t-test was used. A
P-value of 0.05 was chosen as the statistical limit of
significance. Unless otherwise indicated, data in the fig-
ures are arithmetic means and standard deviations
from at least three independent experiments: *P < 0.05,
**P < 0.01, ***P < 0.005.
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3. Results
3.1. Nuclear resident HDAC4 induces senescence
in human fibroblasts (BJ-TERT)
To explore the contribution of HDAC4 to the transfor-
mation process we used skin-derived BJ fibroblasts,
immortalized with the telomerase catalytic subunit
(TERT). Since HDAC4 is subjected to intense nuclear
export following phosphorylation-mediated 14-3-3
binding, we took advantage from a Ser/Ala mutated
version in the three 14-3-3 binding sites (HDAC4-TM).
This mutant exhibits stronger repressive activity and is
sufficient to transform NIH-3T3 murine fibroblasts (Di
Giorgio et al., 2013). Additional HDAC4 mutants
tested were a nuclear resident form lacking the MEF2-
binding site (HDAC4-TMDMEF2) and a mutant in the
nuclear export sequence (HDAC4-L1062A), which simi-
larly to the TM, accumulate in the nucleus (Fig. 1A) (Di
Giorgio et al., 2013).
All HDAC4 versions were expressed in BJ-TERT
fibroblasts after retroviral infections. We also used
well-known oncogenes such as RAS (H-RAS-G12V)
and AKT1 (myr-AKT1), for comparison. Expression
of the different transgenes was verified by immunoblot
(Fig. 1B).
Non-transformed human fibroblasts respond to the
introduction of oncogenes by activating OIS (Astle
et al., 2012; Kennedy et al., 2011; Serrano et al.,
1997). Hence, we evaluated the presence of cells posi-
tive for SA-b-galactosidase activity (Fig. 1C). After
selection, few cells were recovered when nuclear local-
ized forms of HDAC4 were expressed. The few cells
expressing HDAC4-TM were positive on SA-b-gal
staining, with a score comparable to RAS and AKT1
(Fig. 1D). Cells expressing two nuclear mutants of
HDAC4 such as L1062A (Paroni et al., 2004) and
TMDMEF2 (Di Giorgio et al., 2013) were only moder-
ately positive on SA-b-gal staining (Fig. 1D). Both
mutants accumulate into the nucleus with a rate com-
parable to HDAC4-TM but are less strongly bound to
chromatin (Paroni et al., 2007). SA-b-gal positivity
was not relevant in cells expressing HDAC4-WT
(which is largely cytoplasmic in BJ/TERT cells) or the
negative control GFP (Fig. 1D).
To characterize the massive induction of senescence, we
generated an estrogen receptor alpha (ER)-inducible ver-
sion of HDAC4-TM, HDAC4-WT and H-RAS/G12V.
HDAC4-TM was expressed less compared with the
wild type (Fig. 1E), possibly because of the protea-
some-dependent nuclear degradation of HDAC4 (Cer-
notta et al., 2011). Next, we analyzed cell proliferation
2 or 8 days after transgene induction (Fig. 1F).
HDAC4-TM triggered a rapid block in DNA synthesis.
By contrast, RAS initially enhanced cell proliferation;
only after 8 days of induction DNA synthesis was
blocked. When the presence of SA-b-gal-positive cells
was investigated, only the induction of HDAC4-TM
and RAS stimulated SA-b-gal activity (illustrated in
Fig. 1G and quantified in Fig. 1H). Finally, to corrob-
orate these data and to exclude a contribution of
tamoxifen to the process of senescence, we used a sec-
ond inducible system. The different transgenes were
efficiently induced by the doxycycline-inducible system
(Fig. 1I). The SA-b-gal staining confirmed that the
induction of HDAC4-TM triggers senescence with
rates comparable to RAS and AKT1 (Fig. 1J). In sum-
mary, nuclear resident HDAC4 can trigger senescence
in immortalized human fibroblasts. In contrast to
RAS, an early proliferative block characterizes
HDAC4-TM-induced senescence.
3.2. DNA damage in HDAC4-TM-induced
senescence
OIS in RAS-overexpressing cells is triggered by the
accumulation of unrepaired damaged DNA caused by
unscheduled DNA synthesis (Di Micco et al., 2006).
Fig. 1. The HDAC4 expression in human fibroblasts. (A) Schematic representation of the different HDAC4 versions used in this study.
Phosphorylated serine residues, binding sites for 14-3-3 proteins are indicated. (B) Immunoblot analysis using the indicated antibodies in BJ/
TERT expressing the indicated transgenes. Vimentin was used as loading control. (C) Normal human diploid fibroblasts (BJ) expressing the
telomerase catalytic subunit (TERT) infected with retrovirus expressing the indicated genes and stained for senescence-associated
b-galactosidase (SA-b-gal) marker. Scale bar: 50 lm. (D) Quantitative analysis of SA-b-gal positivity from experiments described in (C). Data
are expressed as means  SD, n = 3. Student t-test: *P < 0.05, ***P < 0.005. (E) Immunoblot analysis using the indicated antibodies in BJ/
TERT expressing the indicated transgenes following treatment with 4-OHT for 48 h. RACK1 was used as loading control. (F) Analysis of
cells synthesizing DNA, as scored after BrdU staining at the indicated times. Data are expressed as means  SD, n = 4. Student t-test:
**P < 0.01, ***P < 0.005. (G) BJ-TERT expressing the indicated transgenes after 8 days of induction were stained for SA-b-gal activity.
Scale bar: 50 lm. (H) Quantitative analysis of SA-b-gal positivity from experiments described in (G). Data are expressed as means  SD,
n = 4. ***P < 0.005. (I) Immunoblot analysis using the indicated antibodies in BJ/TERT expressing the indicated transgenes following
treatment with doxycycline for 48 h. Vimentin was used as loading control. (J) Quantitative analysis of SA-b-gal positivity in BJ-TERT cells
expressing doxycycline-inducible versions of the indicated transgenes after 8 days of induction. Data are expressed as means  SD, n = 3.
Student t-test: *P < 0.05, **P < 0.01, ***P < 0.005.
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Hence, we compared by time course the kinetics of
accumulation of cH2AX-positive cells in cells
expressing HDAC4-TM/ER, HDAC4-WT/ER and
H-RAS-G12V/ER. As early as 2 days after transgene
induction, HDAC4-TM-expressing cells showed an
accumulation of DNA damage (Fig. 2A). In contrast,
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in RAS-expressing cells, DNA damage became consis-
tent only after 8 days of induction with tamoxifen
(Fig. 2B). A few cH2AX-positive cells were also
observed in the case of HDAC4-WT (Fig. 2B). When
immunofluorescence was analyzed in more detail, two
phenotypes appeared evident: (a) nuclei in TM- and
RAS-expressing cells were larger than in control and
HDAC4-WT cells; (b) nuclei of TM cells showed fewer
but bigger cH2AX-positive foci than did RAS cells
(Fig. 2C). Quantitative analysis confirmed this obser-
vation (Fig. 2D,E).
Next, we evaluated the epigenetic modifications
induced by the different transgenes. The global levels
of histone H3 lysine 27 acetylation (H3K27ac), a mar-
ker of open and transcriptional active chromatin, and
of H3K27me3, a marker of facultative heterochro-
matin, were evaluated after 2 and 8 days of transgene
induction. We also evaluated the levels of Lamin B1,
which is down-regulated during senescence (Freund
et al., 2012). Whereas H3K27ac and Lamin B1 showed
a similar behavior in TM and RAS cells, with a dra-
matic decrease at day 8 (Fig. 2F), the pattern of
H3K27me3 was different between the two senescence
responses. Only in RAS cells did a transient reduction
occur at day 2, as recently observed (Ito et al., 2018).
Senescent cells produce and release a range of
cytokines, chemokines and proteases in the extracellu-
lar environment: the senescence-associated secretory
phenotype (SASP) (Coppe et al., 2008). Hence, we
compared the kinetics of appearance of senescence and
SASP after HDAC4-TM or RAS induction by analyz-
ing the expression levels of SASP components (IL1B,
IL8 and CSF2) and those of the CDK inhibitors
CDKN1A and CDKN2A, key regulators of the senes-
cent response. QRT-PCR analysis proved that
HDAC4-TM anticipated the appearance of senescence
with respect to RAS (Fig. 2G) in terms of SASP and
CDKN2A induction. In RAS-expressing cells this
response was only evident after 8 days of induction.
3.3. HDAC4-induced senescence depends on TP53
activation
The induction of DNA damage in TM-expressing cells
prompted us to investigate the contribution of TP53.
Immunoblot analysis performed after 8 days of trans-
gene induction demonstrated a strong up-regulation of
TP53 levels in TM cells (Fig. 3A). To investigate the
contribution of TP53 in TM-induced senescence, we
generated BJ-TERT cells expressing TP53 mutant
R175H (Fig. 3B). This mutant is frequently found in
human cancers and acts as a dominant negative
(TP53DN) (Gualberto et al., 1998). The DN effect was
shown on the TP53-target genes DEC1 and GADD45A
(Fig. 3C). Subsequently, we generated BJ-TERT/TP53
cells expressing HDAC4-TM, RAS or GFP as control.
Immunoblot analysis confirmed the expression of the
different transgenes and showed that Lamin B1 was
not down-regulated in TM cells, thus suggesting the
escape from senescence (Fig. 3D). SA-b-gal activity
(Fig. 3E) and the relative quantitative analysis
(Fig. 3F) confirmed the failure of TM in triggering
senescence, once the TP53 response was blunted. In
contrast, in RAS-expressing cells, suppression of TP53
activities was not sufficient to block the occurrence of
senescence (Fig. 3E,F), as previously observed (Ser-
rano et al., 1997).
These experiments demonstrate that HDAC4-TM
triggers senescence, which is markedly different from
RAS, since it is characterized by: (a) an early prolifera-
tive block, (b) an early and peculiar induction of DNA
damage and (c) a strong TP53-dependency.
3.4. Down-regulation of MEF2 transcription is
sufficient to promote senescence
HDAC4 can interact with several proteins, among
which MEF2 TFs represent important partners (Cloc-
chiatti et al., 2013a). Since HDAC4-TM deleted in the
Fig. 2. HDAC4-induced senescence is characterized by DNA damage. (A) Quantitative analysis of the immunofluorescence staining for
cH2AX after 2 days of induction of the indicated transgenes in BJ-TERT cells. Data are expressed as means  SD, n = 4. Student t-test:
*P < 0.05, **P < 0.01, ***P < 0.005. (B) Quantitative analysis of the immunofluorescence staining for cH2AX after 8 days of induction of
the indicated transgenes in BJ-TERT cells. Data are expressed as means  SD, n = 4. Student t-test: **P < 0.01, ***P < 0.005. (C)
Immunofluorescence picture of cH2AX positivity after 8 days of induction of the indicated transgenes. Nuclei were stained with Hoechst
33342. Scale bar: 5 lm. (D) Quantitative analysis of nuclear dimension in BJ-TERT cells following 8 days of induction of the different
transgenes. Measures were obtained with IMAGEJ. At least 50 nuclei were scored for each condition. The means and the 1st and 3rd quartiles
are indicated. *P < 0.05, ***P < 0.005. (E) Percentage of cH2AX-positive cells with the indicated numbers of cH2AX foci in the nuclei of BJ-
TERT cells, after 8 days of expression of the indicated transgenes. (F) Immunoblot analysis using the indicated antibodies in BJ-TERT cells
expressing the different transgenes for 2 or 8 days. Actin was used as loading control. (G) mRNA expression levels of the indicated genes,
as measured by qRT-PCR in BJ/TERT cells expressing the different transgenes following treatment for the indicated days with 4-OHT. Data
are expressed as means  SD, n = 3. Student t-test: *P < 0.05, **P < 0.01.
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MEF2-binding region triggers senescence less potently
compared with HDAC4-TM (Fig. 1C), we hypothesized
that the induction of senescence could be partially due
to the repression of these TFs. To clarify this point, we
generated BJ-TERT cells expressing MEF2-ENG, a
repressive version of these TFs in which the C-terminal
MEF2 activation domain is substituted by the Engrailed
repressor domain (Arnold et al., 2007). Cells overex-
pressing MEF2D or HYGRO were used as controls
(Fig. 4A). Appearance of senescence was clearly
observed in BJ-TERT-MEF2/ENG cells but not in the
controls (Fig. 4B). To alternatively down-regulate the
expression of MEF2-target genes, we silenced the expres-
sion of MEF2D using a shRNA (Fig. 4C). MEF2D
downregulation triggered a senescence response, charac-
terized by a strong impairment in S-phase entry
(Fig. 4D) and the accumulation of SA-b-gal-positive
cells (Fig. 4E and quantitative analysis in Fig. 4F).
Finally, similarly to HDAC4-TM, senescence in
response to MEF2 transcriptional repression is TP53-
dependent. BJ-TERT-TP53DN cells expressing RAS
entered into senescence, whereas SA-b-gal-positive cells
were not detected when MEF2-ENG was introduced
(Fig. 4G and quantitative analysis in Fig. 4H).
3.5. HDAC4-mediated repression cooperates with
SV40-LT in transforming human fibroblasts
To prove that BJ/TERT cells expressing the nuclear
version of HDAC4 enter senescence as part of a pro-
tective response against an oncogenic dysfunction, it is
imperative to prove that HDAC4 provides some trans-
forming properties. Since anchorage-independent
growth is a clear marker of cellular transformation, we
initially decided to monitor this feature in BJ/TERT/
TP53DN/HDAC4-TM cells that escape senescence.
We also analyzed the effect of the overexpression of
HDAC4-WT, MEF2-ENG and RAS.
Expression of the different transgenes was verified by
immunoblot (Fig. 5A) and soft agar assays were per-
formed to evaluate the anchorage-independent growth.
In none of the engineered cell lines was growth in soft
agar detectable (Fig. 5B). This result indicates that
HDAC4-TM- or MEF2-mediated gene repression can-
not sustain anchorage-independent growth once senes-
cence is suppressed by TP53 mutations.
The SV40 large T antigen (LT) can inactivate two
major tumor suppressor genes, p53 and retinoblastoma
protein (pRb) (Hahn et al., 2002). In several
Fig. 3. The HDAC4-induced senescence is characterized by TP53 activation. (A) TP53 levels in BJ-TERT cells expressing the indicated
transgenes for 8 days. RACK1 was used as loading control. (B) Immunoblot analysis proving the generation of BJ-TERT cells expressing the
DN TP53. Actin was used as loading control. (C) qRT-PCR analysis evaluating the expression of two TP53 target genes in the different BJ-
TERT cell lines as indicated. mRNA levels are relative to BJ-TERT/HYGRO cells. Data are expressed as means  SD, n = 3. **P < 0.01. (D)
Immunoblot analysis evaluating the levels of indicated proteins in BJ-TERT cells after 8 days of 4-OHT treatment. The HDAC4-TM is
expressed as fusion with GFP. Actin was used as loading control. (E) BJ-TERT/TP53DN expressing the indicated transgenes and stained for
SA-b-gal activity. Scale bar: 50 lm. (F) Quantitative analysis of SA-b-gal positivity from experiments described in (F). Data are expressed as
means  SD, n = 4. **P < 0.01.
2172 Molecular Oncology 12 (2018) 2165–2181 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Class IIa HDACs and human cell transformation H. Paluvai et al.
experiments LT has proved to cooperate in the trans-
formation of human cells (Hahn et al., 1999). Hence,
we generated BJ-TERT/LT cells (Fig. 5C) to evaluate
oncogenic cooperation with HDAC4-TM, HDAC4-
WT and RAS as a control (Fig. 5D). In contrast to
TP53DN, LT expression suppressed OIS by RAS
(Fig. 5E and quantitative analysis in Fig. 5F). Growth
in soft agar was performed and the appearance of foci
was scored 21 days later. We also evaluated the size
distribution of the colonies (Fig. 5G) using already
published criteria (Cifone and Fidler, 1980). Small
colonies with a 50-lm diameter or less were frequently
observed in RAS- and HDAC4-TM-expressing cells
(Fig. 5H). Rarely, larger colonies with a diameter of
100–150 lm were present. Interestingly, foci of small
dimensions were also observed when TERT/LT/
HDAC4-WT were co-expressed. Analysis of the trans-
formation efficiency confirmed that HDAC4-TM and
RAS showed comparable activities. A much weaker
transforming effect was observed for HDAC4-WT
(Fig. 5I).
To confirm the induction of a transformed pheno-
type we evaluated random motility and invasiveness
using the Matrigel invasion assay. Figure 5J shows
that only HDAC4-TM enhanced random cell motility
but both RAS and HDAC4-TM strongly promoted
invasiveness in TERT/LT human cells (Fig. 5K).
To have a full transformation of human fibroblasts,
both the LT and the SV40 small T antigen (ST) must
be co-expressed with TERT and RAS (Hahn et al.,
Fig. 4. Myocyte enhancer factor transcriptional activity counteracts senescence. (A) Immunoblot analysis evaluating the levels of the
indicated proteins in BJ-TERT cells. MEF2D and MEF2-ENG contain a Flag epitope. Actin was used as loading control. (B) Quantitative
analysis of SA-b-gal positivity in BJ-TERT cells expressing the indicated transgenes. (C) Immunoblot analysis of MEF2D, HDAC4 and
CDKN1A levels in BJ-TERT cells expressing the control shRNA or a shRNA against MEF2D. shRNA was delivered by lentiviral infection.
Actin was used as loading control. (D) Analysis of DNA synthesis, as scored after BrdU staining in BJ-TERT cells expressing the two
shRNA. Data are expressed as means  SD, n = 3. *P < 0.05. (E) BJ-TERT expressing the indicated shRNA were stained for SA-b-gal
activity. Scale bar: 50 lm. (F) Quantitative analysis of SA-b-gal positivity from experiments described in (E). Data are expressed as means 
SD, n = 4. **P < 0.01. (G) BJ-TERT/TP53 expressing the indicated transgene were stained for SA-b-gal activity. Scale bar: 50 lm. (H)
Quantitative analysis of SA-b-gal positivity from experiments described in (G). Data are expressed as means  SD, n = 4. ***P < 0.005.
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Fig. 5. The HDAC4-TM cooperates with SV40 LT in sustaining a transformed phenotype. (A) Immunoblot analysis of indicated proteins as
expressed in BJ-TERT/TP53DN cells infected with retrovirus encoding the indicated genes. HDAC4 was expressed as fusion with GFP and
the recombinant proteins detected with an anti-GFP antibody. Actin was used as loading control. (B) Growth in soft agar of the BJ-TERT/
TP53 cells expressing the indicated transgene. After staining with MTT, foci with diameter > 50 lm were counted. Data are expressed as
means  SD, n = 3. Student t-test: *P < 0.05, **P < 0.01, ***P < 0.005. (C) Immunoblot analysis of indicated proteins as expressed in BJ-
TERT cells infected with retrovirus encoding the indicated genes. Actin was used as loading control. (D) Immunoblot analysis of indicated
proteins as expressed in BJ-TERT/LT cells infected with retrovirus encoding the indicated genes. HDAC4 was expressed as fusion with GFP
and the recombinant proteins detected with an anti-GFP antibody Actin was used as loading control. (E) BJ-TERT/LT cells expressing the
indicated transgenes were stained for SA-b-gal activity. Scale bar: 50 lm. (F) Quantitative analysis of SA-b-gal positivity from experiments
described in (E). Data are expressed as means  SD, n = 3. Student t-test: *P < 0.05, **P < 0.01, ***P < 0.005. (G) Representative images
of MMT positive soft agar foci of BJ-TERT/LT cells expressing HDAC4-TM or RAS. Scale bars are indicated. (H) Quantitative analysis of soft
agar foci of BJ-TERT/LT cells expressing the indicated transgenes grouped for foci dimensions related to (G). Data are expressed as
means  SD, n = 4. Student t-test: *P < 0.05, **P < 0.01, ***P < 0.005. (I) Soft agar transformation efficiency represents the total number
of foci generated by BJ-TERT/LT cells expressing the indicated transgenes, divided by the total number of seeded cells. Data are expressed
as means  SD, n = 4. ***P < 0.005. (J) Motility properties of BJ-TERT/LT cells expressing RAS, HDAC4-TM or HYGRO as control. Data
are expressed as means  SD, n = 3. ***P < 0.005. (K) Invasive properties, as measured by Matrigel invasion assay of BJ-TERT/LT cells
expressing RAS, HDAC4-TM or Hygro as control. Data are expressed as means  SD, n = 3. *P < 0.05, ***P < 0.005.
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Fig. 6. The HDAC4-TM cooperates with SV40 LT in sustaining a transformed phenotype. (A) Immunoblot analysis of indicated proteins as
expressed in BJ-TERT/LT/ST cells infected with retrovirus encoding the indicated genes. HDAC4 was expressed as fusion with GFP and the
recombinant proteins detected with an anti-GFP antibody. Actin was used as loading control. (B) Representative images of MMT-positive
soft agar foci of BJ-TERT/LT/ST cells expressing HDAC4-TM or RAS. Scale bars are indicated. (C) Quantitative analysis of soft agar foci of
BJ-TERT/LT/ST cells expressing the indicated transgenes grouped for foci dimensions related to Fig. 6B. Data are expressed as
means  SD, n = 4. Student t-test: *P < 0.05, **P < 0.01, ***P < 0.005. (D) Soft agar transformation efficiency represents the total
number of foci generated by BJ-TERT/LT/ST cells expressing the indicated transgenes divided by the total number of seeded cells. Data are
expressed as means  SD, n = 4. **P < 0.01, ***P < 0.005. (E) Percentage of invasive soft agar foci. Foci were scored for the presence of
cells showing extensive growth in the surrounding agar. The means and the 1st and 3rd quartiles are indicated. n = 19 (HDAC4-TM) and
n = 15 (RAS). ***P < 0.005. (F) Motility properties of BJ-TERT/LT/ST cells expressing RAS, HDAC4-TM or Hygro as control. Data are
expressed as means  SD, n = 3. Student t-test: **P < 0.01. (G) Invasive properties, as measured by Matrigel invasion assay of BJ-TERT/
LT/ST cells expressing RAS, HDAC4-TM or Hygro as control. Data are expressed as means  SD, n = 3. **P < 0.01. (H) Confocal images
representing the equatorial section of BJ-TERT/LT/ST cells expressing RAS or HDAC4-TM grown in Matrigel plugs. Nuclei were visualized
using Hoechst 33342 and actin filaments with phalloidin-Alexa 546.
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2002). Hence, we generated human fibroblasts express-
ing the combination of TERT/LT/ST together with
HDAC4-WT, HDAC4-TM or RAS as a positive con-
trol of transformation. Immunoblot analysis verified
the expression of the different transgenes (Fig. 6A).
Next, soft agar assay was performed and after
21 days, colonies were stained with MTT and foci
were counted and grouped for dimensions as exempli-
fied (Fig. 6B). Quantitative analysis proved that the
expression of the ST increased the number of foci and
particularly their dimensions (Fig. 6C) as well as the
transformation efficiency (compare Fig. 6D with
Fig. 5I). Interestingly, cells expressing HDAC4-TM
frequently show extensive invasion and some branch-
ing into the agar (Fig. 6B). Quantitative analysis con-
firmed the invasive properties of foci generated by
HDAC4-TM (Fig. 6E). Here, again, growth in soft
agar was also observed when HDAC4-WT was
expressed, although with reduced efficiency compared
with HDAC4-TM (Fig. 6C,D).
To confirm the invasive properties of TERT/LT/ST/
HDAC4-TM cells we performed the Matrigel invasion
assay. Random cell motility and invasion were mea-
sured (Fig. 6F,G). These experiments confirmed the
strong invasive behavior of HDAC4-TM-expressing
cells.
Finally, we analyzed TERT/LT/ST cells expressing
HYGRO, RAS and HDAC4-TM in three-dimensional
Matrigel plugs. Only cells expressing RAS or HDAC4-
TM exhibited robust growth and invasion into the
matrix (Fig. 6H).
3.6. Common and specific transcriptomic
adaptations characterize RAS and HDAC4-TM
transformed cells
To gain insight into the molecular mechanisms responsi-
ble for the RAS- and HDAC4-TM- mediated oncogenic
transformation, we performed gene expression profile
studies. The transcriptomes of TERT/LT/ST/HYGRO,
TERT/LT/ST/RAS and TERT/LT/ST/HDAC4-TM
were compared. DEGs were analyzed relative to TERT/
LT/ST/HYGRO cells. Figure 7A shows that RAS and
HDAC4-TM influence the expression of a comparable
number of genes (respectively 892 and 920). In both
cases, the number of repressed genes is more than the
double that of the induced ones. Moreover, HDAC4-
TM and RAS have a larger pool (15.5%, n = 156 genes)
of all the repressed genes in common, in contrast to
6.5% (n = 40) of up-regulated genes. Since HDAC4 is a
transcriptional repressor, we focused our analysis on the
repressed genes. The 156 commonly repressed genes
turned out to be highly enriched for elements of the
interferon (IFN) pathways (Fig. 7B). In addition and in
agreement with the transformed state of these cells, a
subset of the commonly silenced genes belong to the
category of genes repressed by serum/growth
factors (Fig. 7B). Next, we evaluated RAS- and
HDAC4-TM-specific repressive signatures. IFN and, in
general, inflammatory signatures were prevalent among
genes (n = 400) specifically repressed by RAS (Fig. 7C).
In contrast, genes that are specifically repressed by
HDAC4-TM are involved in more heterogeneous regu-
lative processes, including the epithelial-mesenchymal
transition, the hypoxia response and differentiation/
morphogenesis (Fig. 7D). The high number of genes
regulating cell adhesion and migration, as disclosed by
the Gene Ontology analysis, could explain the peculiar
phenotype of the soft agar colonies generated by TERT/
LT/ST/HDAC4-TM cells (Fig. 6).
Finally, the comparison of the transcriptomic pro-
files indicated that the transformation phenotype eli-
cited by HDAC4-TM in TERT/LT/ST cells resembles
adaptations in gene expression previously described in
other models of human fibroblast transformation
(Fig. 7E).
4. Discussion
In this manuscript we used human fibroblasts to evalu-
ate the oncogenic cooperative properties of HDAC4.
The transforming potential of class IIa HDACs has
been shown in different murine models (Di Giorgio
et al., 2013; Gil et al., 2016; Lei et al., 2017; Peruzzo
et al., 2016; Rad et al., 2010). However, since there are
substantial interspecies differences in the biology of cell
transformation (Boehm et al., 2005), we decided to ver-
ify the oncogenic properties of HDAC4 in human cells.
The combined expression of HDAC4-TM with the
viral oncogene LT and much more strongly with LT
and ST viral oncogenes can sustain growth in soft agar,
similarly to RAS oncogene. Although at reduced levels,
HDAC4-WT can also promote anchorage-independent
growth when co-expressed with LT and ST.
The ability of LT to cooperate with HDAC4
strongly indicates that inactivation of the pRb and
TP53 tumor suppressor pathways is required to
unleash the HDAC4-transforming potential. However,
in the absence of ST, the growth is not robust and foci
are less frequently observed and of small size. This
behavior was previously reported in the case of RAS
(Hahn et al., 2002).
ST is required to increase dramatically the anchor-
age-independent growth of both HDAC4 and RAS.
ST-transforming activities rely on the binding and
inhibition of some isoforms of the serine-threonine
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phosphatase, PP2A (Hahn et al., 2002). PP2A can
dephosphorylate and regulate several targets, thus
making it difficult to hypothesize which pathway could
synergize with HDAC4. Recently, it has been shown
that the PAK1-YAP axis can mediate ST-transforming
activity (Nguyen et al., 2014). Interestingly, a
Fig. 7. Gene expression profiles of RAS and HDAC4-TM transformed human fibroblasts. (A) Pie-chart indicating the number of genes
significantly up- and down-regulated in TERT/LT/ST/RAS and TERT/LT/ST/HDAC4-TM cells compared with TERT/LT/ST/HYGRO cells. (B)
GSEA for the 156 genes commonly repressed by RAS and HDAC4-TM using the hallmark and the GO/biological process MSigDB gene
sets. (C) GSEA for the 400 genes specifically repressed by RAS using the hallmark and the curated (CPG) MSigDB gene sets. (D) GSEA for
the 450 genes specifically repressed by HDAC4-TM using the hallmark and the GO/biological process MSigDB gene sets. (E) GSEA plots
showing significant enrichment for HDAC4-regulated genes in a BJ transformation model (GSE43010), considering both HDAC4-positively
regulated genes (left) and HDAC4-repressed genes (right).
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contribution of HDAC4 in mediating YAP-repressive
activity has been reported (Wang et al., 2014).
Transcriptomic analysis has revealed that HDAC4-
TM and RAS trigger the transformation processes via
both common and peculiar adaptive responses. Repres-
sion of genes marking the IFN responses was commonly
found in RAS- and HDAC4-TM-transformed cells.
IFN and inflammatory signaling were highly enriched
also among genes specifically repressed by RAS.
Although it is well known that RAS and its downstream
elements suppress the IFN-induced antiviral responses
and favor virus spreading (Battcock et al., 2006; Chris-
tian et al., 2009; Noser et al., 2007), how this repressive
wave could impact on the in vitro transformation pro-
cess is less clear (Christian et al., 2012). Gene signatures
specifically influenced by HDAC4-TM are more hetero-
geneous and involve adaptation to hypoxia, adhesion,
motility and differentiation processes. It is possible that
RAS more potently suppresses the IFN responses
compared with HDAC4-TM, which instead represses
additional pathways.
The ability of HDAC4-TM to regulate genes
involved in adhesion and motility was confirmed in the
morphological analysis of soft agar foci as well as in
the results obtained with Matrigel invasion and
evasion assays. These results indicate that HDAC4-
expressing cells exhibit a strong invasive phenotype,
further supported by previous studies on the invasive,
migrating and metastatic activities of class IIa HDACs
(Cao et al., 2017; Cernotta et al., 2011; Di Giorgio
et al., 2013; Fabian et al., 2016; Mottet et al., 2007).
Normal cells in response to oncogenic signals enter
into senescence, a state of irreversible/permanent
growth arrest that prevents cells from undergoing fur-
ther cell divisions, defined as OIS (Serrano et al., 1997).
Activation of OIS depends on the pRB and/or TP53
tumor suppressor pathways (Serrano et al., 1997). We
have proved that HDAC4-TM, in TERT-immortalized
human fibroblasts, can activate senescence. This senes-
cent response can be also triggered by other class IIa
HDACs such as HDAC7, when localized into the
nucleus (Supporting Information Fig. S1). Since the
expression of HDAC4-TM in the opportune genetic
environment (LT/ST co-expression) can transform cells,
and since the senescent response is p53-dependent, we
can define senescence triggered by HDAC4-TM as OIS.
However, OIS induced by RAS cannot be reversed by
simply blocking TP53 activity, but requires the suppres-
sion of pRB, possibly through the CDK inhibitor p16
(Serrano et al., 1997). The difference between HDAC4-
TM and RAS can be appreciated also at the earliest
stages of their induction. RAS triggers hyperprolifera-
tion and S-phase-associated DNA damage response
(DDR). The oncogene-dependent increase in prolifera-
tion leads to accumulation of incomplete replication
intermediates, resulting in DNA damage and activation
of the DDR (Di Micco et al., 2006).
In contrast, HDAC4-TM triggers suddenly growth
arrest, senescence and SASP, which could be caused
by the rapid activation of TP53. The absence of the
hyperproliferative response correlates with the failure
to trigger H3K27 global demethylation, as observed in
RAS-expressing cells.
4.1. How can HDAC4-TM trigger TP53
stabilization and senescence?
Induction of DNA damage, marked by cH2AX posi-
tivity, was observed. In contrast to RAS, the number
of cH2AX spots per cell was reduced in HDAC4-TM
cells. Hence, the induction of DNA damage and TP53
activation seems to involve different pathways com-
pared with the replication stress induced by RAS. Pre-
vious reports have described correlations between
HDAC4 and the DNA damage response, and also
with TP53 regulation (Cadot et al., 2009; Marampon
et al., 2017). Unfortunately, these preliminary observa-
tions have not led to further studies and currently the
correlations between class IIa HDACs and the DNA
damage response remain unknown.
Although RAS-induced OIS is among the foremost
pathways, alternative OIS pathways exist. PI3K/AKT-
induced senescence is characterized by TP53 and
CDKN1A induction in the absence of overt DNA
damage. mTORC1-dependent regulation of TP53
translation and stabilization of TP53 protein, as a
result of MDM2 nucleolar localization and inactiva-
tion, is the mechanism activated in this senescent
response (Astle et al., 2012; Kennedy et al., 2011).
Importantly, similarly to HDAC4, AKT promotes a
rapid proliferative arrest in the absence of hyperprolif-
eration (Astle et al., 2012; Kennedy et al., 2011).
Interestingly, in certain cancer types, particularly in
leiomyosarcomas, class IIa HDACs and PI3K/AKT
can regulate common genetic programs that are under
the influence of MEF2 TFs. Class IIa HDAC binds
MEF2 on target promoters and favors the establish-
ment of a closed chromatin configuration (Di Giorgio
et al., 2017). In contrast, PI3K/AKT can trigger
polyubiquitylation and degradation of certain MEF2
isoforms (Di Giorgio et al., 2015). As MEF2s are pos-
sible common targets of these pathways, it is impor-
tant to underline that the repression of MEF2 TFs is
required for the OIS response triggered by HDAC4
and that the knock-down of MEF2D is sufficient to
trigger senescence.
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5. Conclusions
Our results provide further evidence concerning the
contribution, as cooperating oncogenes, of class IIa
HDACs in human cancer. This finding is encouraging
for further investigations aimed at discovering and
evaluating inhibitors of these epigenetic regulators as
anticancer drugs.
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Abstract: Cancer complexity relies on the intracellular pleiotropy of oncogenes/tumor suppressors
and in the strong interplay between tumors and micro- and macro-environments. Here we followed
a reductionist approach, by analyzing the transcriptional adaptations induced by three oncogenes
(RAS, MYC, and HDAC4) in an isogenic transformation process. Common pathways, in place of
common genes became dysregulated. From our analysis it emerges that, during the process of
transformation, tumor cells cultured in vitro prime some signaling pathways suitable for coping with
the blood supply restriction, metabolic adaptations, infiltration of immune cells, and for acquiring the
morphological plasticity needed during the metastatic phase. Finally, we identified two signatures of
genes commonly regulated by the three oncogenes that successfully predict the outcome of patients
affected by different cancer types. These results emphasize that, in spite of the heterogeneous
mutational burden among different cancers and even within the same tumor, some common hubs
do exist. Their location, at the intersection of the various signaling pathways, makes a therapeutic
approach exploitable.
Keywords: RAS; MYC; HDAC4; G0S2; DOCK4; SRPX interferon; inflammation; TCGA
1. Introduction
Cancer is a complex disease that arises through the accumulation of specific genetic lesions,
affecting oncogenes and tumor suppressor genes. These lesions hijack transcriptional/epigenetic
machineries to reprogram the gene expression profile of the cells [1]. The final goal is to sustain a
robust proliferation, invasion, and the suppression of cell death programs. The tumorigenic process
is the consequence of the adaptations that tumor cells must achieve to overcome different crises.
Escaping senescence, suppressing apoptosis, resolving starvation from blood supply, impinging the
metabolic circuits, and evading immune surveillance represent the major achieved adaptations [2].
Cancer cells are part of a complex ecosystem. Together with fibroblasts, endothelial and the
immune cells constitute and organize the tumor microenvironment [3]. These cells establish different
interactions that are transduced and maintained by interconnected networks of signals. To unveil
this complexity, system biology approaches can be adopted to integrate genomic and epigenomic
data collected from tumor biopsies [4,5]. Moreover, the initial assumption of considering cancer as
the expansion of a monoclonal population has been recently replaced by the evidence obtained by
single-cell sequencing [6]. In each cancer, several subclones can co-exist and can expand or contract as
a function of their fitness [6].
Within this complexity, it is important to define the crucial events that can be target for a therapeutic
intervention. The social impact of the tumorigenic process must prompt us to focus all efforts in
unveiling the key oncogenic addictions for each different tumor type.
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Historically, in vitro transformation models have provided the first approach to understand the
tumorigenic process [7]. The identification of oncogenes and tumor suppressor genes and the demonstration
of the cooperation among oncogenes represent the major accomplishments of these model systems.
Traditionally, rodent cells have been largely used. However, transformation of murine cells and human cells
greatly differ [8]. Human cells are more resistant to oncogenic transformation and require more events [9].
In vitro transformation approaches frequently adopt viral oncoproteins to switch off important tumor
suppressor genes, such as RB and TP53. Nevertheless, transformation of human cells can also be obtained
in absence of viral genes [10]. An innovative version of the in vitro transformation studies is represented by
the generation of human organoids. Under a 3D growth condition and a selected microenvironment, these
primary cells can be engineered in vitro, using CRISPR/Cas9 genome editing approaches, to recapitulate
the key oncogenic lesions of the primary tumors [11].
Importantly, in vitro tumorigenic models must find validation in vivo. The resetting of the
transcriptomic output represents the major tool through which cancer cells modulate their plasticity
and adapt to the microenvironment. Hence, in this manuscript, we have compared the transcriptional
profiles of three different isogenic models of in vitro transformation. Our goal is to demonstrate
a correspondence between the in vitro transformation process and cancer development in patients.
Moreover, we would like to define a minimal gene signature, shared among different transformation
models, that could represent a useful tool to unveil the Achilles’ heel of many cancers.
2. Results
2.1. In Vitro Transformation of Human Fibroblasts Achieved by Different Oncogenes Leads to the Activation of
Both Distinct and Common Genetic Programs
In vitro transformation of human cells requires a limited number of genetic changes [7].
Viral genes such as the SV40 early region, which encodes both the large T and small t oncoproteins,
in combination with the catalytic subunit of the telomerase (hTERT) have been commonly used to
drive the immortalization and to circumvent senescence of normal human fibroblasts and kidney
cells [12]. The subsequent introduction of strong oncogenes such as RAS or MYC triggers the cellular
transformation. These cells are characterized by an anchorage independent growth and by the ability
to generate tumors when injected in immunocompromised mice [12,13].
Here, we deeply investigated the strength of the transcriptome reprogramming, triggered during
the in vitro transformation process, in predicting the outcome of different human cancers. With this
aim we compared the gene expression profiles of human foreskin fibroblasts expressing hTERT,
the early region of SV40 and subsequently transduced with HRAS/G12V [13], MYC [14], or an oncogenic
nuclear resident form of HDAC4 (HDAC4-TM) [13,15]. These oncogenes have been chosen for their
heterogeneity. As frequently reported for other oncogenic combinations [12,13], when mutations,
amplifications, or transcript dysregulations of these oncogenes were analyzed in different human
cancers, the co-occurrence of their alterations appears to be restricted to a small number of cases.
In Figure 1, we report the oncoprint of TCGA PanCancer ATLAS datasets selected among some of the
most frequent solid tumors. We included breast, colorectal, lung, prostate, stomach, and uterine cancers
(Figure 1). As expected, point mutations in RAS are not common in breast and prostate cancer [16].
Interestingly, genetic alterations in HDAC4 are more frequent in uterine and stomach cancers, with a
conspicuous incidence of truncations and point mutations of still unknown impact on the activities of
this deacetylase (Figure 1).
The simultaneous dysregulations of HDAC4, MYC, and RAS oncogenes are relatively rare.
There are some co-occurrences between HDAC4 and MYC or HDAC4 and RAS as well as between
MYC and RAS. Most frequently, patients carry alterations only in one of the three oncogenes
(Figure 1). This evidence suggests that the three oncogenes can act through completely distinct
and non-complementary mechanisms or through at least partially overlapping pathways.
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Figure 1. Summary of the genetic alterations reported for HRAS, KRAS, NRAS, MYC, and HDAC4 in
some human cancers. Oncoprints of HDAC4, HRAS, KRAS, NRAS, and MYC mutations and alterations
in the indicated tumor types. Images were cropped to highlight the alterations. Data were obtained
from the TCGA database. The heatmap was generated through cBioPortal (http://www.cbioportal.org).
The different genetic alterations are indicated by the provided color code.
2.2. RAS, MYC, and HDAC4-Mediated Oncogenic Transformation Is Marked by the Dysregulation of Common
Pathways Rather Than of Common Genes.
To prove the above enounced concept, we interrogated the gene expression profiles of
BJ-hTERT/ST/LT/MYC [14], BJ-hTERT/ST/LT/HRASG12V [13], and BJ-hTERT/ST/LT/HDAC4-S246A, S467A,
S632A [15], relatively to the isogenic pre-transformed control cells, expressing the SV40 LT and ST or
the entire early region.
By adopting as cut-off criteria 1.5-fold change and FDR < 0.05, we obtained six signatures of genes
regulated by the three oncogenes. Overall, 519 and 634 transcripts were respectively upregulated and
downregulated by MYC, 556 and 595 by RAS and finally, 551 and 979 by HDAC4.
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Few genes turned out to be commonly dysregulated by the three oncogenes. Only three genes
were upregulated either in RAS, MYC, and HDAC4 transformed cells (Figure 2A), while 22 were the
commonly repressed genes (Figure 2B).
Figure 2. Analysis of the transcriptional profiles in three different models of in vitro transformation.
(A) Venn diagram showing the number of transcripts upregulated during the transformation process in
BJ/hTERT/LT/ST cells expressing RAS, MYC, or HDAC4 as indicated. (B) Venn diagram showing the
number of transcripts downregulated during the transformation process in BJ/hTERT/LT/ST cells expressing
RAS, MYC, or HDAC4 as indicated. (C) Venn diagram showing the number of different hallmarks gene sets
significantly upregulated by RAS, MYC, and HDAC4. (D) Venn diagram showing the number of different
hallmarks gene sets significantly downregulated by RAS, MYC, and HDAC4. All the Venn diagrams were
created by using this software http://bioinformatics.psb.ugent.be/webtools/Venn/.
Although the commonly dysregulated genes are rare, the three oncogenes could influence the
same pathways through alterations of different genes, operating at different steps of the same pathway.
To prove this hypothesis, we applied the Gene Set Enrichment Analysis (GSEA) algorithm to compare
the six signatures obtained to the MSigDB HALLMARK gene sets [17,18]. The “HALLMARKS” is a
collection of 50 gene sets; each of them groups genes that display coordinate expression and represent
well-defined biological processes. Tables SIA–SIC summarize the statistically significant genes sets
identified by the analysis for the upregulated genes and Tables SIIA–SIIC for the downregulated
genes. Venn diagrams show that the three oncogenes share several gene sets, which control important
biological functions related to the transformation process. For the upregulated genes, 14 different gene
sets were commonly regulated by RAS, MYC, and HDAC4 (Figure 2C). For the repressed genes this
number increased up to 23 (Figure 2D).
In summary, although the number of genes commonly regulated in the three models of in vitro
transformation is small, the pathways and the biological processes under the influences of HDAC4,
RAS, and MYC testify a convergence towards common strategies of hijacking specific cellular responses.
Int. J. Mol. Sci. 2019, 20, 6283 5 of 22
2.3. Identification of the Pathway Reprogramming Core that Defines the Common Trait of the in Vitro
Transformation Process
Having found that the three transformation models influence common gene sets, we next analyzed
which genes were under the regulation of the three oncogenes in the different gene sets.
Figure 3 shows the result of such analysis for the upregulated genes. As above mentioned, only
three genes (DOCK4, G0S2, SRPX) were commonly induced by the three oncogenes. These genes are
represented in more than one gene set. The Venn diagrams illustrate also the common genes among
two models of in vitro transformation (Figure 3). Interestingly, the gene set “p53 pathway” includes
all the three genes. Although no other genes were in common between RAS and MYC or RAS and
HDAC4, all genes (n = 9) were in common between MYC and HDAC4. This observation suggests that
HDAC4 and MYC share similar strategies to dysregulate the p53 pathway. Another relevant gene
set is the “inflammatory response”. Here common genes were not identified. However, this cellular
response is equally modulated by all three oncogenes, with a similar number of genes. Some of them
are in common between RAS and HDAC4 (n = 2), RAS and MYC (n = 2), and MYC and HDAC4 (n = 3).
In the case of the gene set “glycolysis” several genes are under the influence of RAS and a good overlap
is observed with MYC (n = 5). By contrast, HDAC4 shows a peculiar influence on this metabolic gene
set, possibly reflecting its non-conventional activities on the metabolism of the transformed cells [19].
When we analyzed the repressed genes, the number of statistically significant hallmarks gene sets
was higher (n = 23) (Figure 4 and Tables SIIA–SIIC). The gene set “epithelial-mesenchymal transition”
scored the highest number of common hubs (n = 5). In addition, a significant number of genes were
similarly dysregulated by RAS and HDAC4 (n = 7) and by MYC and HDAC4 (n = 5). The EMT gene
set was the most statistically significant enriched gene set in the RAS and HDAC4 transformed cells,
whereas in MYC-transformed it scored the fourth position. An opposite behavior was observed for the
gene set “complement”. The total number of genes regulated was 46 but only 2 genes were in common
between RAS and MYC and HDAC4 and MYC. This observation indicates that the complement
pathway is targeted through alternative mechanisms in the three models of in vitro transformation.
Other statistically significant repressed gene sets are the interferon-α (IFNα) and the interferon-γ
(IFNγ) responses. In RAS-transformed cells they resulted the second and the third top hits, respectively,
whereas in MYC-transformed cells the second and the first. Finally, in the case of HDAC4 they scored
as the seventh and the third hits.
Only three genes were commonly repressed in the IFNs hallmarks gene sets: ARID5B, ELF1,
and MX1. The last was present in both the IFNα and the IFNγ gene sets. When RAS and MYC were
compared, 20 genes were in common for the IFNγ response and 15 in the case of the IFNα. On the other
side, HDAC4 shows stronger similarities with MYC. Nine genes belonging to IFNγ and to IFNα gene
sets were in common between MYC and HDAC4 in IFNγ as well as in IFNα gene sets. Few similarities
were found between HDAC4 and RAS, with only a gene in common for IFNγ (Figure 4).
In summary, this analysis indicates the IFNα and IFNγ signaling are significantly and robustly
repressed in different models of in vitro transformation. This can be due to: (i) the key role that the
repression of the pathways plays in the transformation process, as previously reported [20–24]; (ii) a
certain degree of purifying selection that supervise the conservation of IFN signaling [25].
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Figure 3. Hallmarks and genes commonly upregulated by the three oncogenes (HDAC4, RAS, MYC)
during the in vitro transformation process. Venn diagram showing different sets of hallmarks and the
number of upregulated genes, which are shared by HDAC4, RAS, and MYC.
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Figure 4. Hallmarks and genes commonly downregulated by three oncogenes (HDAC4, RAS, MYC)
during the in vitro transformation process. Venn diagram showing different sets of hallmarks and
number of downregulated genes that were commonly shared by HDAC4, RAS, and MYC.
2.4. Definition of the Minimal Signatures Regulated during in Vitro Transformation
The final goal of our approach is to verify if the pathways dysregulated during the in vitro
transformation can predict the outcome of malignant cancers in patients. For this reason, we extracted
three signatures: Two for the repressed and one for upregulated genes (Table 1). Both signatures are
made up of genes commonly and significantly upregulated or downregulated by the three oncogenes.
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CDH11 Downregulated A EMT/APICAL
DKK1 Downregulated A EMT
GREM1 Downregulated A EMT
MYLK Downregulated A Adipogenesis/Myogenesis/EMT
SPRY2 Downregulated A KRAS
ARID5B Downregulated B Androgen/IFNγ
DUSP4 Downregulated B TNFα-NFKB
ELF1 Downregulated B IFNα/ESTROGEN
LPAR1 Downregulated B Inflammation/UV
MX1 Downregulated B IFNα/IFNγ
SOCS2 Downregulated B IL2-STAT5
TNFRSF11B Downregulated B EMT/APICAL
The signature of the upregulated genes groups DOCK4, G0S2, and SRPX (Table 1). DOCK4 encodes
for a guanine nucleotide exchange factors that participates in the regulation of cell adhesion and membrane
trafficking [26,27]. It is reported to be mutated in cancer [26] and to influence cancer aggressiveness through
the modulation of WNT and TGF-β pathways [28,29]. Since also anti-proliferative activities have been
reported, its oncogenic potential seems to be context specific [30,31].
G0S2 (G0/G1 switch gene 2) encodes for a potent inhibitor of adipose triglyceride lipase. In this
manner, G0S2 acts as a master regulator of the tissue-specific balance of triglyceride storage vs.
mobilization [32]. Correlations with cancer are unclear with anti-proliferative effects described
by some reports [33–35]. Finally, SRPX (sushi repeat containing protein X-linked), known also as
ETX1 or DRS, was initially isolated as deleted in patients with X-linked retinitis pigmentosa [36],
as well as downregulated by v-src [37]. A tumor suppressive activity for SRPX was proposed [38].
Moreover, its expression seems to be downregulated in different aggressive cancers [39–41].
For the repressed genes we selected two different signatures. The first signature (repressed
signature A) includes five genes (CDH11, DKK1, GREM1, MYLK, SPRY2). These genes do not belong to
the inflammatory and interferon gene sets (Table 1). A second signature of genes (repressed signature
B) groups the remaining commonly repressed genes that belong to inflammatory-immune responses
(ARID5B, DUSP4, ELF1, LPAR1, MX1, SOCS2, TNFRSF11B).
2.5. High mRNA Levels of the Upregulated Genes Correlate with Reduced Patients’ Survival in a Group of
Different Tumors
In order to understand if the identified signatures can predict cancer aggressiveness and patients’
outcome, they were used to interrogate the survival data of 32 cancer types deposited in the Cancer
Genome Atlas (TCGA).
For the upregulated genes, we segregated the patients in two groups. The first group is
characterized by high expression levels of the signature (above the third quartile). The second group is
characterized by moderated upregulation, unperturbed or repressed expression of the signature (below
the third quartile). Figure 5A illustrates that in six different cancer types (colorectal adenocarcinoma,
kidney chromophobe, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, testicular
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germ cell tumors, and uveal melanoma) high levels of DOCK4, G0S2, and SRPX significantly correlate
with a worst survival.
Figure 5. High mRNA levels of upregulated genes during in vitro transformation process influence
patients’ survival. (A) Kaplan-Meier survival analysis related to the three upregulated genes DOCK4,
G0S2, SRPX. All cases were analyzed and clustered into two groups according to DOCK4, G0S2,
and SRPX expression levels. High levels of expression group (> the third quartile/high expressing)
compared to all other cases (< the third quartile/low expressing). Cases were: Colorectal adenocarcinoma
(all n = 382, high expressing n = 95), kidney chromophobe (all n = 65, high expressing n = 16), kidney
renal clear cell carcinoma (all n = 510, high expressing n = 127), kidney renal papillary cell carcinoma
(all n = 283, high expressing n = 70), testicular germ cell tumors (all n = 149, high expressing n = 37),
and uveal melanoma (all n = 80, high expressing n = 20). (B) Kaplan-Meier survival analysis related
to G0S2 in adrenocortical carcinoma (ACC). High level expression (above the third quartile) of G0S2
in ACC were observed in 19 cases. All cases were n = 78. (C) Kaplan-Meier survival analysis related
to DOCK4 and SRPX in ACC. High level expression (> the third quartile) of DOCK4 and SRPX were
observed in 19 cases, all cases were n = 78.
On the opposite high levels of the signature predicts a better overall survival in adrenocortical
carcinoma (ACC) (Figure 5B). This behavior could depend on G0S2. In fact in ACC, which is a rare,
aggressive malignancy, G0S2 hypermethylation is a hallmark of rapidly recurrent or fatal disease,
amenable to targeted assessment using routine molecular diagnostics [35]. Very low levels of G0S2
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mRNA expression characterize tumors with G0S2 hypermethylation. Although low G0S2 expression
marks 40% of ACC and independently predicts shorter disease-free and overall survival, the role of
this gene in adrenocortical biology is still unknown [42]. To confirm this data, we repeated the survival
analysis without the G0S2 gene. In this case the positive correlation with ACC survival was abrogated
(Figure 5C). For the remaining 25 cancer types the signature failed to predict any patients’ survival.
2.6. High Levels of DOCK4, G0S2, and SRPX Expression Are Related to Worse Survival in Similar but also
Different Tumor Types
The influence of G0S2 methylation on cancer mortality is peculiar of ACC. As expected from the
in vitro transformation models, in many other tumors (n = 9) high levels of G0S2 mRNA are indicative
of a reduced survival (Figure 6).
Figure 6. High levels of G0S2 expression correlate with reduced survival in different cancer types.
TCGA survival data analysis on tumors grouped for high levels of G0S2 expression alone (> the third
quartile/high expressing) compared to all other cases (< the third quartile/low expressing). Cases were:
Adrenocortical carcinoma (all n = 78, high expressing n = 19), cervical squamous cell carcinoma (all
n = 294, high expressing n = 73), colorectal adenocarcinoma (all n = 592, high expressing n = 148), kidney
renal clear cell carcinoma (all n=510, high expressing n=127), kidney renal papillary cell carcinoma (all
n = 283, high expressing n = 70), brain low grade glioma (all n = 514, high expressing n = 128), lung
adenocarcinoma (all n = 510, high expressing n = 127), lung squamous cell carcinoma (all n = 484, high
expressing n = 121), stomach carcinoma (all n = 412, high expressing n = 103), and uveal melanoma (all
n = 80, high expressing n = 20).
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To verify whether G0S2 is the key gene in predicting patients’ survival, we repeated the analysis
for DOCK4 and SRPX. High levels of DOCK4 correlates with a reduced survival in five different
tumors (colorectal, kidney chromophobe, brain low grade glioma, stomach adenocarcinoma, and uveal
melanoma) and with a better prognosis in two cancer types (mesothelioma and skin cutaneous
melanoma) (Figure S1). Increased levels of SRPX correlates with an increased hazardous rate in
seven different cancer types (bladder, colorectal, head and neck squamous carcinoma, kidney renal
clear cell and papillary carcinomas, thyroid carcinoma, and uterus corpus endometrial carcinoma).
Conversely, it predicts a better outcome in melanoma (Figure S2). This analysis suggests that the three
upregulated genes could exert independent activities to influence cancer aggressiveness.
2.7. A Group of Genes Repressed during in Vitro Transformation Predicts Patients’ Survival.
Next, we interrogated the TCGA survival data with the repressed signature A. The patients were
segregated in two groups accordingly to the median value of expression of the signature. In two
different cancer types, high levels of the signature correlate with increased survival, while in other six
cancer types high levels of the same signature correlate with reduced survival. Hence, we discarded
this signature for further analysis.
A different result was obtained with the repressed signature B that groups inflammatory and
interferon genes. Low levels of the repressed signature correlate with a worst prognosis in five cases:
Kidney chromophobe carcinoma, kidney clear cell carcinoma, sarcoma, skin cutaneous melanoma,
and uterine carcinosarcoma (Figure 7A). On the opposite, low levels of this signature predict a better
outcome in patients with brain lower grade glioma and ovarian serous cystadenocarcinoma (Figure 7B).
For simplicity we named this signature “oncogene-repressed inflammatory signature”.
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Figure 7. Patients’ survival and expression levels of oncogene-repressed inflammatory signature.
(A) Kaplan-Meier survival analysis related to the oncogene-repressed inflammatory signature. All cases
were analyzed and clustered into two groups according to median expression levels (high median;
expression levels > the median and low median; expression levels< the median). Cases were: Kidney
chromophobe (all n = 65, high expressing n = 32), kidney renal clear cell carcinoma (all n = 510, high
expressing n = 255), sarcoma (all n = 253, high expressing n = 126), skin cutaneous melanoma (all
n = 443, high expressing n = 221), and uterine carcinosarcoma (all n = 57, high expressing n = 28).
(B) Kaplan-Meier survival analysis related to the oncogene-repressed inflammatory signature. All cases
were analyzed and clustered into two groups according to median expression levels (high median;
expression levels > the median and low median; expression levels < the median). Cases were: Brain
low grade gliomas (all n = 514, high expressing n = 257) and ovarian serous cystadenocarcinoma (all
n = 300, high expressing n = 150).
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2.8. Inflammatory Genes Repressed during the in Vitro Transformation Process and Tissue-Infiltrating
Immune Cells
Tumors are characterized by a variegated abundance of tissue infiltrating immune cells, which can
influence the prognosis [43]. Since the oncogene-repressed inflammatory signature comprises many
inflammatory genes, our in vivo analysis could be influenced by the presence of tumor infiltrating
immune cells. Recent studies have shown that the abundance of immune cells in tissue transcriptomic
data can be predicted by specific mRNA signatures [44].
We applied the microenvironment cell populations-counter (MCP-counter) to evaluate the
contribution of different immune cells to the survival outcomes of patients analyzed for the
oncogene-repressed inflammatory signature. With the exclusion of kidney chromophobe, uterine
carcinosarcoma, and ovarian serous cystadenocarcinoma, in the other cancer types the survival was
also influenced by the presence of immune cells, although with different outcomes (Figures S3 and S4).
Prognosis of skin cutaneous melanoma, sarcoma, and brain low grade glioma (LGG) is influenced by
the infiltration of different subtypes of immune cells. These tumors behave differentially, with only
LGG showing a worst outcome. On the contrary, the better outcome of kidney renal cell carcinoma
results significantly and specifically associated with the presence of myeloid dendritic cells (Figure S4).
In conclusion, although in some tumor types the repression of the inflammatory signature and the
resulting reduced patients’ survival can be specifically ascribed to the transcriptional reprogramming of
the neoplastic cells; in other tumors, we cannot exclude a contribution of the immune cells. These cells
may have been isolated along with the tumor tissue and thus contribute to the transcriptional landscape
as reported by the TCGA data.
2.9. Oncogene-Repressed Inflammatory Signature Provides an Additional Contribution to Overall Survival
As a final analysis, we decided to evaluate the impact on patients’ survival of both the tumor
infiltrating immune cells and of the expression levels of the oncogene-repressed inflammatory signature.
The analysis was restricted to tumor types that showed significant correlations between the overall
survival and the presence of the immune cell infiltrates (Figures S3 and S4).
The three tumor types analyzed were LGG, skin cutaneous melanoma, and sarcoma (Figure 8).
In LGG, the coexistence of high levels of expression of the oncogene-repressed inflammatory signature
and the presence of immune cells, particularly of T cells, cytotoxic lymphocytes and neutrophils
represent a negative prognostic condition (Figure 8B,C,G). In agreement with our data, strong
correlations between the risk score and T cells, macrophage-related immune response, as well as the
expression of immunomodulators were recently reported in LGGs [3,45].
Interestingly, in sarcoma and melanoma tumors where high levels of the oncogene-repressed
inflammatory signature correlate with an increased survival, two different behaviors can be appreciated.
In sarcoma the presence of immune cells is dominant. In fact, when immune cell infiltrates (particularly
CD8 T cells and cytotoxic lymphocytes) are observed, increased survival is maintained, also in the
presence of low levels of the oncogene-repressed inflammatory signature (Figure 8E,G). In contrast,
in skin cutaneous melanoma low expression levels of the signature are sufficient to reduce the overall
survival (Figure 8A,C,D,F,G). In melanoma, the best prognosis is observed in the presence of high
expression of the oncogene-repressed inflammatory signature and the concomitant presence of immune
cells, particularly T cells, NK, CD8 T cells, and cytotoxic lymphocytes.
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Figure 8. The contribution of infiltrating immune/inflammatory cells to overall survival. Kaplan-Meier
survival analysis related to the immune/inflammatory signature and the infiltration of different
Int. J. Mol. Sci. 2019, 20, 6283 15 of 22
immune/inflammatory cells. Infiltrating immune/inflammatory cells were defined as described
in materials and methods. Patients were grouped high/high (high levels of both infiltrating
cells and immune signature), high/low (high levels of infiltrating cells and low levels of the
oncogene-repressed inflammatory signature), low/high (low levels of infiltrating cells and high levels
of the oncogene-repressed inflammatory signature), and as low/low (low levels of both infiltrating cells
and of the oncogene-repressed inflammatory signature). The four groups were generated according
to median expression levels of the two signatures. Cases: (A) Sarcoma (all = 253, high/high = 75,
high/low = 51, low/high = 51, low/low = 76) and skin cutaneous melanoma (all = 428, high/high = 133,
high/low = 82, low/high = 82, low/low = 131). (B) Brain low grade glioma (all = 512, high/high = 155,
high/low = 102, low/high = 101, low/low = 154). (C) Brain low grade glioma (all = 512, high/high = 164,
high/low = 92, low/high = 92, low/low = 164) and skin cutaneous melanoma (all = 428, high/high = 148,
high/low = 66, low/high = 67, low/low = 147). (D) Skin cutaneous melanoma (all = 428, high/high = 143,
high/low = 72, low/high = 72, low/low = 141). (E) Sarcoma (all = 253, high/high = 70, high/low = 56,
low/high = 56, low/low = 71) and skin cutaneous melanoma (all = 428, high/high = 136, high/low = 77,
low/high = 79, low/low = 136). (F) Brain low grade glioma (all = 512, high/high = 164, high/low = 93,
low/high = 92, low/low = 163) and skin cutaneous melanoma (all = 428, high/high = 140, high/low = 73,
low/high = 75, low/low = 140). (G) Brain low grade glioma (all = 512, high/high = 153, high/low = 104,
low/high = 103, low/low = 152), sarcoma (all = 253, high/high = 74, high/low = 52, low/high = 52,
low/low = 75) and skin cutaneous melanoma (all = 428, high/high = 142, high/low = 74, low/high = 73,
low/low = 139). (H) Kidney renal clear cell carcinoma (all = 510, high/high = 132, high/low = 123,
low/high = 123, low/low = 132), sarcoma (all = 253, high/high = 70, high/low = 56, low/high = 56,
low/low = 71) and skin cutaneous melanoma (all = 428, high/high = 126, high/low = 89, low/high = 89,
low/low = 124).
3. Discussion
In this manuscript, we compared three isogenic models of in vitro transformation and we identified
minimal signatures that characterize the transformation process. We figured out that most of the
oncogenic programs driven by the three oncogenes rely on the activation of common pathways.
Curiously, these pathways seem to be activated through alternative/complimentary mechanisms, as the
modulated transcripts deeply differ and overlap only partially. This could be expected as RAS and
MYC in cancer establish a cooperation based on the integration rather than on the intersection of their
genetic programs [46]. Moreover, this evidence suggests that the third selected oncogene, HDAC4,
triggers a different transformation process, as suggested previously [19,47–50]. However, even if
through alternative roads, the three oncogenes converge on some common hubs [2].
A minimal signature of three upregulated transcripts identified through our analysis successfully
predict worse prognosis in some cancers. Among these genes emerges G0S2. This inhibitor of adipose
triglyceride lipase governs lipolysis and fatty acid (FA) availability. G0S2 is abundantly expressed
in adipose tissue and G0S2 transgenic mice experience difficulties in shifting from carbohydrate to
FA oxidation during fasting [51]. In vivo studies have indicated that G0S2 could ensure the usage of
glycogen-derived glucose as the primary source of rapid energy output [32,51]. This influence could
be relevant for the metabolic adaptation of cancer cells. However, preliminary studies have provided
conflicting data on a role of G0S2 in cancer cells [34,52–54]. Our discovery about the existence of strong
correlations between G0S2 levels and patients’ survival in different cancers suggests the needing of
a more extensive investigation about the impact of this gene on the metabolism and proliferation of
transformed cells.
Repression of interferon-inducible genes is a well-known feature of the RAS-dependent
transformation process [55–59]. Similarly, correlations between MYC and interferon have been
known since a long time. Initially, it was discovered that IFNs can regulate MYC expression [60,61].
Subsequently, a suppressive activity of MYC on IFN signaling was reported [62]. This repressive
influence was further proved by transcriptomic studies [63–67]. The recent discovery that the targeting
of MYC through an epigenetic therapy provides an important advantage for an efficient immunotherapy
could represent an important clinical perspective of all these studies [68,69].
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Our results justify the inclusion of HDAC4 in the group that comprises two historically oncogenes
for being similarly able to repress IFN genes during the transformation process. In the in vitro
model of transformation, the presence of SV40 genes—which promote the expression of the interferon
response [70]—could overestimate the repressive influence of the cellular oncogenes on this pathway.
Nevertheless, alterations of the interferon genes were observed also in vivo and independently from the
presence of the immune cells (Figure 8). Switching off the IFN and the inflammatory responses could
provide a double advantage to the transformed cells, both in a cell autonomous and non-autonomous
manner. It can favor the transformation process, by limiting tumor suppressive actions (such as
apoptosis), and it can influence the tumor microenvironment and the immune response [71]. In vivo
experiments on murine models of cancer have clarified that, in the initial tumorigenic steps, a strong
inflammatory environment is promoted by the cancer cells themselves [72]. The release of chemokines,
cytokines, and growth factors, as a consequence of the DNA damage accumulated during the early
transformation process, promotes the infiltration and proliferation of immune cells that set up the
first line of anti-cancer extracellular responses [73]. When full transformation is achieved, cancer
cells drive a strong anti-inflammatory response, through intracellular clues—such as the activation of
the IL10-Stat3 pathway and the release of extracellular molecules—which recall immune suppressor
cells [74]. The balance of the anti-tumor response is then further compromised by the effect of the
stroma and of the microenvironment, with the involvements of cancer associated fibroblasts (CAFs)
and of tumor associated macrophages (TAMs).
It is curious that these two steps are exactly recapitulated during the in vitro transformation, with
the arising of a type I IFN response during oncogene induced senescence or in the steps that come
immediately before the full oncogenic conversion. After this step, the anti-inflammatory responses
become predominant, as examined in this manuscript. The concept that some of these key features
are triggered also in cancer cells cultured in petri dish suggests that the microenvironment acts by
sculpting pathways that are already well established and poised in tumor cells in face of intracellular
survival needs [75].
In conclusion, our analysis evidences that different oncogenes use common pathways to reach
malignancy and to set up a barrier against the immune aggression.
4. Materials and Methods
4.1. Data Retrieval and Analysis
The transcriptional profiles of the three isogenic transformation models were obtained by
re-analyzing the datasets GSE17941 [13], GSE72530 [14], and GSE120040 [15] deposited as raw
files in GEO (Gene Expression Omnibus). The CEL files were processed with affy package in
R [76]. Multiple callings coming from redundant probes were reduced to a single signal per gene
by using Unigene ID centered CDFs (Chip Description Files) retrieved from the Molecular and
Behavioral Neuroscience Institute Microarray Lab (URL: http://brainarray.mbni.med.umich.edu/
Brainarray/Database/CustomCDF/genomic_curated_CDF.asp) [77]. RMA algorithm was used for
normalization [78]. In the three datasets selected, the hybridization was done on three different
Affymetrix chips (platforms HG-U133A_2, HuGene-1_0-st-v1 and Clariom_S). For the identification of
differentially expressed genes (DEGs), the limma package [79] was used. The calling of significance was
based on a 1.5-fold change/FDR < 0.05 criteria. In each dataset, the transformation model represented by
pre-transformed BJ cells expressing RAS G12V (GSE17941) or MYC (GSE72530) or HDAC4 (GSE120040)
was compared to the pre-transformation model which is represented by BJ fibroblasts expressing
hTERT, LT, and ST SV40 genes.
4.2. Enrichment Analysis
The “HALLMARK” collection of 50 gene sets deposited in the Molecular Signatures Database
(MSigDB) (subject) was interrogated with the three DEG lists generated (query). The MSigDB analysis
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tool (Broad Institute (http://www.broadinstitute.org/gsea/msigdb/index.jsp) algorithm was used to
score the overlap between queries and subjects. The identified hits were ranked by the enrichment
score and the p-value (FDR < 0.05) [17,18].
4.3. Generation of the Signatures of Transformation
The signature of the induced genes includes three genes that were significantly upregulated
in the three selected models of transformation. The signature of the repressed genes includes
13 genes commonly downregulated in the three models of transformation. This signature was
further sub-divided in sub-signatures A and B, where A includes six genes that do not belong to the
HALLMARK gene sets “inflammation” and “interferon response” and B includes the other seven genes.
4.4. Analysis of Survival
mRNA expression data coming from RNAseq studies and normalized by the
expectation-maximization (RSEM) method and patients’ clinical data about 32 cancer studies were
retrieved from TCGA, using the R package cgdsr [80]. Hits corresponding to patients with incomplete
expression or survival data were discarded. The final created dataset groups 11,424 samples belonging to
individual censored patients, distributed as follows: Adrenocortical Carcinoma (ACC, n = 93), Bladder
Urothelial Carcinoma (BLCA, n = 411), Breast Invasive Carcinoma (BRCA, n = 1108), Cervical Squamous
Cell Carcinoma (CESC, n = 310), Cholangiocarcinoma (CHOL, n = 51), Colorectal Adenocarcinoma
(COADREAD, n = 640), Diffuse Large B-Cell Lymphoma (DLBC, n = 48), Esophageal Carcinoma (ESCA,
n = 186), Glioblastoma Multiforme (GBM, n = 615), Head and Neck Squamous Cell Carcinoma (HNSC,
n = 530), Kidney Chromophobe (KICH, n = 66), Kidney Renal Clear Cell Carcinoma (KIRC, n = 538),
Kidney Renal Papillary Cell Carcinoma (KIRP, n = 293), Acute Myeloid Leukemia (LAML, n = 200),
Brain Lower Grade Glioma (LGG, n = 530), Liver Hepatocellular Carcinoma (LIHC, n = 442), Lung
Adenocarcinoma (LUAD, n = 588), Lung Squamous Cell Carcinoma (LUSC, n = 511), Mesothelioma
(MESO, n = 87), Ovarian Serous Cystadenocarcinoma (OV, n = 609), Pancreatic Adenocarcinoma
(PAAD, n = 186), Pheochromocytoma and Paraganglioma (PCPG, n = 178), Prostate Adenocarcinoma
(PRAD, n = 499), Sarcoma (SARC, n = 265), Skin Cutaneous Melanoma (SKCM, n = 480), Stomach
Adenocarcinoma (STAD, n = 478), Testicular Germ Cell Cancer (TGCT, n = 156), Thyroid Carcinoma
(THCA, n = 516), Thymoma (THYM, n = 124), Uterine Corpus Endometrial Carcinoma (UCEC, n = 549),
Uterine Carcinosarcoma (UCS, n = 57), Uveal Melanoma (UVM, n = 80). For each sample/patient,
the median expression values of the investigated signatures were calculated. According to these
values, patients were divided in two groups characterized by high or low expression of the signatures.
The Kaplan-Meier survival analysis was performed by using the survival package in R [81].
4.5. Estimation of the Contribution/Perturbation of the Immune Infiltration to the Survival Analysis
The infiltration of immune cells in the tumor biopsies was evaluated by using MCP counter
method [44]. Briefly, immunological signatures were retrieved by using the R package MCPcounter.
The previously described dataset of 11,424 samples was interrogated with these signatures [44] and
each sample was associated to the median value of expression of each signature. According to these
values, patients were segregated in two groups and the Kaplan-Meier method was applied to calculate
the survival rate.
To evaluate the contribution/disturbance of the inflammatory infiltrate to the prediction of survival
based on the transformation signatures, patients were divided into four groups accordingly to the
expression levels of genes belonging to the MCPcounter signatures and to the transformation signatures:
High-high (high levels of both), high-low (high MCP/low transformation), low-low (low levels of both),
or low-high (low MCP-high transformation).
The ‘survfit’ function and the ‘survdiff’ function were used to generate the Kaplan-Meier curves
and to calculate the significance.
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ABSTRACT
Transcriptional networks supervising class IIa HDAC
expression are poorly defined. Here we demon-
strate that MEF2D is the key factor controlling
HDAC9 transcription. This control, which is part of
a negative feed-back loop during muscle differenti-
ation, is hijacked in cancer. In leiomyosarcomas the
MEF2D/HDAC9 vicious circuit sustains proliferation
and cell survival, through the repression of the death
receptor FAS. Comprehensive genome-wide studies
demonstrate that HDAC4 and HDAC9 control different
genetic programs and show both specific and com-
mon genomic binding sites. Although the number
of MEF2-target genes commonly regulated is sim-
ilar, only HDAC4 represses many additional genes
that are not MEF2D targets. As expected, HDAC4−/−
and HDAC9−/− cells increase H3K27ac levels around
the TSS of the respective repressed genes. How-
ever, these genes rarely show binding of the HDACs
at their promoters. Frequently HDAC4 and HDAC9
bind intergenic regions. We demonstrate that these
regions, recognized by MEF2D/HDAC4/HDAC9 re-
pressive complexes, show the features of active en-
hancers. In these regions HDAC4 and HDAC9 can dif-
ferentially influence H3K27 acetylation. Our studies
describe new layers of class IIa HDACs regulation,
including a dominant positional effect, and can con-
tribute to explain the pleiotropic actions of MEF2 TFs.
INTRODUCTION
Class IIa HDACs are important regulators of different
adaptive and differentiative responses. During embryonic
development, these deacetylases influence specific differen-
tiation pathways and tissue morphogenesis (1–3). In ver-
tebrates HDAC4, HDAC5, HDAC7 and HDAC9 consti-
tute the class IIa subfamily. Because of the Tyr/His sub-
stitution in the catalytic site, they exhibit a negligible lysine-
deacetylase activity (2,3). However, the deacetylase domain,
through the recruitment of the NCOR1/NCOR2/HDAC3
complex, can influence histones modifications, including
acetylation (4–6). The repressive influence of class IIa
HDACs can also be exploited independently from HDAC3
recruitment. In fact MITR, a HDAC9 splicing variant, can
still repress transcription in the absence of the deacety-
lase domain (7). The amino-terminus of class IIa HDACs
is dedicated to the binding of different transcription fac-
tors (TFs), among which MEF2 family members are the
foremost characterized (3). Overall, class IIa HDACs ge-
nomic activities require their assembly into multiprotein
complexes where they operate as platforms coordinating the
activity of TFs, as well as of other epigenetic regulators (1–
3,8).
These deacetylases are subjected to multiple levels of
regulation. The phosphorylation-dependent control of the
nuclear/cytoplasmic shuttling has been the most com-
monly investigated (3,9). Curiously, although the lineage-
dependent expression is a main feature of class IIa, sig-
nalling pathways and mechanisms controlling their tran-
scription are largely unknown (3). An exception is the mus-
cle tissue. Here HDAC9 transcription is under the direct
control of MEF2D. In this manner, the MEF2D-HDAC9
axis sustains a negative-feedback loop in the transcrip-
tional circuit of muscle differentiation to buffer MEF2D
activities (10). Importantly, in specific cancer types, this
circuit seems to be misused. In pre-B acute lymphoblas-
tic leukaemia MEF2D oncogenic fusions dramatically up-
regulate HDAC9 expression (11,12). Abrogation of the
MEF2D-HDAC9 negative circuit was also observed in
highly aggressive malignant rhabdoid tumor, non-small cell
lung cancer, oral squamous cell carcinoma and leiomyosar-
coma (13). Since the pro-oncogenic roles of class IIa HDAC
have been proved by different studies, understanding the
reasons and the importance of such abrogation is of primary
interest in cancer research (14–18).
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In this manuscript, we have investigated the MEF2-
HDAC axis in cellular models of leiomyosarcoma (LMS).
LMS are rare highly malignant tumors of mesenchymal ori-
gin, with cells presenting features of the smooth muscle lin-
eage (19). We have demonstrated that theMEF2D-HDAC9
axis plays a key role in the maintenance of the transformed
phenotype and deciphered the genomic, epigenomic, and
transcriptomic landscapes under the control of class IIa
HDACs.
MATERIALS AND METHODS
Cell cultures and cytofluorimetric analysis
Leiomyosarcomas cells (LMS), SK-UT-1, SK-LMS-1,
MES-SA and DMR were grown as previously described
(15). HEK-293T and AMPHO cells were grown in Dul-
becco’s modified Eagle’s medium (DMEM) supplemented
with 10% FBS. For PI staining, cells were collected and
resuspended in 0.1 ml of 10 g/ml propidium iodide (PI)
(Sigma-Aldrich), in PBS and incubated for 10 min at
RT. After washes, cells were fixed with 1% formaldehyde
(Sigma-Aldrich) and treated with 10 g/ml RNase A. Flu-
orescence was determined with a FACScan™ (Beckman
Dickinson).
CRISPR/Cas9 technology
The generation of HDAC4 and HDAC9 null SK-UT-1
cells was previously described (6). SK-UT-1 cells mu-
tated in the MEF2-binding sites within the HDAC9
promoter were obtained after co-transfection of the
pSpCas9-2A Puro plasmid expressing the two sgRNA
(GGTCGGCCTGAGCCAAAAAT, CTGGACAGCT





10:1). After selections, clones were screened by PCR and
immunoblot. Sanger sequencing was applied for the final
validation.
Immunofluorescence, random cell motility and immunoblot-
ting
Cells were fixed with 3% paraformaldehyde and perme-
abilized with 0.1% Triton X-100. The secondary antibod-
ies were Alexa Fluor 488-, 546- or 633-conjugated anti-
mouse and anti-rabbit secondary antibodies (Molecular
Probes). Actin was labelled with phalloidin-AF546 (Molec-
ular Probes). Cells were imaged with a Leica confocal scan-
ner microscopy SP2. Nuclei were stained with Hoechst
33258 (Sigma-Aldrich). For S phase analysis, cells were
grown for 3 h with 50 M bromodeoxyuridine (BrdU). Af-
ter fixation, coverslips were treated with HCl and processed
for immunofluorescence. For random cell motility measure-
ments, cells were seeded in six-well plates coated with fi-
bronectin and subjected to time-lapse analysis. Images were
recorded every 15 min for 6 h with a Leica AF6000 station.
Time-lapse experiments were analyzedwith theMetamorph
software (Molecular Devices).
Cell lysates after SDS-PAGE and immunoblotting on ni-
trocellulose (Whatman) were incubated with primary an-
tibodies. HPR-conjugated secondary antibodies were ob-
tained from Sigma-Aldrich and blots were developed with
Super Signal West Dura (Pierce), as previously described
(20).
Antibodies and chemicals
The primary antibodies used were anti: MEF2D (BD Bio-
science); MEF2A (C-21), Caspase-3 (E-8) and FAS (M-
20) (Santa Cruz Biotechnology); RAN and Caspase 8
(D35G2) (Cell Signaling Technology); Actin, BrdU, and
FLAG/M2 (Sigma-Aldrich); GFP, HDAC4 and Caspase-
9 (15); HDAC5 (21); H3K27ac (ab4729) and H3K27me3
(ab6002) (Abcam); H3K4me3 (GTX128954, GeneTex).
The anti-HDAC9 antibody was produced in rabbit by in-
jecting a His-tagged fragment of HDAC9 (aa 275–600) ex-
pressed in Escherichia coli. The antiserum was affinity puri-
fied against the same fragment GST-tagged of HDAC9.
The following chemicals were used: Doxorubicin and
Metformin (Alexis); Lapatinib and Imatinib (LC Labora-
tories); MKK2206 and SAHA (Cayman Chemicals); BrdU
(Sigma-Aldrich); FasL (Peprotech).
Plasmid construction, transfection, retroviral and lentiviral
infection, silencing
pLENTI-CRISPR/V2 (Plasmid #52961) and
pSpCas9(BB)-2A-GFP(PX458) (Plasmid #48138) were
from Addgene. pWZL-HYGRO FLIPs FLAG was
obtained by a restriction-based approach from pcDNA3-
FLIPs. pWZL-HYGRO FLAG plasmid was used as
acceptor plasmid and as control for infection. The knock-
down of MEF2D and MEF2A was achieved by using
pLKO.1 shRNAs (TRCN0000015897, TRCN00000274054,
TRCN00000432718, TRCN000005133), as already de-
scribed (6). For the Luc assay on HDAC9 promoter
the 15897 and 432718 shRNAs were selected and used
in consideration of their higher efficiency (6). HDAC9
promoter (6) (bp –1160/+23) activity was measured in
transfected 293-T or SK-UT-1 cells according to the man-
ufacturer (Dual-Glo Luciferase Assay System, Promega)
and expressed as a ratio to the luciferase activity of pRe-
nilla. Transfections, viral infections and siRNA delivery
were done as previously described (20,21). The following






Caspase and Resazurin reduction assays
The caspase activity was evaluated using the Apo-ONE
caspase-3/7 homogeneous assay (Promega). Cells grown in
96-well plates were treated with the different insults and
tested for caspase activity as recommended by the vendor.







niversita' degli Studi di U
dine C
ISB di Scienze user on 28 D
ecem
ber 2019
Nucleic Acids Research, 2019 3
cells were incubated for 150 min. at 37◦C with resazurin so-
lution (0.15mg/ml) (Sigma-Aldrich). The product of reduc-
tion was quantified by using the PerkinElmer EnSpire 2300
Multilabel Reader.
ChIP, library construction, ChIP-seq and NGS data analysis
ChIP was performed as previously described (18). Chro-
matin was immunoprecipitated with 2 g of anti-H3K27ac,
2.5 g of anti-MEF2D, 4 g of anti-HDAC4 and anti-
HDAC9 antibodies or control IgG. Three independent ex-
periments were pulled and 5 ng of total DNA were used
to prepare ChIP-seq libraries, according to TruSeq ChIP
Sample Preparation guide (Illumina). Libraries were se-
quenced on the Illumina HiSeq 2000 sequencer. The qual-
ity of sequencing reads was evaluated using the ShortRead
R/Biocoductor package (23). Sequencing reads fromChIP-
seq experiments were aligned to the NCBI GRCh38 human
reference with Bowtie 2 (24). Peak calling was performed
against input sequences using MACS2 (25). Gene annota-
tion, Venn diagrams and bar plots representing the peak lo-
calization in genomic elements/distance from TSS were ob-
tained using the ChIPseeker R/Bioconductor package (26).
Peak heatmaps and genomic loci visualization were gener-
ated using the gplots, biomaRt and Gviz R/Bioconductor
packages (27–30). H3K27ac signals were normalized using
theMAnormmethod for quantitative comparison of ChIP-
seq data (31).
RNA extraction and quantitative qRT-PCR
Cells were lysed using Tri-Reagent (Molecular Research
Center). 1.0g of total RNAwas retro-transcribed by using
100 units of M-MLV Reverse transcriptase (Life Technolo-
gies) in the presence of 1.6 M oligo(dT) and 4 M Ran-
dom hexamers. qRT-PCRs were performed using SYBR
green technology (KAPA Biosystems). Data were analyzed
by comparative threshold cycle (delta delta Ct Ct) us-
ingHPRT andGAPDH as normalizer. A list of the primers
used for qRT-PCR and ChIP-qPCR is provided in Supple-
mentary Table S1.
RNA expression array and data analysis
Aliquots of RNAs, purified using RNeasy columns (Qia-
gen), were amplified according to the specifications of the
Illumina TotalPrep RNAAmplification Kit (Ambion). Hy-
bridization on Illumina whole-genome HumanHT-12 v 4.0
chip (Illumina), scanning and background subtraction were
done according to the manufacturer’s specification. Fold-
change and P-values for each probe set were calculated
as previously described (18). P-values data were then cor-
rected for multiple hypotheses testing using the Benjamini–
Hochberg methods. Differentially expressed genes (DEGs)
were selected based on fold changes and adjusted P-values
<0.05. Gene set enrichment analysis (GSEA) and the
MSigDB database http://software.broadinstitute.org/gsea/
index.jsp (32,33) were used to investigate statistically rele-
vant biological associations.
Gene lists were analyzed separately using the Ge-
neOntology (BiologicalProcess and ImmuneSystemPro-
cess; Min GO Level = 3 and Max GO Level = 8),
KEGG, WikiPathways, CORUM-FunCat-MIPS, REAC-
TOME Pathways and REACTOME Reactions databases
as source of information. A right-sided hypergeometric test
(corrected using the Benjamini–Hochberg) was applied to
find enriched terms.
Statistics
For experimental data Student t-test was employed.Mann–
Whitney test was applied when normality could not be as-
sumed. P < 0.05 was chosen as statistical limit of signif-
icance. For comparisons between samples >2, the Anova
test was applied coupled to Kruskal–Wallis and Dunn’s
Multiple Comparison Test. We marked with *P< 0.05, **P
< 0.01, ***P < 0.001. Unless otherwise indicated, all the
data in the figures were represented as arithmetic means ±
the standard deviations from at least three independent ex-
periments.
RESULTS
HDAC9 is a MEF2-target gene highly transcribed in
leiomyosarcomas cells
Class IIa HDACs and particularly HDAC5 and HDAC9,
are overexpressed in approximately 30% of leiomyosar-
comas (LMS) (20,34). The mechanisms responsible for
this up-regulation are not defined. The TCGA data anal-
ysis (Figure 1A) shows that in LMS patients the co-
overexpression of one class IIa HDAC and one MEF2 TF
is frequent. In fact, a significant co-occurrence of MEF2D
and HDAC9 overexpression (P-value 0.035, log odds ra-
tio 1427) and a trend of co-occurrence for MEF2A and
HDAC5 mark these patients. ENCODE data evidence
the presence of MEF2 binding sites, which are conserved
through evolution, in the proximal promoter of HDAC9
(Figure 1B). We proved that MEF2D up-regulates the tran-
scription from the HDAC9 promoter in different cell lines
including LMS cells (Figure 1C). SK-UT-1 cells faith-
fully reflect LMS in terms of MEF2D and HDAC9 de-
regulation. Both proteins are highly up-regulated in these
aggressive cells (6). When MEF2D was silenced, HDAC9
expression was down-regulated at the mRNA and pro-
tein levels (Figure 1D, F). By contrast, MEF2A silenc-
ing does not influence HDAC9 levels (Supplementary Fig-
ure S1A, B). Finally, in SK-UT-1 cells transcription from
the HDAC9 promoter was strongly dependent on MEF2D
(Figure 1E).
ChIP experiments demonstrated that MEF2D binds the
promoter of HDAC9 (Figure 1G). MEF2D is required to
sustain an open chromatin status, characterized by high lev-
els of H3K4me3 and H3K27ac, on the HDAC9 promoter
but not on the control TK promoter (Figure 1H and Sup-
plementary Figure S1C). MEF2D down-regulation favors
the appearance of H3K27me3 (Figure 1H and Supplemen-
tary Figure S1C). In summary, MEF2D is a key TF that
boosts HDAC9 transcription in SK-UT-1 cells.
HDAC4 and HDAC9 show different subcellular localizations
in LMS cells
To study the role of class IIa HDACs in LMS, we gener-







niversita' degli Studi di U
dine C
ISB di Scienze user on 28 D
ecem
ber 2019
4 Nucleic Acids Research, 2019
Figure 1. The MEF2D-HDAC9 circuit in leiomyosarcomas. (A) Oncoprint of mRNA expression variations for the indicated MEF2 and class IIa HDACs
family members. Data were obtained from the TCGA database and include RNAseq data of 100 patients with LMS. The heatmap shows the expression
levels (z-score normalized log2 (FPKM) values) andwas generated through cBioPortal (http://www.cbioportal.org). (B) The evolutionary conserved binding
site, validated by ENCODE, for MEF2A (blue) and for MEF2C (red) in the proximal promoter of HDAC9 are shown. (C) Luciferase assay for HDAC9
promoter activity in HEK-293 cells transfected with MEF2D-GFP or GFP and the promoter regions (bp –1160/+23) amplified from IMR90, SK-LMS-1
and SK-UT-1 cells. 3xMEF construct, presenting three binding sites for MEF2, was used as positive control. Data were normalized by co-transfecting
pRenilla and expressed as mean ± S.D., n = 3. (D) mRNA expression levels of the indicated genes, as measured by qRT-PCR, in MEF2D knock-down
cells with respect to control. Two independent shRNA were used. Data are expressed as mean ± S.D., n = 3. (E) Luciferase assay for HDAC9 or control
promoter activities in SK-UT-1 cells silenced for MEF2D expression. Data were normalized by co-transfecting pRenilla and expressed as mean ± S.D., n
= 3. (F) Immunoblot analysis in SK-UT-1 MEF2D knock-down cells, using the indicated antibodies. Actin was used as loading control. (G) Chromatin
was immunoprecipitated from SK-UT-1 cells WT or silenced for MEF2D, using the anti-MEF2D antibodies. Normal rabbit IgGs were used as control.
The HDAC9 promoter region (-758:-528) containing the MEF2 binding sites was amplified. Data are presented as mean ± S.D., n = 4. (H) Chromatin
was immunoprecipitated using the anti-H3K4me3, anti-H3K27ac and anti-H3K27me3 antibodies from SK-UT-1 cells and SK-UT-1 silenced forMEF2D.
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using the CRISPR/Cas9 technology (6). Two different
clones, generated using two different guides, were selected
for each KO. Immunoblot analysis shows that LMS cells
express HDAC9 and high levels of its splicing variant
MITR (Figure 2A). As predicted, in HDAC9 KO cells
both isoforms are absent. Curiously, in HDAC4−/− cells
a different pattern of HDAC9 can be appreciated. Levels
of the full-length HDAC9 are reduced and a shorter iso-
form is increased. Similarly, also the levels of MITR are
augmented. In HDAC9−/− cells, a fast migrating HDAC4
isoform is detectable, which shows a size similar to the
caspase-cleaved fragment of this deacetylase (35) (see be-
low). The levels of HDAC5 are augmented in the two KO
cells, more strongly in HDAC9−/− cells, possibly as part
of a compensatory mechanism. HDAC7 is expressed at ex-
tremely low/undetectable levels in SK-UT-1 cells. Similarly,
MEF2A andMEF2D levels are augmented in the KO cells,
withMEF2A showing a higher increase inHDAC9−/− cells.
These increases correlate with elevated levels of the corre-
sponding mRNAs (Supplementary Figure S3A).
Regulation of class IIa HDACs nuclear-cytoplasmic
shuttling is a key aspect for the control of their repressive ac-
tivities. Immunofluorescence analysis proved that HDAC9
is prevalently nuclear in these LMS cells (Figure 2B). As
a consequence, its localization is not influenced by lepto-
mycin B treatment (Figure 2B). By contrast, HDAC4 shows
a pan/diffused localization, which can be converted into nu-
clear after the inhibition of the CRM1-dependent nuclear
export (Figure 2B). Ran localization was used as counter-
staining. The KOs cells have proved the antibodies speci-
ficity. In summary, while HDAC9 is largely nuclear resident,
HDAC4 is constantly subjected to nuclear/cytoplasmic
shuttling.
Transcriptomes under HDAC4 and HDAC9 regulation in
LMS cells
To investigate the genetic repertoire under the control of
HDAC4 and HDAC9 in LMS, the transcriptome of two
HDAC4−/− clones (26 and 125) and twoHDAC9−/− clones
(167 and D43) generated with independent guide pairs were
compared.
The vast majority of the up- and down-regulated genes
(n = 566 and n = 533, respectively), were shared be-
tween the two HDAC4−/− clones (Figure 3A). By con-
trast, HDAC9−/− clones have much less commonly regu-
lated genes (n = 130 up- and n = 71 down-regulated) and
a consistent number (n = 192 up- and n = 159 down-
regulated) were clone-specific (Figure 3B, Supplementary
Tables S2, S3 and Figure S2).
In order to define a common gene signature, we com-
pared the lists of up- and down-regulated genes between
HDAC4−/− andHDAC9−/− cells. Twenty nine induced and
21 repressed genes represent the common signature of the
two class IIa HDACs (Figure 3C). This result suggests that
the two HDACs play distinct roles in LMS cells.
Since class IIaHDACs are well-known repressors of tran-
scription, we focused the attention on transcripts whose lev-
els increased after the knock-outs. To further confirm the
specific activities of the two HDACs, we compared the lev-
els of genes up-regulated in HDAC4−/− cells with those in
Figure 2. Characterization of SK-UT-1 cells knocked-out for HDAC4 and
HDAC9. (A) Immunoblot analysis of HDAC9,MITR, HDAC4, HDAC5,
MEF2A and MEF2D in SK-UT-1 cells WT and in two KO clones for
HDAC4 (125 and 26) and HDAC9 (167 and D43). Asterisk points to a
non-specific band. Actin was used as loading control. (B) Immunofluores-
cence analysis in SK-UT-1WT,HDAC4−/−, HDAC9−/− cells stainedwith
the indicated antibody.Where indicated, cells were treated for 2 hwith Lep-
tomycin B (Lept. 50 ng/ml) to inhibit the nuclear export. The anti-RAN
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Figure 3. HDAC4 and HDAC9 regulate different patterns of genes, only partially overlapping. (A) Venn diagrams showing the number of transcripts
commonly and differentially up-regulated or downregulated between the two clones of HDAC4−/− cells. (B) Venn diagrams showing the number of
transcripts commonly and differentially up-regulated or downregulated between the two clones of HDAC9−/− cells. (C) Venn diagrams showing the
number of transcripts commonly and differentially up-regulated or downregulated among the different clones of HDAC4−/− and HDAC9−/− cells. (D)
Heatmap of the 566 significantly up-regulated genes inHDAC4−/− cells and their expression levels inHDAC9−/− cells. In the heatmap genes up-regulated
are shown in green and down-regulated in blue, as fold changes. (E) Heatmap of the 130 significantly up-regulated genes in HDAC9−/− cells and their
behavior in HDAC4−/− cells. In the heat map genes up-regulated are shown in green and down-regulated in blue, as fold changes. (F) Bar plots of the
Cytoscape-ClueGOmost significantly enriched functional terms according to the GO: Biological Process, Reactome or WikiPathways databases. Analysis
were performed for the indicated groups of up-regulated genes, retaining the top 3 terms defined by the two most informative functional databases. (G)
Pie charts illustrating the dependency on MEF2 of the genes up-regulated in HDAC4−/− and HDAC9−/− cells. The dependency on MEF2 was scored
by looking at the genes affected by MEF2A/D knock-down (6). (H) Effect of MEF2A and MEF2D silencing on the gene lists associated with the most
significantly enriched functional terms of the Cytoscape-ClueGO analysis as shown in (A) in SK-UT-1 HDAC4−/− cells. The dependency on MEF2 was
expressed as percentage. (I) Effect of MEF2A and MEF2D silencing on the gene lists associated with the most significantly enriched functional terms of
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HDAC9−/− cells and vice versa. Heatmaps show that al-
though a group of genes was similarly up-regulated by the
knock-out of the two HDACs, many genes were specific for
each HDAC, as they were unperturbed in the other KO or,
in some instances, repressed (Figure 3D and E). qRT/PCR
analysis on a panel of these differentially regulated genes
further validated these results (Supplementary Figure S3A).
The genetic programs regulated by HDAC4 and HDAC9
We used the Cytoscape plugin ClueGO (36,37) to under-
stand the functions of genes up-regulated in HDAC4−/−
and HDAC9−/− cells, as well as of genes induced in both
conditions. As expected, the most significantly enriched
functional terms differ from HDAC4 and HDAC9 (Fig-
ure 3F). HDAC4-repressed genes are involved in the ox-
idative stress response, proliferation and programmed cell
death. By contrast, HDAC9 repressed genes include nega-
tive regulators of cell migration/locomotion and regulators
of actin cytoskeleton. Interestingly, death receptor signaling
emerged as a pathway under HDAC9 influence. A common
genetic program regards the mineral absorption.
In order to identify genes under the influence of the
MEF2-HDAC axis, we compared the lists of genes up-
regulated in HDAC4−/− and HDAC9−/− cells with genes
that are repressed by MEF2A and MEF2D in the same
cells (6). Figure 3G highlights such overlaps, indicating a
similar and strong contribution of these TFs to HDAC9-
mediated repression. Although themajority of theHDAC4-
repressed genes are not under the influence of MEF2A or
MEF2D, the absolute number of MEF2A/D target genes
is similar to HDAC9. Furthermore, within the HDAC4-
repressed genes, MEF2A influence is more pronounced
compared to MEF2D. This observation was confirmed by
GSEA (Genes Set Enrichment Analysis). Here significant
enrichmentswere obtained onlywhen the comparisonswere
performed between HDAC9 and MEF2A or MEF2D reg-
ulated genes (Supplementary Figure S3B).
Subsequently, we wondered to what extent MEF2-
HDAC co-targets could recapitulate the previously identi-
fied biological functions associated with genes repressed by
HDAC4 or HDAC9. Figures 3H/I summarizes the number
(n) of genes associated with each enriched term, the per-
centage of genes that are also MEF2A or MEF2D targets,
the percentage of those in common between MEF2A and
MEF2D (MEF2A &MEF2D) and the percentage of those
that are targets of at least oneMEF2 (MEF2A +MEF2D).
Finally, we used a right-sided Fisher’s exact test to deter-
mine the probability that each biological function was sig-
nificantly enriched in one of the HDAC/MEF2 co-target
subsets with respect to the corresponding list of upregu-
lated genes in HDAC4−/− or HDAC9−/− cells. Firstly, this
allowed the identification of ‘response to oxygen-containing
compound’ and ‘programmed cell death’ as terms enriched
in both MEF2A (P-value = 7e–03 and P-value = 7e–04,
respectively) and MEF2D targets common to HDAC4 (P-
value = 7.5e–03 and P-value = 5.3e–03, respectively). We
also defined ‘negative regulation of locomotion’ as specifi-
cally enriched (P-value = 4.6e–02) in the HDAC9/MEF2A
targets subset, representing the only HDAC9-related bio-
logical process showing specificity for one of the twoMEF2
regulators.
In summary our data demonstrate that different MEF2-
HDAC complexes can regulate distinct gene-networks.
Mapping the genomic regions bound by HDAC4, HDAC9
and MEF2D
ChIP-seq experiments were performed to investigate, at a
genomic level, HDAC4 and HDAC9 binding in relation
to MEF2D. As expected from the transcriptomic analysis,
HDAC4 shows a higher genomic binding (n = 7732) com-
pared toHDAC9 (n= 1257), whileMEF2Dpeaks are 2214,
in agreement with previous studies (38). 68% of MEF2D
peaks contains at least a MEF2 binding sites (Supplemen-
tary Table S4). By comparing the binding locations, 45% of
MEF2D peaks co-localize with HDAC4, HDAC9 or both
(Figure 4A). In particular, 56% of these events are in com-
monwithHDAC4 andHDAC9, 43% areMEF2D/HDAC4
specific and only 1.2% are MEF2D/HDAC9 specific.
HDAC4 displays a substantial MEF2D-independent activ-
ity as 82% of its peaks are bound neither by MEF2D nor
by HDAC9. On the contrary, HDAC9 specific peaks are
less frequent (20%). DNA motif analysis on the HDAC4-
specific peaks showed an enrichment for SMAD3 and
CENPB binding motifs. When the same analysis was per-
formed on HDAC4-specific peaks localized in H3K27ac
enriched regions, BACH2 and ZNF384 showed the high-
est enrichments (Supplementary Figure S4). The ChIP-seq
data for MEF2D, HDAC4, HDAC9 and the variations in
H3K27ac were confirmed by ChIP-qPCR for 11 distinct
genomic regions (Supplementary Figure S5). Overall, the
analysis of the genomic binding sites confirms the different
activities of the twoHDACs, as emerged from the transcrip-
tomic analysis.
The majority of HDAC4 and HDAC9 peaks localize in
intergenic regions, (68% and 76%, respectively), as previ-
ously observed for other class IIa HDACs (18,39,40). By
contrast only 36% of MEF2D peaks map in intergenic re-
gions while 27% are in promoter regions (Figure 4B). In-
terestingly, MEF2D peaks localization undergoes signif-
icant changes when associated with common binding of
HDAC4/HDAC9. In these cases 64% occur in intergenic,
14% in introns and only 18% in promoter regions. This re-
localization seems to only partially depend on the presence
of HDAC4 alone, since MEF2D/HDAC4 common map-
ping is 47% intergenic, 29% intronic and 17% in promoter
regions. To further evaluate the chromatin status around
these peaks, we mapped the H3K27 acetylation either as a
perfect overlap (min. 1 bp in common) or in a 2 kb interval
from the peak summit (Figure 4C). Overall, the presence of
HDAC4 frequently correlates with an open chromatin sta-
tus, while HDAC9 peaks are commonly confined in regions
marked by poor H3K27 acetylation. These correlations are
MEF2-independent. In general, the co-presence ofMEF2D
increases H3K27 acetylation incidence (Figure 4C).
It is plausible that the genomic binding sites of the two
class IIa HDACs and possibly of MEF2D, within the reg-
ulative elements of the genes up-regulated after the KO of
HDAC4 and HDAC9, may influence their epigenetic sta-
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Figure 4. Defining the genomic binding sites and influences of MEF2D, HDAC4 and HDAC9 on H3K27ac. (A) Venn diagrams showing the overlaps
between the MACS2-definedMEF2D, HDAC4 and HDAC9 ChIP-seq enriched peaks in SK-UT-1 cells. (B) Genomic distribution of the MACS2-defined
MEF2D, HDAC4 and HDAC9 ChIP-seq enriched peaks in SK-UT-1 cells. (C) Proximity, expressed as percentage, of H3K27ac marks to the MEF2D,
HDAC4 and HDAC9 ChIP-seq enriched peaks in SK-UT-1 cells. The minimum distance is 0bp (overlapping) and 1kbp, respectively, for the left and right
panel. (D) Heatmaps showing the differences inH3K27ac distribution betweenHDAC4−/− andHDAC4+/+ orHDAC9−/− andHDAC9+/+ SK-UT-1 cells.
The displayed regions are located ±3kb around the TSS of a subset of 475 microarray-defined HDAC4 repressed genes (left panel) and of 118 microarray-
defined HDAC9 repressed genes (right panel). Binding peaks for MEF2D, HDAC4 and HDAC9 in the same regions are also provided. The differences in
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evaluated variations of the H3K27ac status around the TSS
(-/+3kb) of these genes. In the same regions, we also in-
vestigated the presence of MEF2D, HDAC4 and HDAC9
peaks. We excluded from the analysis transcripts with un-
defined functional annotations, thus resulting in 475 genes
for HDAC4−/− and 118 genes for or HDAC9−/− cells.
The levels of H3K27ac were augmented around the
TSS of several genes up-regulated in HDAC4−/− and
HDAC9−/− cells. This increase was evident also in regions
more distal with respect to the TSS (Figure 4D). Frequently,
acetylation spreading emerged as a consequence ofHDAC4
and HDAC9 deletions.
Fourteen genes are characterized by HDAC4 binding
within 3 kb from the TSS and six of them also show co-
binding withMEF2D. Among these six genes,ARMC4 and
MPP7 evidence multiple binding events for MEF2D and
HDAC4 (Figure 4D). These two genes are marked by in-
tense spreading ofH3K27ac in the absence ofHDAC4. Sur-
prisingly, peaks for HDAC9were not found around the TSS
of genes up-regulated in knocked-out cells, even though for
4 genes (CXCL1, ENC1, PLK2 and SORT1)MEF2D bind-
ing was observed.
Next, we expanded the analysis up to ±30 kb from the
TSS to find evidence of distal regulative elements. The in-
crease of H3K27ac and the spreading effects elicited by the
absence of the two HDACs was confirmed (Figure 5A).
ARMC4, MKX, MPP7, NFIB, ROR1, ZNRF3 are among
the most evident examples of this behavior in the absence of
HDAC4. CXCL1, CXCL8/IL8 and SMAD3 in the case of
HDAC9 absence. Importantly, CXCL1 and IL8 are among
the highest up-regulated genes inHDAC9−/− cells (Supple-
mentary Table S2).
Twenty five genes show HDAC4 binding within 30kb
from the TSS and frequently with multiple binding events.
Peaks for HDAC9 were again rare, with only RAB31 with
a positive hit. MEF2D genomic binding was found in 28
genes up-regulated in HDAC4−/− cells, of which seven
shared with HDAC4 and in eight genes up-regulated in
HDAC9−/− cells (Figure 5A).
HDAC4 and HDAC9 regulate H3K27ac levels in regulative
regions distal from the TSS
The previous analysis has revealed that, although changes
in H3K27ac are prominent in regions around the TSS
of genes up-regulated after the KO of the two HDACs,
only a fraction of these genes displays the binding of
HDAC4 (5,3%) and rarely of HDAC9 (0.8%). Certainly,
some of these genes could be indirect target of the deacety-
lases. However, since several HDAC4 and HDAC9 peaks
were found in the intergenic regions, we hypothesized that
HDAC4 and HDAC9 in particular, could preferentially in-
fluence gene expression from distal regulative elements such
as enhancers.
To explore this possibility, we investigated the variations
of H3K27ac status after the knock-out of the two HDACs,
at the distal regions marked by the co-presence of MEF2D,
HDAC4 and HDAC9 peaks (Figure 4A; n= 510). Through
this strategy we should identify the functional/active distal
regulative regions of MEF2D target genes.
Approximately 42% of these common peaks lie inH3K27
acetylated regions. 57% of these acetylated regions are
found away from a TSS (>30 kb from the TSS).
Next, we investigated whether some of these distal re-
gions showed HDAC4 or HDAC9 dependent regulation
of H3K27ac levels. Three different groups of peaks can
be identified (Figure 5B). A first group comprises com-
mon peaks that do not show strong variations in rela-
tive H3K27ac fold increases, after the knock-out of both
deacetylases (gray dots). A second group of common
peaks shows increases in relative H3K27ac, which are more
marked in the absence of one of the two deacetylases, more
frequently in HDAC4−/− cells. The third group comprises
H3K27ac peaks that appeared exclusively enriched after the
knock-out of either HDAC4 or of HDAC9.
Within these distal regions differentially modulated by
the two class IIa HDACs, we could expect to find regulative
elements that orchestrate the expression of genes differen-
tially regulated by HDAC9 and responsible for the different
impact on the proliferation of SK-UT-1 cells.
Chromosome conformation capture (3C) assay, com-
bined with Next Generation Sequencing (Hi-C) can pro-
vide a global view of all chromosomal interactions across
the genome and maps Topologically Associated Domains
(TADs) (41,42). Within these domains distal regulative re-
gions can be identified. A distal intergenic region, where
H3K27ac was modulated by HDAC9, is located almost
100kb downstream from ARHGEF28 locus. To understand
whether it could act as a distal enhancer, we compared our
ChIP-seq data to available Hi-C data obtained from the
IMR90 cell line (43).
Figure 6 shows that a region, marked by multiple bind-
ing sites for MEF2D, HDAC4 and HDAC9 dramatically
increases H3K27ac acetylation levels only after the knock-
out of HDAC9. Hi-C data indicate that this region lies
within a defined TAD and that, through chromatin loop-
ing, it could act distally to influence a region close to the
TSS of ENC1. As a matter of fact, the ablation of HDAC9
augments H3K27ac levels in the proximity of ENC1.
Overall this analysis suggests that an intergenic region,
where H3K27ac acetylation is modulated by HDAC9,
could act as distal regulative region (enhancer) for the
ENC1 gene. The detection of eRNAs in the same region reg-
ulated by HDAC9, as defined by SlideBase – FANTOM5
Human Enhancers Selector, further supports this possibil-
ity (44). Importantly, the ENC1 transcript is specifically up-
regulated in HDAC9−/− cells (Supplementary Figures S3B
and S5).
Another example of HDAC9-controlled, distal regulative
region is represented by the intragenic locus of INSYN2B,
which perfectly superimposes to a sub-TAD characterized
by the presence of eRNAs (Supplementary Figure S6A).
Finally, an example of a distal regulative region under the
specific influence of HDAC4 is represented in Supplemen-
tary Figure S6B. This regulative intergenic region is located
∼35 kb upstream from the SLC8A1 locus.Within the TAD,
binding of MEF2D, HDAC4 and HDAC9 can be found.
In this case, however, it is the KO of HDAC4 that causes
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Figure 5. Impact ofHDAC4 andHDAC9 onH3K27 acetylation at genomic regions distal from the TSS. (A) Heatmaps showing the differences inH3K27ac
distribution betweenHDAC4−/− andHDAC4+/+ orHDAC9−/− andHDAC9+/+ SK-UT-1 cells. The displayed regions are located±30kb around the TSS
of a subset of 475 microarray-defined HDAC4 repressed genes (top panel) and of 118 microarray-defined HDAC9 repressed genes (mid panel). Binding
peaks forMEF2D, HDAC4 and HDAC9 in the same regions are also provided. The differences in mRNAs levels are indicated by the heatmaps at the right
side. (B) Acetylation status of MEF2D/HDAC4/HDAC9 co-localizing peaks. Distances from the TSS of the closest coding genes are shown. The increase
of the relative H3K27ac signal after the knock-out of HDAC4 (orange) or HDAC9 (light blue) is indicated. H3K27ac peaks that are exclusively enriched
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Figure 6. Example of a distal regulative region under HDAC9-specific regulation. Detailed view of the MEF2D, HDAC4, HDAC9 and H3K27ac tracks
at the ARHGEF28 locus. H3K27ac normalized tracks are shown for WT, HDAC4−/− and HDAC9−/− SK-UT-1 cells. Gene structure and chromosomal
location are shown, with the red boxes highlighting the presence of enhancer RNAs. The boxes (light blue) evidence the chromatin looping between the
enhancer, under specific regulation of HDAC9 and the promoter of ENC1 whose expression is specifically up-regulated inHDAC9−/−cells. Hi-C data (43)
were used to represent the TADs within the ARHGEF28/ENC1 locus (http://promoter.bx.psu.edu/hi-c/view.php).
HDAC9 influences actin cytoskeleton organization, cell
spreading and motility
The gene expression studies discovered a role of HDAC9
as a coordinator of actin-cytoskeleton organization, cell
adhesion and migration. We proved the relevance in vivo
of this result by comparing the actin cytoskeleton among
the different engineered LMS cell lines. SK-UT-1 wt and
HDAC4−/− cells show a similar phenotype. Cells are bipo-
lar and scattered. Accumulation of F-actin is well evi-
dent in specific localizations at the cell periphery, indica-
tive of membrane ruffles, filopodia and lamellipodia (Fig-
ure 7A). In HDAC9−/− cells, these structures are much
less evident. Cells establish stable contacts resembling ep-
ithelial colonies. We also compared the mitochondrial net-
work using an antibody against DIABLO. Although mito-
chondria were highly fragmented in SK-UT-1 cells, in wt
andHDAC4−/− cells they cluster in the perinuclear regions
whereas in HDAC9−/− cells they are distributed through-
out the cytoplasm (Figure 7A). Quantitative morphome-
tric analysis was performed to compare the spread area
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Figure 7. HDAC9 controls spreading andmotility in LMS cells. (A) Confocal images of the indicated LMS cell lines stained for actin (red), using phalloidin
and DIABLO (green), by immunofluorescence to visualize mitochondria. Bar 50 m. (B) Dot plot representing the spread area of the indicated SK-UT-1
cells. Themedian and the first and third quartiles are indicated; n> 25. (C) Dot plot representing themean speed of the indicated SK-UT-1 cells. Time-lapse
experiments were performed over a period of 6 h. The median and the first and third quartiles are indicated n > 134. (D) Dot plot representing the mean
speed of the indicated SK-UT-1 cells. Time-lapse experiments were performed over a period of 6 hours. The median and the first and third quartiles are
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rescence studies, the spreading was markedly increased in
HDAC9−/− cells (Figure 7B).We also performed time-lapse
studies to compare the random cell motility of the different
cell lines. HDAC9−/− but not HDAC4−/− cells are charac-
terized by a dramatically reduced random cell motility (Fig-
ure 7C, D). Overall these studies demonstrate that HDAC9,
by repressing the expression of cytoskeletal components,
controls cell adhesion, morphology and motility.
HDAC9 sustains cell survival by repressing FAS expression
The transcriptomic studies indicate that HDAC9 could re-
press apoptosis and particularly the activation of the ex-
trinsic apoptotic pathway (Figure 3I). FAS emerged as a
gene specifically up-regulated in HDAC9−/−cells. Analysis
of Hi-C data shows that the FAS locus is embedded within
a subTAD adjacent to the subTAD containing the ACTA2
locus, which is transcribed in the opposite orientation. In-
terestingly, a specific ACTA2 isoform share with FAS the
promoter region (Figure 8A). The ChIP-seq did not iden-
tify peaks for MEF2D and HDAC9 within the FAS lo-
cus. Despite this, H3K27 acetylation is clearly augmented
around the TSS and throughout the first intron of FAS,
in the absence of HDAC9. Similarly a downstream inter-
genic region (approx. 40kb from the FAS TSS) is highly
acetylated in HDAC9−/− cells. Interestingly, Hi-C data in-
dicate that this intergenic region can make contact with the
FAS promoter. H3K27 acetylation in HDAC9−/− cells was
augmented also at the ACTA2 locus (Figure 8A). We vali-
dated the contribution ofHDAC9 in the control of FAS and
ACTA2 mRNA levels by qRT-PCR. As expected, FAS and
ACTA2 expression was up-regulated in HDAC9−/− cells
(Figure 8B). Up-regulation of the FAS protein was also ver-
ified by immunoblot (Figure 8C).
Overall these data suggest that HDAC9 can sustain
SK-UT-1 transformation by repressing the extrinsic apop-
totic pathway. To prove this hypothesis, we analyzed the
proliferative features of the different engineered SK-UT-1
cells. HDAC9 absence marginally reduced the percentage
of cells in S phase. HDAC4−/− cells did not show overt
defects (Supplementary Figure S7A). Time-course experi-
ments showed that HDAC4−/− cells have a partial prolifer-
ative deficit, whereas proliferation of HDAC9−/− cells was
dramatically impaired (Supplementary Figure S7B) and
marked by an increased level of cell death. This low con-
stitutive activation of the apoptotic machinery was con-
firmed by theCaspase-9 andCaspase-3 processing observed
in the absence of apoptotic insults (Supplementary Fig-
ure S7C). When the different LMS cells were grown with-
out serum, cell death was dramatically induced in the ab-
sence of HDAC9 (Supplementary Figure S7D). Finally, we
compared the proliferation of the different SK-UT-1 cells
when incubated with different pro-apoptotic drugs includ-
ing: tyrosine-kinase, HDACs, isopeptidases (22) andAkt in-
hibitors or metmorfin.With the exclusion of the two TK in-
hibitors, only inHDAC9−/− cells all drugs showed a signif-
icant stronger anti-proliferative outcome (Supplementary
Figure S7E). As expected, apoptosis elicited by FAS lig-
and (FASL) was clearly augmented inHDAC9−/− SK-UT-
1 cells (Figure 8D). In vivo, analysis of TCGA data on
leiomyosarcomas showed low levels of FAS mRNA and a
significant anti-correlation between the FAS and HDAC9
mRNA levels (Figure 8E).
The extrinsic apoptotic pathway is activated in the absence of
HDAC9
To prove the involvement of the extrinsic pathway we ex-
pressed the inhibitor of DISC activation FLIPs, the short
isoform of CFLAR/FLIP (45). FAS-induced caspase ac-
tivation was strongly attenuated in the presence of FLIPs
(Figure 8F). Importantly, also the increase of caspase activ-
ity observed in the KO cells in the absence of added apop-
totic insults, was blunted by FLIPs (Figure 8F). Next, we
evaluated the percentage of cell death in untreated cells. The
increase of cell death observed in the HDAC9−/− cells was
completely abrogated by the presence of FLIPs (Figure 8G).
To exclude that the HDAC9-dependent regulation of
FAS levels was a peculiar aspect of SK-UT-1 cells, we ana-
lyzed a panel of LMS cells for HDAC9 expression. HDAC9
levels were abundant also inDMRcells but not in SK-LMS-
1 and MES-SA uterine sarcoma cells (Supplementary Fig-
ure S8A). When HDAC9 was downregulated by two dif-
ferent siRNAs in DMR cells, FAS, ACTA2 and IL8 levels
were all augmented (Supplementary Figure S8B). The up-
regulation of these genes was not observed after HDAC4
silencing. In agreement with SK-UT-1 cells, apoptosis was
increased after HDAC9 silencing also in DMR cells (Sup-
plementary Figure S8C). We also investigated whether an
anti-correlation between class IIa HDACs and FAS levels
could be observed in leiomyosarcomas in vivo. Supplemen-
tary Figure S8D shows that a significant anti-correlation
with FAS expression in LMS involves also HDAC5, in ad-
dition to HDAC9.
We also investigated whether HDAC9 absence increased
the apoptotic susceptibility of SK-UT-1 cells to different
apoptotic insults such as: DNA damage (doxorubicin), Akt
inhibition (MKK2206) and the proteotoxic stressor G5
(Figure 8H). Only apoptosis triggered by doxorubicin and
G5 was potentiated by HDAC9 deletion. This increase was
largely suppressed by the presence of FLIPs, thus suggesting
an involvement of the extrinsic pathway. Analysis of caspase
activation confirmed that the up-regulation of the extrinsic
pathway characterizes the increased apoptotic susceptibil-
ity of HDAC9−/− cells in response to doxorubicin (Figure
8I).
Deletion of the MEF2-binding sites in the HDAC9 promoter
recapitulates the knock-out of HDAC9
Our manuscript opened with the demonstration that
MEF2D is the critical TFs involved in the up-regulation of
HDAC9. Subsequently, we proved thatHDAC9 plays a crit-
ical role in FAS expression and in the regulation of SK-UT-
1 survival. To conclude our study we needed to demonstrate
that the abrogation of the vicious loop between MEF2D
andHDAC9 suppresses cell proliferation, up-regulates FAS
expression and triggers apoptosis.
To this purpose we used the CRISPR/Cas9 technology
to mutagenize the MEF2 binding sites in the HDAC9 pro-
moter (Figure 9A). ChIP experiment demonstrated the ab-
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Figure 8. HDAC9 promotes cell survival by repressing FAS transcription. (A) Genomic view of the ACTA2/FAS locus on chromosome 1 (GRCh38).
Detailed view of H3K27ac normalized tracks (green) for WT, HDAC4−/− and HDAC9−/− SK-UT-1 cells. The boxes (light blue) evidence the chromatin
looping between a distal regulative element and the FAS promoter. Hi-C data were used to define the TADs within the FAS locus. (B) mRNA expression
levels of ACTA2, FAS and GAPDH, as measured by qRT-PCR. Data are presented as mean ± S.D relative to wild-type SK-UT-1 cells, n = 3. (C) Im-
munoblot analysis of FAS levels in the indicated SK-UT-1 clones. Actin was used as loading control. (D) Histogram representing the percentage of PI
positivity in the indicated SK-UT-1 cells, treated with 25 and 50ng/ml of FASL Data are presented as mean ± S.D. n= 3. (E) Scatter dot plot representing
the z-scores of FAS mRNA levels in individual TCGA tumors (n = 100) divided in two classes accordingly to HDAC9 levels. (F) Histogram representing
the percentage of PI positivity in the indicated SK-UT-1 cells, expressing or not FLIPs and treated for 24 hours with 25ng/ml FASL. Data are expressed
as mean ± S.D. n = 3. (G) Caspases activation (DEVDase activity) in the indicated SK-UT-1 cells, expressing or not FLIPs and treated for 24 hours with
25ng/ml of FASL. Data are expressed as mean ± S.D. n = 3. (H) Histogram representing the percentage of PI positivity in the indicated SK-UT-1 cells,
expressing or not FLIPs. Data are expressed as mean ± S.D. n = 3. (I) Caspases activation (DEVDase activity) in the indicated SK-UT-1 cells, expressing
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Figure 9. MEF2D regulative elements in the HDAC9 promoter are required for HDAC9 overexpression, FAS silencing and cell survival (A) Scheme
of the CRISPR-mediated mutagenesis of the two MEF2-binding sites in the HDAC9 promoter (B) Chromatin was immunoprecipitated from SK-UT-1
cells WT or mutagenized in the 2 MEF2D binding sites, using anti-MEF2D antibody. Normal rabbit IgGs were used as control. The HDAC9 promoter
region containing the MEF2 binding sites was amplified. Data are presented as mean ± S.D., n = 3. (C) Chromatin was immunoprecipitated using the
anti-H3K4me3, anti-H3K27ac and anti-H3K27me3 antibodies from SK-UT-1 cells WT or mutagenized in the 2 MEF2D binding sites Data are presented
as mean and standard error. n = 3. (D) Relative mRNA expression levels of GAPDH and HDAC9, as measured by qRT-PCR in WT and SK-UT-1 cells
with mutated MEF2 binding sites in the HDAC9 promoter (MEF2). Data are presented as mean ± S.D. n = 3. (E) Immunoblot analysis of HDAC9,
FAS, Caspase-8 and Actin in SK-UT-1 cells WT and with mutated MEF2 binding sites in the HDAC9 promoter (MEF2). Actin was used as loading
control. Asterisks point to non-specific bands, arrowhead to the caspase-8 cleaved form. (F) Relative mRNA expression levels of GAPDH, IL8, FAS and
ACTA2, as measured by qRT-PCR in WT and SK-UT-1 cells with mutated MEF2 binding sites in the HDAC9 promoter (MEF2). Data are presented
as mean ± S.D. n= 3. (G) Dot plot representing the spread area of the indicated SK-UT-1 cells. The median and the first and third quartiles are indicated.
n>70. (H) Histogram representing the doubling time of the indicated SK-UT-1 cells over a period of three days in culture. Data are presented as mean ±
S.D. n= 3. (I) Histogram representing the percentage of PI positivity in the indicated SK-UT-1 cells, growing in the absence of any added apoptotic insult.
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neered SK-UT-1 cells (MEF2) (Figure 9B). As a conse-
quence, epigenetic markers of open and active chromatin
are reduced (H3K27ac and H3K4me3) while marker of
closed/repressed chromatin (H3K27me3) appeared once
MEF2 binding site were removed from the HDAC9 pro-
moter. HDAC9 mRNA levels were dramatically decreased
(Figure 9C). Immunoblot analysis confirmed the strong
downregulation of HDAC9 expression, the concomitant
up-regulation of FAS and the activation of Caspase-8 (Fig-
ure 9D). Similarly to FAS, other HDAC9 target genes (IL8
and ACTA2) were up-regulated at the mRNA level when
the MEF2 binding sites in the HDAC9 promoter were mu-
tagenized (Figure 9E). Finally, cell spreading, growth arrest
and cell death were all up-regulated in SK-UT-1 cells with
mutated HDAC9 promoter.
In summary, abrogation ofMEF2 binding at theHDAC9
promoter mirrors the effect ofHDAC9 deletion on SK-UT-
1 cells survival.
DISCUSSION
Dysregulations of class IIa HDACs expression have been
reported in different tumors (1,3,6,13,46). How these al-
terations influence the epigenetic plasticity of cancer cells
is still unknown. In this manuscript we have investigated
the altered expression and dissected the functions of class
IIa HDACs in LMS. These tumors are considered ge-
netically complex soft tissue sarcomas, with a high mu-
tational burden and a complex karyotype with several
losses, gains and amplifications (19,47). Alterations in the
PI3K/AKT/PTEN pathway, deletions of the tumor sup-
pressors TP53 and RB1 and mutations in ATRX and
MED12 (34,48,49) are frequent in LMS. Up-regulation of
miR-143 and miR-145 and low expression of inflamma-
tory response genes are also common in LMS (34). Ap-
proximately 30% of LMS express high levels of a class IIa
HDACs, and of HDAC9 in particular (6).
We have demonstrated that the increased expression of
HDAC9 stems from an alteration of the MEF2-HDAC
feed-back loop. Silencing of MEF2D causes a parallel
downregulation of HDAC9 levels and it is coupled to
the appearance of a repressive epigenetic state at its pro-
moter. Furthermore, the CRISPR-mediated deletion of the
MEF2D binding sites in the HDAC9 promoter switches off
HDAC9 transcription and perfectly recapitulates the prolif-
erative defects of SK-UT-1 cells knocked out for HDAC9.
Our in vitro studies find substantiation in vivo. In LMS
patients the high levels of HDAC9 are significantly corre-
latedwith high levels ofMEF2D expression. A similar alter-
ation in the MEF2-class IIa HDACs loop could be respon-
sible for the overexpression ofHDAC5. In this caseMEF2A
seems to be involved.Dysfunctions of theMEF2D-HDAC9
circuit might be common to other tumor types (50). For
example in pre-B acute lymphoblastic leukemia, character-
ized by MEF2D translocations, HDAC9 is frequently up-
regulated (11–13).
Three important questions still deserve specific answers:
i) which is themechanism that up-regulatesMEF2D expres-
sion in LMS? ii) why does not the MEF2D-HDAC9 com-
plex repress HDAC9 transcription, by binding the HDAC9
promoter? iii) why is the relationship between MEF2D and
HDAC9 so exclusive? Does HDAC9 play a different epige-
netic role with respect to the other class IIa HDACs?
We do not have an answer to the first question. However,
by defining the genomic binding sites for MEF2D, HDAC4
and HDAC9 we provide some cues to the others points.
Class IIa HDACs have been described as tissue specific
deacetylases (1–3,46). Certain phenotypes, observed after
members specific knock-outs in mice or ablation in hu-
man cells, have been explained as the consequence of their
lineage-dependent expression (6,18,21,51–54). Our study
demonstrates that further levels of complexity do exist.
The first level concerns the genomic bindings. HDAC4 and
HDAC9 share several genomic binding sites but HDAC4,
in particular, binds many additional regions, which possi-
bly escape a HDAC9-dependent regulation.
The second level of complexity concerns MEF2D. This
important class IIa HDACs partner can assemble onto spe-
cific genomic regions both the HDAC4 and the HDAC9
repressive complexes, while in other regions only a spe-
cific repressive complex is recruited, most frequently con-
taining HDAC4 rather than HDAC9. Through the selec-
tive recruitment of a specific HDAC or a combination of
more HDACs, MEF2 can monitor different patterns of
gene expression, as verified by the transcriptomic analy-
sis and proved by the different genetic programs under the
control of the two HDACs examined. Within this level of
complexity also the MITR isoform can be included. In
fact, although MITR has been described as a transcrip-
tional repressor, it contains16 aa of unknown function at
the carboxy-terminus that differ from the HDAC9 canoni-
cal isoform (55). Perhaps this complex, when assembled on
the HDAC9 promoter, could impair the manifestation of a
full repressive state.
A third level of complexity is obtained by a locus-
dependent influence of a specific class IIa HDAC. In fact,
even though a region is characterized by the co-presence
ofMEF2D/HDAC4/HDAC9 complexes, frequently only a
family member plays an active role in the epigenetic regula-
tion. We define this phenomenon as the dominant positional
effect of a specific class IIa HDAC. An example is the inter-
genic region distal from the AHRGEF28 locus. This region
shows features of an enhancer and through chromatin loop-
ing could regulate the expression of ENC1. Although both
HDAC4 and HDAC9 bind this region, only the knock-out
of HDAC9 increases H3K27ac levels at the enhancer and
promoter sites thus augmenting ENC1 expression.
In general, the paucity of promoter regions bound by
HDAC9 suggests that this HDAC is recruited by MEF2D
or by alternative TFs to repress gene expression princi-
pally from distal regulative elements showing features of en-
hancers.
Another important difference marks HDAC9 with re-
spect to HDAC4. HDAC9 very rarely binds the genome in
open chromatin regions, as defined by H3K27ac. This data
indicates that HDAC9 typifies stably repressed chromatin
domains while HDAC4 influences more dynamic genomic
regions, or could suggest that HDAC4 acts as the priming
pioneering repressive factor for HDAC9.
Finally, a further layer of regulation is represented
by MEF2D complexes that are not recognized by both
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should be taken into account, the demonstration that
MEF2A andMEF2D can still sustain transcription on spe-
cific loci discourages the HDAC5 hypothesis (6). On these
loci,MEF2D acts positively by promoting the transcription
of the associated genes. This evidence demonstrates that
MEF2D has the capability to selectively escape the surveil-
lance of class IIa HDACs on some well-defined genomic re-
gions.
Despite the less numerous genomic binding sites and re-
duced number of genes under its influence, HDAC9 shows
a strong impact on LMS cells proliferation. Cells deprived
of HDAC9 show a higher apoptotic index that limits their
prolonged maintenance in tissue culture. In this respect, we
speculate that a certain degree of transcriptional hetero-
geneity, observed among the different HDAC9−/− clones,
could reflect adaptive mechanisms that cells engage to sur-
vive the strong apoptotic pressure.
FAS up-regulation and the activation of the extrinsic
pathway are responsible for the increased apoptotic pres-
sure. Cytokines such as TNF-, IL12 and IFN can sustain
FAS transcription through the engagement of NF-kB, SP1,
STAT1 and IRF8 (56–60). Also TP53 family members are
involved in FAS transcription (61,62).
We could not find HDAC9 and MEF2D binding sites
at the promoter region of FAS. However H3K27ac was in-
creased after the deletion of HDAC9, both at the promoter
and at a distal site within the subTAD. This distal region
can undergo looping with the FAS promoter.
How HDAC9 could influence H3K27 acetylation at the
FAS/ACTA2 locus is mysterious. It could operate through
a distal enhancers or indirectly by controlling the expres-
sion of specific TFs. In fact, approx. 10% of the genes re-
pressed by HDAC9 encode for TFs or epigenetic regulators
and among them SMAD3 has been demonstrated to up-
regulate FAS transcription (63). Although FAS is a key el-
ement of the increased apoptotic response in HDAC9 defi-
cient SK-UT-1 cells,MEF2 are pleiotropic TFs and in other
contexts their pro-survival activities can be mediated by the
regulation of different pro-survival or pro-death genes (64–
66).
The impact of HDAC9 on LMS cells proliferation/su
rvival is not limited to SK-UT-1 cells. DMR cells sim-
ilarly overexpress HDAC9 and HDAC9 downregulation
up-regulates FAS levels and triggers apoptosis in DMR
cells too. We are confident that the repressive influence of
HDAC9 on FAS transcription is a critical event for LMS
survival/aggressiveness, as proved by the anti-correlation
observed in tumors.
CONCLUSIONS
LMS are aggressive cancers, local recurrence and metas-
tasis develop in approximately 40% of cases, which drasti-
cally reduce survival (19,34,47–49). Under these conditions
available therapies are largely ineffective and the identifi-
cation of new therapeutic targets is mandatory. Our stud-
ies point to class IIa HDACs and HDAC9 in particular
as interesting targets to revitalize the extrinsic apoptotic
pathway. Furthermore, the simultaneous up-regulation of
chemokines, cytokines and secreted factors, exemplified by
CXCL1, IL8, THBS1 andCYR61, after HDAC9 depletion,
can sustain FAS-induced apoptosis and the action of the
immune system for a better elimination of the neoplastic
cells (67–69). This represent a strong incitement to evaluate
HDAC9 inhibitors as possible onco-immunological drugs.
Finally, we are confident that our deep investigation and de-
scription of the genomic preferences of MEF2D-HDAC4-
HDAC9 complexes can fit to other models and help re-
searchers in finding a genetic and epigenetic explanation to
the pleiotropic actions of MEF2 TFs.
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Abstract
The contribution of MEF2 TFs to the tumorigenic process is still mysterious. Here we clarify
that MEF2 can support both pro-oncogenic or tumor suppressive activities depending on the
interaction with co-activators or co-repressors partners. Through these interactions MEF2
supervise histone modifications associated with gene activation/repression, such as H3K4
methylation and H3K27 acetylation. Critical switches for the generation of a MEF2 repres-
sive environment are class IIa HDACs. In leiomyosarcomas (LMS), this two-faced trait of
MEF2 is relevant for tumor aggressiveness. Class IIa HDACs are overexpressed in 22% of
LMS, where high levels of MEF2, HDAC4 and HDAC9 inversely correlate with overall sur-
vival. The knock out of HDAC9 suppresses the transformed phenotype of LMS cells, by
restoring the transcriptional proficiency of some MEF2-target loci. HDAC9 coordinates also
the demethylation of H3K4me3 at the promoters of MEF2-target genes. Moreover, we show
that class IIa HDACs do not bind all the regulative elements bound by MEF2. Hence, in a
cell MEF2-target genes actively transcribed and strongly repressed can coexist. However,
these repressed MEF2-targets are poised in terms of chromatin signature. Overall our
results candidate class IIa HDACs and HDAC9 in particular, as druggable targets for a ther-
apeutic intervention in LMS.
Author summary
The tumorigenic process is characterized by profound alterations of the transcriptional
landscape, aimed to sustain uncontrolled cell growth, resistance to apoptosis and metasta-
sis. The contribution of MEF2, a pleiotropic family of transcription factors, to these
changes is controversial, since both pro-oncogenic and tumor-suppressive activities have
been reported. To clarify this paradox, we studied the role of MEF2 in an aggressive type
of soft-tissue sarcomas, the leiomyosarcomas (LMS). We found that in LMS cells MEF2
become oncogenes when in complex with class IIa HDACs. We have identified different
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sub-classes of MEF2-target genes and observed that HDAC9 converts MEF2 into tran-
scriptional repressors on some, but not all, MEF2-regulated loci. This conversion corre-
lates with the acquisition by MEF2 of oncogenic properties. We have also elucidated some
epigenetic re-arrangements supervised by MEF2. In summary, our studies suggest that the
paradoxical actions of MEF2 in cancer can be explained by their dual role as activators/
repressors of transcription and open new possibilities for therapeutic interventions.
Introduction
MEF2 is a family of transcriptional regulators involved in the control of pleiotropic responses
during development and adult life. In vertebrates four members, MEF2A/B/C/D, compose the
family. MEF2 are characterized by the presence of a highly conserved N-terminal MADS/MEF2
domain involved in dimerization and DNA-binding, followed by the less conserved C-terminal
transactivation region [1]. Although some actions of MEF2 are redundant, functional studies
have also credited specific activities to each member of the family [2–6].
The transcriptional programs under MEF2 supervision diverge in different cell types.
MEF2-targets include genes involved in various differentiation activities [7–9]. Some of these
targets must be switched off, if they are not part of the ongoing differentiation program, even
though a transcriptionally active MEF2 is present in the same cell. Dominant epigenetic regu-
lations and/or the existence of multiple MEF2 transcriptional partners contribute to orches-
trate the context-dependent MEF2 transcriptional landscape [3,4,8]. The four family members
and their splicing variants can provide further layers of complexity to the MEF2 transcriptome
[10–13]. Furthermore, MEF2 can be converted into transcriptional repressors after the binding
to Cabin1, G9a or class IIa HDACs [14–16]. Among these transcriptional co-repressors, class
IIa HDACs (HDAC4/5/7/9) play a pivotal role and their activity is subjected to tight cellular
and environmental controls [17].
Dysfunctions in MEF2 characterize several pathological conditions, including cognitive dis-
orders, cardiac hypertrophy and cancer [18–21]. Specifically, pro-oncogenic roles of MEF2
have been reported for certain hematological malignancies and hepatocarcinomas, which are
linked to the increased expression, mutations or genetic rearrangements of these TFs [22–27].
By contrast, actions as tumor suppressors have been described in the case of soft-tissue sarco-
mas or in the case of mutations, mostly of MEF2B, in non-Hodgking lymphomas [11, 28–30].
The antagonistic roles of MEF2 in oncogenesis, suggested by these studies, cannot be
completely explained by the context-dependent regulation of their target genes [24, 30–32]. In
this scenario, the ability of MEF2 to act either as transcriptional activators or as repressors on
varying the environmental and genetic backgrounds has been so far underestimated. Hence,
we decided to address this point by dissecting the contribution of MEF2 to the tumorigenic
process using the leiomyosarcomas (LMS) as a model. LMS are rare soft tissue sarcomas show-
ing certain degrees of smooth muscle differentiation [33, 34]. In this manuscript we have
explored the transcriptional landscape and the epigenetic modifications under the control of
these TFs in relation to the tumorigenic process.
Results
The MEF2-HDAC axis in leiomyosarcomas
We have previously observed that among STS, LMS evidenced the highest repression of a
MEF2 signature, identified in HDAC4-transformed mouse fibroblasts and described in S1
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Table [28]. Hence, we used the LMS as a model to better explore the role of MEF2 on tumor
aggressiveness. Fig 1A confirms that the MEF2-signature was significantly repressed in uterine
LMS compared to benign leiomyomas and normal tissues. This repression could be mediated
by the activation of the PI3K/AKT/SKP2 pathway, which triggers the degradation of MEF2
proteins [35]. Alternatively, it might depend on the engagement of MEF2 transcriptional
repressors. In LMS, among the different MEF2-repressors, only HDAC4 and HDAC9 mRNA
levels negatively correlate with the expression of MEF2-targets (Fig 1B and 1C). We validated
these data by IHC analysis, scoring HDAC4, MEF2C and SKP2 levels in a Tissue-MicroArray
(TMA) of 57 LMS. HDAC4 levels were increased in tumors featuring higher proliferative
activity (Ki67 positivity and high mitotic index M.I.) (Fig 1D and 1E and S2 Table). Moreover,
a negative correlation between SKP2 and MEF2C was significant only in samples characterized
by low (<20) M.I. (Fig 1F and 1G and S2 Table). This observation suggests that SKP2-depen-
dent degradation of MEF2C occurs preferentially in low proliferating tumors. Interestingly, in
LMS showing the highest expression of MEF2, the Kaplan-Meier analysis indicates that high
levels of class IIa HDACs are associated with reduced patients’ survival (Fig 1H).
To prove the role of the MEF2-HDACs axis in LMS, we used well-established LMS cell
lines. As a first step, we investigated if the repression of MEF2-target genes observed in LMS
could be recapitulated in a cellular model. Two LMS cell lines, SK-LMS-1 and SK-UT-1, origi-
nally isolated from tumors with different grading (G2 and G3 respectively) [36], evidenced a
robust decrease of MEF2 transcriptional activities, when compared to normal smooth muscle
cells (SMC) (Fig 1I). Therefore, they could be used for our purpose.
Differential regulation of MEF2 proteins in leiomyosarcoma cells
SK-LMS-1 and SK-UT-1 cells were characterized for the expression of MEF2D, MEF2C and
HDAC4. The levels of HDAC4 were slightly increased in SK-UT-1 cells, whereas MEF2C and
MEF2D levels were dramatically augmented (Fig 2A). Importantly, proteasome inhibition
increased MEF2 levels only in SK-LMS-1. The UPS-independence and the high-levels of
MEF2C and MEF2D in SK-UT-1 cells can be explained by the presence of a cytoplasmic
retained, splicing variant of SKP2, the E3 ligase responsible for MEF2 poly-ubiquitylation [35,
37].
We also evaluated the expression of the ubiquitously expressed MEF2Dα1 isoform and of
the muscle-specific splicing variant MEF2Dα2 [10]. MEF2Dα2 was expressed only in SK-
LMS-1 cells (Fig 2A), in agreement with the less aggressive G2 phenotype. MG132 treatment
did not influence MEF2Dα2 levels. This result indicates that the exon-switch allows escaping
from inhibitory controls, probably because the α2 isoform is defective in SKP2-binding [35].
Similarly to MG132 treatment, the introduction of a dominant negative version of SKP2
(SKP2DN) augmented MEF2Dα1, but not MEF2Dα2 levels and only in SK-LMS-1 cells (Fig
2B). By contrast, introduction of an inducible version of SKP2 (SKP2-ER) diminished MEF2D
levels in both cell lines (Fig 2C). Finally, poly-ubiquitylation of MEF2Dα1 can be abrogated in
SK-LMS-1 cells in the presence of SKP2DN (Fig 2D), whereas this poly-ubiquitylation was
almost undetectable in SK-UT-1 cells (Fig 2E). In summary, these data demonstrate that in the
two LMS cells the MEF2-HDAC axis is subjected to different regulations.
Context dependent pro-oncogenic and tumor-suppressive roles of
MEF2D
To clarify the contribution of MEF2 to the tumorigenic process, we knocked down (KD)
MEF2D expression in SK-LMS-1 using two different shRNAs (Fig 3A). MEF2D silencing was
accompanied by the down-regulation of CDKN1A. mRNA quantities of a set of MEF2-target
MEF2 activities in leiomyosarcomas
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Fig 1. Analysis of MEF2 signature, HDAC4, SKP2 and MEF2C expression levels in leiomyosarcomas. A) Turkey box-plots
illustrating the mRNA expression levels (GSE764) of MEF2-target genes in normal uterus, benign leiomyomas and malignant
leiomyosarcomas. The latter are characterized by a significant (Kruskal-Wallis p<0.1) repression of MEF2 targets. B-C) The mRNA
expression levels of the MEF2 targets in malignant leiomyosarcoma (GSE21124) were clustered in two sub-groups according to the
expression levels of well-known MEF2 repressors (HDAC4, HDAC5, HDAC7, HDAC9, CABIN1). Only in the case of HDAC4 and HDAC9
a higher expression is significantly correlated to a decrease in the expression of MEF2 targets, as depicted in the Turkey box-plots. Mann-
Whitney p< 0.05. D) Top pictures representing a case of uterine LMS with low Ki67 and weak and focal HDAC4 cytoplasmic expression;
bottom pictures representing a case of uterine LMS with high Ki67 and diffuse cytoplasmic expression of HDAC4. E) IHC analysis of
HDAC4 protein levels in LMS samples, clustered into two groups according to Ki67 positivity (1st quartile = low; 3rd quartile = high) (left)
and M.I. (1st quartile = low; 3rd quartile = high) (right). Mann-Whitney p< 0.05. n = 22. F) A case of uterine LMS with nuclear expression of
SKP2 in the majority of the cells and weak and focal cytoplasmic expression of MEF2C. Nuclear expression of MEF2C is present in non-
neoplastic endothelial cells. Quantitative data are presented in S2 Table. G) Correlations between SKP2 and MEF2C protein levels in
LMS samples, characterized by a M.I.<20. n = 20. R2 = 0.3. H) Kaplan-Meier survival analysis related to the expression levels of class IIa
HDACs in TCGA LMS samples. From all cases (n = 106), the ones characterized by high levels of MEF2s (above the third quartile, n = 26)
were analysed and clustered into two groups according to class IIa HDAC expression levels (high levels = above the third quartile, n = 8);
Wilcoxon p<0.05. I) Turkey box-plots illustrating the mRNA expression levels (GSE39262) of MEF2 target genes in LMS cell lines (filled in
white) compared to the normal smooth muscle cells (filled in gray). Anova p<0.05, Turkey p<0.05. * p < 0.05, ** p < 0.01, *** p < 0.001
https://doi.org/10.1371/journal.pgen.1006752.g001
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genes (CDKN1A, KLF2, RHOB, CDKN1A, JUN, CNN1, IRS1) were reduced in MEF2D silenced
cells (Fig 3B). In SK-LMS-1 cells, MEF2D KD increases the number of cells in S phase (Fig
3C), the random cell motility (Fig 3D) and invasiveness, as scored by in vitro Matrigel invasion
assay (Fig 3E and S1 Fig). Finally, to complete the analysis of the tumorigenic properties, we
investigated the ability to grow in soft agar. SK-LMS-1 cells with KD MEF2D develop a higher
number of colonies, when grown in soft agar (Fig 3F).
When MEF2D expression was down-regulated in SK-UT-1 cells (Fig 3G) the scenario was
the opposite. CDKN1A was not affected, and other MEF2-targets showed a heterogeneous
behavior (Fig 3H). RHOB and CNN1 expression was down-regulated, whereas KLF2, JUN and
IRS1 were up-regulated. DNA replication was not augmented, instead a trend toward a slight
reduction was observed (Fig 3I). The random cell motility, the invasiveness properties and the
growth in soft agar were all impaired in SK-TU-1 cells KD for MEF2D (Fig 3J, 3K and 3L and
S1 Fig).
To exclude that the opposite tumorigenic functions of MEF2D were due to the presence of
the muscle-specific MEF2Dα2 splicing variant only in SK-LMS-1 cells, we specifically silenced
the MEF2Dα1 isoform. We then compared the phenotype with the KD of both α1 and α2 iso-
forms (S2A and S2B Fig). Expression of MEF2-target genes was similarly repressed in cells
silenced for both isoforms or for only the α1 (S2C Fig). In addition, the impact on the growth
in soft agar was undistinguishable between cells KD for both isoforms or only for the
MEF2Dα1 splicing variant (S2D Fig).
After MEF2D, MEF2A is the MEF2 paralogue more expressed in LMS. We then asked
whether also MEF2A plays a similar bi-faced role. MEF2A silencing in SK-LM-1 cells photo-
copied the MEF2D KD in terms of MEF2-target genes expression (S3A and S3B Fig), prolifera-
tion, cell motility, invasiveness and growth in soft agar (S3C, S3D, S3E and S3F Fig). Also in
SK-UT-1 cells MEF2A silencing replicated MEF2D KD. Certain MEF2-targets were up-regu-
lated (KLF2, JUN, IRS1) (S3G and S3H Fig), random cell motility, invasiveness and growth in
soft agar were all impaired in MEF2A silenced cells (S3J, S3K and S3L Fig). In summary these
data demonstrate that MEF2 exert opposite transforming activities in the two LMS cells.
HDAC4 binding to promoters of MEF2-target genes is increased in
SK-UT-1 cells
Our data indicate that only in SK-UT-1 cells MEF2 can exert a dominant repressive influence
on certain targets. Well-known repressive partners of these TFs are the class IIa HDACs [17].
Hence, we compared the status of HDAC4 among the two cell lines. HDAC4 levels were
increased in SK-UT-1 cells (Fig 2A) and also its nuclear/pan fraction (Fig 4A). In both LMS
cells, HDAC4 underwent nuclear/cytoplasmic shuttling, as proved by the nuclear accumula-
tion in response to leptomycin treatment.
Fig 2. Defect in UPS-mediated MEF2-degradation in the most aggressive LMS cell line. A) Immunoblot
analysis of HDAC4, SKP2 and MEF2 family members in LMS cells. Cells were treated for 8 hours with 2.5μM
of the UPS inhibitor MG132. RACK1 was used as loading control. B) Immunoblot analysis of MEF2D isoforms
in LMS cells engineered to express the dominant negative version of SKP2 (DN). RACK1 was used as loading
control. C) Immunoblot analysis of MEF2D in LMS cells engineered to express an inducible version of SKP2
fused to ER as indicated. SKP2 was induced for 30 hours with 0.5μM 4-OHT. RACK1 was used as loading
control and the nuclear relocalization of SKP2 after 4-OHT treatment was scored by immunofluorescence. D)
Cellular lysates obtained in SK-LMS-1 cells expressing the DN mutant of SKP2 were immunoprecipitated
using anti-MEF2Dα1 antibody and immunoblotted with the indicated antibodies. Immunoblots with total
lysates (input) are also included. E) Cellular lysates obtained in SK-UT-1 cells expressing the DN mutant of
SKP2 were immunoprecipitated using anti-MEF2Dα1 isoform and immunoblotted with the indicated
antibodies. Immunoblots with total lysates (input) using the indicated antibodies are also included.
https://doi.org/10.1371/journal.pgen.1006752.g002
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Also the pool of MEF2D in complex with HDAC4 was greater in SK-UT-1 cells (Fig 4B).
Finally, the binding of MEF2D and HDAC4 to the promoters of a set of well-known MEF2--
target genes (IRS1, JUN, CDKN1A, KLF2, RHOB) between the two LSM cell lines was assessed
and compared (Fig 4C). Except for IRS1 and CDKN1A, the binding of MEF2D to the different
promoters was similar between the two LMS cells. By contrast, the binding of HDAC4 to JUN
and KLF2 promoters was more pronounced in SK-UT-1 cells. Importantly, the expression of
these genes was augmented in these cells after MEF2 silencing. Accordingly, binding of
Fig 3. MEF2D silencing causes opposite effect in SK-LMS-1 and SK-UT-1 cells. A) MEF2D expression was silenced by lentiviral infection using two
different shRNAs. Immunoblot analysis of MEF2D and CDKN1A levels in SK-LMS-1 cells expressing the control shRNA or two different shRNAs against
MEF2D. RACK1 was used as loading control. B) qRT-PCR analysis of mRNA expression levels of MEF2D and of some MEF2-target genes (KLF2, RHOB,
CDKN1A, JUN, CNN1, IRS1) in SK-LMS-1 cells expressing the different shRNAs. mRNA levels are relative to control shRNA. Data are presented as
mean ± SD; n = 4. C) Analysis of the cells synthetizing DNA as scored after BrdU staining. Mean ± SD; n = 3. D) SK-LMS-1 cells expressing the indicated
shRNAs were seeded at 2x104/ml in plates coated with 10μg/ml fibronectin, or BSA; after 16h they were subjected to time-lapse analysis for 6 hours. Results
represent the individual migration rate and the average (bar) from at least 140 cells from three independent experiments. Mean and SEM are indicated. E)
Invasion properties of the SK-LMS-1 cells expressing the shRNA2 against MEF2D or the control. Data are presented as mean ± SD; n = 4. Invasion of the
Matrigel was scored after 16 hours and was expressed as ratio between cells invading the matrix in presence (oriented motility) and absence (random
invasion) of the chemoattractant. Cells were evidenced with Hoechst 33342 staining. At least 5 fields for each condition were acquired and the invading cells
were counted by using ImageJ. F) Growth in soft agar of SK-LMS-1 cells expressing the indicated shRNAs, foci were stained with MTT and counted. Data are
presented as mean ± SD; n = 4. G) MEF2D expression was silenced by lentiviral infection using two different shRNAs. Immunoblot analysis of MEF2D and
CDKN1A levels in SK-UT-1 cells expressing the control shRNA or two different shRNAs against MEF2D. RACK1 was used as loading control. H) qRT-PCR
analysis of mRNA expression levels of MEF2D and of some MEF2-target genes (KLF2, RHOB, CDKN1A, JUN, CNN1, IRS1) in SK-UT-1 cells expressing the
different shRNAs. mRNA levels are relative to control shRNA. Data are presented as mean ± SD; n = 4. I) Analysis of the cells synthetizing DNA as scored
after BrdU staining. Mean ± SD; n = 3. J) SK-UT-1 cells expressing the indicated shRNAs were subjected to time-lapse analysis for 6 hours as in Fig 3D.
Results represent the individual migration rate and the average (bar) from at least 140 cells from three independent experiments. Mean and SEM are
indicated. K) Invasion properties of the SK-UT-1 cells expressing the shRNA2 against MEF2D or the control. Data are presented as mean ± SD; n = 4.
Invasion of the Matrigel was scored after 16 hours and was expressed as ratio between cells invading the matrix in presence (oriented motility) and absence
(random invasion) of the chemoattractant. Cells were evidenced with Hoechst 33342 staining. At least 5 fields for each condition were acquired and the
invading cells were counted by using ImageJ. L) Growth in soft agar of SK-UT-1 cells expressing the indicated shRNAs, foci were stained with MTT and
counted. Data are presented as mean ± SD; n = 4. * p < 0.05, ** p < 0.01, *** p < 0.001
https://doi.org/10.1371/journal.pgen.1006752.g003
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Fig 4. Analysis of MEF2D-HDAC4 repressive complexes in LMS cells. A) Quantitative analysis of the immunofluorescence studies. LMS cells were treated
or not for 2 hours with 5ng/ml leptomycin B (LC Laboratories). After fixation of the cells, immunofluorescence analysis was performed to visualize HDAC4.
Nuclei were stained with Hoechst 33342. Data are presented as mean ± SD (n = 3). B) MEF2D-HDAC4 complexes were immunoprecipitated using 1μg of anti-
MEF2 activities in leiomyosarcomas
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HDAC4 to RHOB promoter, whose expression was reduced in both LMS cell lines after MEF2
silencing, was undetectable in SK-UT-1 cells. Finally, ChIP-reChIP experiments confirmed the
co-occupancy by MEF2D and HDAC4 of KLF2 but not of RHOB promoter (S4 Fig).
HDAC9 expression is highly induced in SK-UT-1 cells and in a relevant
proportion of LMS in vivo
By scrutinizing a public available database (http://www.cbioportal.org/), we noticed that also
the expression of HDAC5 and HDAC9, but not of HDAC7, was augmented in certain LMS
patients (Fig 5A). Collectively, approximately 22% of patients present increased expression of
a class IIa HDAC member. This feature is mirrored in the SK-UT-1 cells, which are character-
ized by high levels of HDAC9 and by a reduction in HDAC7 expression (Fig 5B). Only in
SK-UT-1 cells, proteasome inhibition increased the amount of HDAC9. Conversely, MG132
treatment stabilized MEF2A in SK-LMS-1 cells but not in SK-UT-1 cells, as above described
for MEF2C and MEF2D. The high levels of HDAC9 in SK-UT-1 cells correlate with the aug-
mented levels of the corresponding mRNA (Fig 5C). Luciferase assay using the HDAC9 pro-
moter demonstrated that the high levels of HDAC9 in SK-UT-1 cells arise from an increased
transcriptional activity (Fig 5D). ChIP on this promoter demonstrated a dramatic enrichment
of an epigenetic signature (H3K27ac and H3K4me3), typical of open chromatin/active tran-
scription only in SK-UT-1 cells (Fig 5E). Finally, ChIP experiments demonstrated a selective
binding of HDAC9 to the promoters of certain MEF2-target genes (KLF2 and IRS1) only in
SK-UT-1 cells. By contrast, MEF2A binding to the same promoters occurs in both LMS cells
(Fig 5F). In summary these data demonstrate that class IIa HDACs are overexpressed in 22%
of LMS and that SK-UT-1 cells recapitulate this alteration.
MEF2A and MEF2D-dependent transcriptional landscapes in LMS cells:
definition of classical and atypical target genes
To comprehend the molecular basis responsible for the antagonistic effects of MEF2 on cancer
aggressiveness, we compared the transcriptomes of the different MEF2 KD LMS cells. Several
genes resulted modulated in a MEF2-dependent manner (Fig 6A). In addition to a pool of
genes commonly regulated by MEF2D and MEF2A, we observed that in both cell lines some
genes are under the specific regulation of one of the two paralogues (Fig 6A). For the purposes
of this work we focused our attention only on genes commonly regulated by MEF2D and
MEF2A. Gene-Ontology analysis revealed that in SK-LMS-1 cells, the KD of MEF2 elicits the
down-modulation of genes involved in the epithelial/mesenchymal transition and in inflam-
mation, while genes involved in proliferation and cell-cycle progression were up-regulated
(Fig 6B upper part). Interestingly, both MEF2 KDs show opposite effects in SK-UT-1 cells,
since genes involved in inflammation and epithelial/mesenchymal transition were instead up-
regulated, while the E2F targets were repressed (Fig 6B).
Several genes down-regulated after MEF2D and MEF2A KDs in SK-LMS-1 cells were, on
the opposite, up-regulated in SK-UT-1 cells after the same KDs (Fig 6C). This evidence sug-
gests that MEF2 can preferentially behave as transcriptional activators in SK-LMS-1 cells and
as transcriptional repressors in SK-UT-1 cells. To better clarify this occurrence, we focused
HDAC4, or anti-USP33, as a control, antibodies. Immunoblotting using an anti-MEF2D antibody was next used for the detection. The same amounts of cellular
lysates were immunoprecipitated and the immunoblot were developed under the same circumstances. C) Chromatin was immunoprecipitated from SK-LMS-1
or SK-UT-1 cells using the anti-MEF2D and the anti-HDAC4 antibodies. Anti-FLAG antibody was used as control. TK promoter was used as negative control.
The MEF2 binding site, the amplified region and the TSS are indicated for each tested gene, respectively with a vertical arrow, two arrowheads and a horizontal
arrow. The TK promoter was used as negative control.
https://doi.org/10.1371/journal.pgen.1006752.g004
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Fig 5. Class IIa HDACs expression in LMS. A) TCGA samples of leiomyosarcomas were analysed for the mRNA
expression levels of the different class IIa HDACs. Individual tumors (n = 106) were aligned along the x axis. Data were
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our analysis on 85 genes, which, in SK-LMS-1 cells, were repressed after MEF2D as well as
after MEF2A silencing and that were also significantly modulated in SK-UT-1 cells (|FC|>1.5,
p<0.05; S3 Table).
Many (n = 58) of these 85 MEF2-target genes were up-regulated in SK-UT-1 cells after
MEF2 KD (Fig 6D and 6E). We defined as “atypical loci” genes that were up-regulated after
MEF2 silencing in SK-UT-1 cells, and as “classical loci” genes repressed by the KD of MEF2 in
both cell lines. By contrast, the majority of genes up-regulated by MEF2 KD in SK-LMS-1 cells
(n = 52) were also up-regulated (n = 45) by MEF2 KD in SK-UT-1 cells (Fig 6F). Hence, the
“atypical” behavior specifically originates in SK-UT-1 cells, because of a shift towards a repres-
sive environment under MEF2 supervision. These common MEF2-target genes, with divergent
behavior, could be responsible for the antagonistic effects of MEF2 on cancer aggressiveness in
the two LMS cells.
We also compared the absolute levels of expression of the classical and atypical genes
between the two LMS cells. Only the atypical genes were significantly less expressed in SK-UT-
1 compared to SK-LMS-1 cells, both in our microarray experiments and in another dataset
(Fig 6G).
To validate the microarray studies, we performed qRT-PCR analysis on sets of classical
(ALDH2, ALDH6A1, MDX4, FUCA1) and atypical (ALPK2, COL1A2, IL8, SMOX, LEPREL1)
MEF2-targets. The expression of all classical genes was reduced in both LMS cells when
MEF2A or MEF2D were silenced (S5A, S5B, S5C and S5D Fig). By contrast, only in SK-UT-1
cells the expression of the atypical MEF2-targets was up-regulated after MEF2A or MEF2D
KD (S5B and S5D Fig). We also compared the binding of MEF2 to the promoters of the newly
identified genes in both LMS cells. The positions of the MEF2 binding sites in the regulatory
elements of these genes are shown in S4 Table. All tested MEF2-targets contain the consensus-
binding site for MEF2, although at different distances from the TSS (S5E Fig). MEF2D equally
binds the promoters of classical and atypical genes and this binding was dramatically reduced
in MEF2D silenced cells (S5E Fig). In summary these data demonstrate that MEF2 can exert
opposite transcriptional influences in different contexts.
MEF2 differentially supervise epigenetic changes at the promoters of
classical and atypical genes
We hypothesized that the differential transcriptional impact of MEF2 KD in the two LMS cells
might reflect a specific epigenetic reprogramming. Since MEF2 can recruit HATs and HDACs
onto promoter/enhancer of target genes [35, 38], levels of H3K27 acetylation were measured
for a selected set of atypical genes (ALPK2, COL1A2, IL8, KLF2, SMOX) and of classical genes
(ALDH6A1, FUCA1, MDX4, RHOB). We also evaluated the status of H3K4me3 at the TSSs,
since this modification is associated to transcriptionally active open chromatin. Data are
extracted from CBio Portal (http://www.cbioportal.org/). B) Immunoblot analysis of class IIa HDACs family members and
MEF2A in LMS cells. Cells were treated for 12 hours with 1μM of MG132. Actin was used as loading control. C) HDAC9
mRNA expression levels in the two LMS cell lines. Data are presented as mean ± SD; n = 3. D) Luciferase activity after
transfection in LMS cells of the empty plasmid pGL3 or the same plasmid with cloned the HDAC9 promoter isolated from
SK-LMS-1 cells (bp –1160/+23). The Renilla luciferase plasmid was used as an internal control. Data are presented as
mean ± SD; n = 3. E) ChIP analysis of the chromatin status in the HDAC9 promoter. Chromatin was immunoprecipitated
from SK-LMS-1 or SK-UT-1 cells using the anti-H3K4me3 and anti-H3K27ac antibodies. Normal rabbit IgGs were used
as control. Data are presented as mean ± SD; n = 3. F) Chromatin was immunoprecipitated from SK-LMS-1 or SK-UT-1
cells using the anti-MEF2A and the anti-HDAC9 antibodies. Normal rabbit IgGs were used as control. TK promoter was
used as negative control. The MEF2 binding site, the amplified region and the TSS are indicated for each tested gene,
respectively with a vertical arrow, two arrowheads and a horizontal arrow. * p < 0.05, ** p < 0.01, *** p < 0.001
https://doi.org/10.1371/journal.pgen.1006752.g005
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illustrated as ratio between the two LMS cell lines and correlated to the levels of the respective
mRNAs (Fig 7A). The extended data are shown in S6 and S7 Figs.
The repression of the atypical genes in SK-UT-1 cells correlated with a dramatic reduction
of H3K4me3 at the respective promoters. By contrast, the levels of H3K27ac were subjected to
minor fluctuations, except for SMOX, which promoter is much more acetylated in SK-LMS-1
cells. For all the classical genes, only minor differences were observed between the two cell
lines in the case of the three investigated parameters.
After MEF2D silencing in SK-LMS-1 cells the abundance of the mRNAs, as well as
H3K27ac and H3K4me3 levels, at the respective regulative regions and TSSs for all tested
genes, were reduced (Fig 7B). When the contribution of MEF2D was evaluated in SK-UT-1
cells the scenario was different. mRNA levels of atypical genes were augmented, as well as
H3K4me3 (Fig 7C). H3K27ac was significantly increased only for KLF2 and COL1A2 (mod-
estly) and reduced for SMOX. In the case of the classical genes, their expression and the two
histone-modifications linked to open chromatin were all reduced after MEF2D silencing, simi-
larly to SK-UT-1 cells (Fig 7C).
Overall this analysis suggests that MEF2 can concurrently supervise H3K27 acetylation/dea-
cetylation and H3K4 methylation/demethylation on different promoters in the same cell
population.
HDAC9 is the critical player for switching MEF2 towards a repressive
influence and it is required for the transformed phenotype of LMS cells
The dominant repressive influence exerted by MEF2 on some promoters in SK-UT-1 cells
could stem from their assembly into a repressive complex. Likely candidates for this role are
HDAC4 and HDAC9. To prove this hypothesis, we used the CRISPR/Cas9 technology [39] to
generate SK-UT-1 cells knock-out (KO) for HDAC4 or HDAC9 (S8 Fig). We analyzed in paral-
lel two different LMS clones for each KO (Fig 8A and 8D). In SK-UT-1 HDAC9-/- cells the
expression of the atypical genes was augmented, except for SMOX, which was weakly up-regu-
lated only in the clone 2. The expression of the classical genes was not influenced by the
absence of HDAC9, with the exclusion of RHOB, which expression was slightly augmented.
Fig 8C extended this analysis to 8 atypical and 6 classical genes and confirmed the specific
effect of HDAC9 deletion on the atypical genes. Moreover, as expected, no residual binding
between HDAC9 and MEF2D could be observed in SK-UT-1 HDAC9-/- cells (S9 Fig).
Among the atypical genes, ablation of HDAC4 provoked the modest up-regulation of only
KLF2 mRNA (Fig 8E). This is an expected result considering the capability of HDAC4 to bind
its promoter (Fig 4C). Surprisingly, the KO of HDAC4 caused the down-regulation of ALPK2
and IL8 mRNAs (Fig 8E). These data prove that class IIa HDACs exert non-redundant
Fig 6. The MEF2 transcriptome. A) Venn diagrams showing the number of transcripts differing significantly in response to MEF2A and
MEF2D silencing in SK-LMS-1 cells (green) or in SK-UT-1 cells (violet). Differentially expressed genes (DEGs) were selected based on
fold change >1.5 and <-1.5 fold and p values <0.05. B) Gene ontology (GO) analysis was performed to interpret the principal biological
processes under the regulation of MEF2 in SK-LMS-1 and SK-UT-1 cells. The NES (normalized enrichment score), the FDR (false
discovery rate) and the p-value are provided. C) GSEA was performed by using SK-UT-1 DNA microarray data and genes repressed or
induced by MEF2D/A KD in SK-LMS-1 cells, as indicated. Two groups were created in SK-UT-1 samples: A = shControl; B = shMEF2D/A.
D) GSEA was performed by using SK-UT-1 DNA microarray data and genes repressed both by MEF2D/A KD in SK-LMS-1 and
significantly modulated also in SK-UT-1 cells. Two groups were created in SK-UT-1 samples: A = shControl; B = shMEF2D/A. E) Scatter
plot representing genes commonly down-regulated after MEF2A and MEF2D silencing in SK-LMS-1 cells (blue dots) and significantly
modulated, after the same silencing, also in SK-UT-1 cells (red squares). F) Scatter plot representing genes commonly up-regulated after
MEF2A and MEF2D silencing in SK-LMS-1 cells (blue dots) and significantly modulated, after the same silencing, also in SK-UT-1 cells
(red squares). G) Turkey box-plots illustrating the mRNA expression levels of classical and atypical MEF2-target genes in SK-LMS-1 and
SK-UT-1 cells in our DNA microarray and in another public available DNA microarray study (GSE39262). * p < 0.05, ** p < 0.01, ***
p < 0.001
https://doi.org/10.1371/journal.pgen.1006752.g006
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Fig 7. MEF2D supervised epigenetic changes on atypical and classical genes. A) Ratio between
SK-LMS-1 and SK-UT-1 cells of H3K27ac, H3K4me3 and mRNA levels for a set of atypical and classical
genes. TK was used as control. B) Ratio between SK-LMS-1 cells, WT and KD for MEF2D expression, of
H3K27ac, H3K4me3 and mRNA levels for a set of atypical and classical genes. TK was used as control. C)
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functions and encourages further studies to clarify this de-regulation. The expression of classi-
cal genes was largely unperturbed in HDAC4-/- cells (Fig 8E). Box plot analysis on 8 atypical
Ratio between SK-UT-1 cells, WT and KD for MEF2D expression, of H3K27ac, H3K4me3 and mRNA levels
for a set of atypical and classical genes. TK was used as control. Data are presented as mean ± SD; n 3.
The binding of MEF2 was validated by ChIP (S5 Fig) and the position of binding was expressed as relative to
the major TSS, according to the hg38 assembly of the human genome. * p < 0.05, ** p < 0.01, *** p < 0.001
https://doi.org/10.1371/journal.pgen.1006752.g007
Fig 8. HDAC4 and HDAC9 KO in SK-UT-1 cells. A) Immunoblot analysis of HDAC4, HDAC9 and MEF2D in the indicated SK-UT-1 clones. Two different
HDAC9 KO clones were selected. Actin was used as loading control. B) mRNA expression levels of the indicated atypical and classical MEF2-target genes in
SK-UT-1 cells WT or KO for HDAC9. Data are presented as mean ± SD; n = 3. C) Turkey box-plots illustrating the mRNA expression levels of classical and
atypical MEF2-target genes in SK-UT-1 cells WT or KO for HDAC9. Dunn’s Multiple Comparison Test was applied to test the significance. D) Immunoblot
analysis of HDAC4 and HDAC9 in the indicated SK-UT-1 clones. Two different HDAC4 KO clones generated by different sgRNAs were selected. Actin was
used as loading control. E) mRNA expression levels of the indicated atypical and classical MEF2-target genes in SK-UT-1 cells WT or KO for HDAC4. Data
are presented as mean ± SD; n = 3. F) Turkey box-plots illustrating the mRNA expression levels of classical and atypical MEF2-target genes in SK-UT-1 cells
WT or KO for HDAC4. Dunn’s Multiple Comparison Test was applied to test the significance. G) Invasion properties of the SK-UT-1 cells WT, KO for HDAC4
or KO for HDAC9, as indicated. Data are presented as mean ± SD; n = 4. H) Example of growth in soft agar of SK-UT-1 cells WT or KO for HDAC9. Foci were
stained with MTT. I) Quantitative results of colony formation assay for SK-UT-1 cells WT, KO for HDAC4 or KO for HDAC9, as indicated. Data are presented
as mean ± SD; n 3. * p < 0.05, ** p < 0.01, *** p < 0.001
https://doi.org/10.1371/journal.pgen.1006752.g008
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and 6 classical genes confirmed the limited impact of HDAC4 on the MEF2-dependent repres-
sive action in SK-UT-1 cells (Fig 8F).
Finally, the tumorigenic potential of SK-UT-1 cells, as assessed in terms of invasiveness (Fig
8G) or by grow in soft agar (Fig 8H and 8I), was strongly dependent on HDAC9 and largely
independent from HDAC4.
The binding of HDAC9 to the promoter of MEF2-target genes correlates
with the classical or atypical behavior
In SK-UT-1 cells, the differential impact of MEF2 on transcription could depend on the selec-
tive recruitment of HDAC9-repressive complexes onto the promoters of atypical and classical
MEF2-target genes. ChIP experiments proved that HDAC9 can be isolated, as a complex, from
promoters of the atypical but not from promoters of classical genes (Fig 9A). Next, we evalu-
ated whether HDAC9 was required to supervise H3 modifications linked to active transcrip-
tion. KO of HDAC9 increased H3K4me3 content at the TSSs of the atypical genes, with again
the exclusion of SMOX. H3K27 acetylation was increased at the promoters of COL1A2, IL8
and KLF2 (Fig 9B). When the analysis was performed on the promoters and TSSs of the classi-
cal genes, no significant changes were observed in the HDAC9-/- cells.
To further confirm the contribution of HDAC9 to LMS development, 26 cases of LMS were
transcriptionally profiled by RNAseq and scrutinized for class IIa HDACs expression levels.
Similarly to the TCGA dataset (Fig 5A), also in our LMS series HDAC9 turned out to be the
most expressed class IIa HDAC (Fig 9C). Moreover, isoform quantification analyses reveled
that MITR [40], the truncated HDAC9 isoform, was the more abundantly expressed (24 out of
26 samples) splicing variant in LMS (Fig 9D). Finally, the Kaplan-Meier analysis, as performed
in Fig 1H but restricted to HDAC9, evidences the association of high MEF2 and HDAC9 levels
with reduced patients’ survival in LMS (Fig 9E). In summary these data demonstrate that
HDAC9 is an important driver of MEF2-repressive influences in SK-UT-1 cells and a key fac-
tor for the maintenance of the transformed phenotype.
Discussion
The involvement of MEF2 in the tumorigenic process is still enigmatic [21–30, 41]. In this
manuscript we provide evidences that could help to solve this controversial issue. We took
advantage from the leiomyosarcoma model to unveil the two-faced of MEF2, but we are confi-
dent that these results can be confirmed also in other cancer types.
Our studies suggest that LMS can be clustered in two groups, in terms of MEF2 dysfunc-
tions. The first group exhibited low proliferation and low levels of MEF2 proteins, possibly
because of the SKP2-mediated degradation [35, 42]. The second group comprised tumors with
high expression of MEF2 and of class IIa HDACs. Under these conditions MEF2 are converted
into transcriptional repressors. The combination of high MEF2 and class IIa HDACs levels is
detrimental for patients’ survival. Although the UPS-mediated degradation can remove MEF2
from promoters and enhancers, their conversion into repressors can provide a strongest
silencing, which is translated in a worse prognosis. HDAC4, HDAC5 and HDAC9 or its splic-
ing variant MITR are the class IIa HDACs more frequently overexpressed in LMS. A condition
not limited to this tumor type, as testified by recent studies [43–47].
These observations can be recapitulated in two LMS cell lines. In SK-LMS-1 cells MEF2 are
under UPS control. MEF2 ablation reduces the expression of MEF2-target genes and enhances
the transformed phenotype. By contrast in SK-UT-1 cells, where HDAC9 is highly expressed,
MEF2 are required for tumorigenesis and to repress the transcription of some MEF2-target
genes. This conversion stems from MEF2 assembly into multi-protein repressive complexes,
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which erase histone marks of open chromatin configuration, such as H3K4me3 and H3K27ac,
and thus repress the transcription of some MEF2-target genes (Fig 9F).
Our genes expression profile studies confirmed the complexity of the MEF2-trascriptome
[2, 8, 48, 49]. Common as well as cell type and isoform specific MEF2-regulated genes exist.
This multifaceted scenario could result from: i) a certain degree in DNA binding preferences
of the different MEF2 [50]; ii) the presence of specific PTMs [1] and iii) the ability of forming
complexes with other TFs, which hijack MEF2 away from canonical targets [4, 8].
Beside this complexity, we identified a common MEF2 signature, which can explain the
opposite impact of MEF2 in the two LMS cells. Regulators of EMT, of the cell cycle and of
inflammation are significantly enriched in this signature. Several genes of this signature are
repressed by MEF2 in SK-UT-1 cells.
HDAC9 is the key factor for switching MEF2 into a repressor. However, HDAC9 is not
recruited onto all promoters bound by MEF2. Hence, some MEF2-target genes are not
repressed, even though SK-UT-1 cells express high levels of HDAC9. It is possible that these
MEF2-targets govern some crucial activities of cancer cells.
The coexistence in the same cell population of TFs with both suppressive and activating
activities on different loci, although surprising, was previously observed [48, 51, 52]. Different
hypothesis have been formulated to explain this paradox but without a conclusive demonstra-
tion. We can exclude that the distance of the MEF2 binding site from the TSS could play a
role, as previously hypothesized [48]. Since the repressive switch is cell lineage-dependent
rather than gene-dependent, we could also exclude contributions of differences in the consen-
sus of binding between promoters, as observed for p53 [52]. A fascinating hypothesis concerns
contributions of the local nuclear organization, which might generate microenvironments pro-
ficient or exploitive for HDAC9 binding to MEF2.
MEF2 are required for H3K27 acetylation and H3K4 methylation. These activities can be
explained by their ability to interact with Ash2L, a core subunit of KMT2 methyltransferase
[53] and with the acetyl-transferase p300/CBP [54]. MEF2, once in complex with HDAC9,
govern H3K27 deacetylation and H3K4 demethylation. Class IIa HDACs can bind the com-
plex HDAC3/NuRD/SMRT, which delivers the deacetylase activity. Currently, we do not
know whether a H3K4 demethylase is part of the same repressive complex with HDAC9. In
principle, HDAC9 could act as a scaffold for a DMTase, as previously reported for HDAC4
and HDAC5 [55–57].
Interestingly, in SK-UT-1 cells genes repressed by MEF2-HDAC9 conserve H3K27 acetyla-
tion levels comparable to SK-LMS-1. These genes are in equilibrium between a closed and
open chromatin conformation, similarly to the poised developmental regulatory genes in stem
Fig 9. Epigenetic changes monitored by HDAC9. A) ChIP in SK-UT-1 cells WT or KO for HDAC9. Chromatin was immuno-
precipitated using the anti-HDAC9 antibody. Normal rabbit IgGs were used as control. TK promoter was used as negative control.
Atypical MEF2-targets are indicated in orange and the classical ones in blue. The genomic regions amplified by qPCR are the
same as reported in S5E Fig. Data are presented as mean ± SD; n = 4. B) ChIP in SK-UT-1 cells WT or KO for HDAC9. Chromatin
was immunoprecipitated using the anti-H3K27ac and the H3K4me3 antibodies as indicated. Normal rabbit IgGs were used as
control. TK promoter was used as negative control. Atypical MEF2-targets are indicated in orange and the classical ones in blue.
The genomic regions amplified by qPCR are the same as reported in S6A and S6B Fig (for H3H27ac) and in S6A and S6B Fig (for
H3K4me3). Data are presented as mean ± SD; n 4. C) Scatter dot plot representing the coding mRNA TPM levels of the four
class IIa HDACs in a cohort of 26 LMS samples. The horizontal lines indicate the median. Dunn’s Multiple Comparison Test was
applied to test the significance of HDAC9 up-regulation. D) Scatter dot plot representing the IsoPCT of the two main isoforms of
HDAC9: HDAC9 WT (red) and MITR (blue). Individual tumors (n = 26) were aligned along the x axis. E) Kaplan-Meier survival
analysis related to the expression levels of HDAC9, performed on the same samples and according to the same criteria as in Fig
1H. F) Summary of the shift in MEF2 transcriptional activities in relation to tumor progression in LMS. Possible co-activators and
co-repressor are illustrated. The scheme describes the condition for the atypical MEF2-targets only. * p < 0.05, ** p < 0.01, ***
p < 0.001.
https://doi.org/10.1371/journal.pgen.1006752.g009
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cells [58]. This condition would make possible to revert the transcriptional output of these
genes by simply inhibiting the demethylase involved.
Therapeutic intervention in advanced leiomyosarcomas represents a challenge. Important
obstacles are the extreme genetic heterogeneity and the relatively low incidence of these malig-
nancies [33, 34, 59]. Here we have found that over 20% of leiomyosarcomas present increased
expression of a class IIa HDAC member. In vitro experiments indicate that the manipulation
of the MEF2-HDAC axis impinges on the transformed phenotype. In conclusion, our discov-
eries suggest that small molecules targeting class IIa HDACs or the interaction between the
deacetylase and MEF2 could afford success for the treatment of certain LMS.
Materials and methods
Ethics statement
The study was conducted according to the principles expressed in the declaration of Helsinki.
Written informed consent was obtained for all patients. Tissue samples were provided by the
Hospital of Treviso and no additional ethics approval was needed
Cell culture and reagents
LMS cells were grown as previously described [28]. Primary antibodies used and reagents
were: anti-SKP2 8D9 (Life Technologies); anti-MEF2C [35] anti-MEF2D α1/α2 [10]; anti-
GFP, anti-HDAC4 [60] and anti-HDAC5 [38]; anti-HDAC7 (sc-74563), anti-MEF2A (C-21
sc-313) and anti-RACK1 (sc-17754, Santa Cruz Biotechnology); anti-MEF2D (BD Transduc-
tion Laboratories); anti-Actin, p21 CP74 and FLAG M2 (Sigma-Aldrich); anti-ubiquitin (Cov-
ance); anti-HDAC9 (ab109446), anti-H3K27ac (ab4729) and anti-H3K27me3 (ab6002)
(Abcam); anti-H3K4me3 (GTX128954, GeneTex); anti-KI67 (556003, BD Pharmingen).
RNA extraction and quantitative qRT-PCR
Cells were lysed using TRI-REAGENT (Sigma-Aldrich). 1.0μg of total RNA was retro-tran-
scribed by using 100 units of M-MLV Reverse transcriptase (Life Technologies). qRT-PCRs
were performed using the Bio-Rad CFX96 and SYBR green (KAPA Biosystems) technology.
Data were analysed by comparative threshold cycle using HPRT and β-actin as normalizer
genes. All reactions were done in triplicate.
Immunofluorescence and immunoblotting
Cells were fixed with 3% paraformaldehyde and permeabilized with 0.1% Triton X-100. Sec-
ondary antibodies were Alexa Fluor 488 anti-rabbit secondary antibodies (Molecular Probes).
Actin was labeled with Phalloidin-AF546 (Molecular Probes). Cells were imaged with a Leica
confocal scanner SP equipped with a 488 λ Ar laser and a 543 to 633 λ HeNe laser. Cell lysates
after SDS/PAGE and immunoblotting were incubated with primary antibodies. Secondary
antibodies were from Sigma-Aldrich and blots were developed with Super Signal West Dura
(Pierce Waltham). For antibodies stripping, blots were incubated for 30min. at 60˚C in strip-
ping solution containing 100mM β-mercaptoethanol (Sigma-Aldrich).
Immunoprecipitation
Co-immunoprecipitations were performed as previously described [35]. Briefly, cells were col-
lected directly from culture dishes into RIPA buffer (50mM Tris-HCl pH8, 150mM NaCl,
0.2%SDS, 1%NP-40, 0.5%sodium deoxycholate), supplemented with protease inhibitors.
Lysates were incubated for 5 h with the primary antibodies. After 1 hour of incubation with
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protein A beads (GE) several washes were performed. Samples were resolved by SDS–PAGE
and analysed by immunoblot.
Chromatin immunoprecipitation
ChIP experiments were performed as previously described [35]. Briefly, for each ChIP, 3x106
cells were employed. DNA-protein complexes were cross-linked with 1% formaldehyde
(Sigma-Aldrich) in PBS for 15 minutes at RT. After quenching and two washes in PBS, cells
were collected and then lysed for 10 minutes with Lysis buffer (5 mM Pipes, 85 mM KCl, 0.5%
NP40) containing protease inhibitor cocktail. Pellets were re-suspended in RIPA-100 and soni-
cated using Bioruptor UCD-200 (Diagenode) with pulses of 30 seconds for 15 minutes, result-
ing in an average size of ~500 bp for genomic DNA fragments. Samples were precleared and
immunoprecipitated O/N with: 1.5μg of anti-MEF2D and anti-MEF2A, 2μg of anti-HDAC4,
4μg of anti-HDAC9, 1μg of anti-H3K27ac, 2.5 of anti-H3K4me3 and H3K27me3 antibodies or
the same amount of control antibodies (FLAG M2 and USP33 serum), followed by incubation
with protein A blocked with BSA and SS DNA (1μg/μl) at 4˚C for 90’. Beads and inputs were
treated with proteinase K at 56˚C for 3h to degrade proteins and the cross-linking was reversed
O/N at 68˚C. Genomic DNA was finally purified with Qiagen Qiaquick PCR purification kit
and eluted in 100 μl water.
Plasmid construction, transfection, retroviral infection and silencing
pBABE-Puro plasmids expressing SKP2, SKP2DN-GFP were described previously [35].
pWZL-Hygro-SKP2 ER plasmid was obtained by subcloning with a PCR method SKP2 into
pWZL-Hygro-MEF2-VP16 ER [28] and the nuclear relocalization of SKP2 after 4-OHT treat-
ment was scored by immunofluorescence. Retroviral infections were performed as previously
described [28]. pLKO-PURO plasmids expressing short hairpin RNAs (shRNAs) directed
against MEF2D (15897 and 274054, referred to here as 1 and 2), MEF2Dα1 (15896, referred to
here as 3) and MEF2A (432718 and 5133, referred to here as 4 and 5) were obtained from
Sigma-Aldrich. pLKO-Hygro plasmid expressing the same shRNAs were obtained by oligo
cloning, checked by restriction and sequencing. For lentivirus-based knock-down, HEK-293T
cells were transfected with 1.8 μg of VSV-G, 5 μg of Δ8.9, and 8 μg of pLKO plasmids. After
36h at 37˚C, virions were collected and opportunely diluted in fresh medium.
Random motility measurements, invasion and soft agar assays
Random motility was assayed by time-lapse video microscopy as previously described [61]. For
soft agar growth, 0.5 x105 sarcoma cells were seeded in 0.3% top agar and incubated at 37˚C.
Foci were evidenced with MTT staining and counted by using ImageJ, as previously described
[62]. For invasion assay, each well of the invasion chamber (CLS3428, Corning) was coated
with 200μl of Matrigel matrix coating solution (Cultrex, Trevigen). Next, a cell suspension of
0.5x105 LMS cells in 0.1%FBS-DMEM was added. As chemoattractant, 20%FBS-DMEM was
added in each lower chamber. As a control 0.1%FBS-DMEM was used to evaluate random
invasion.
RNA expression array and data analysis
Total RNA was extracted using RNeasy columns (Qiagen). Aliquots of RNAs were amplified
according to the specifications of the Illumina TotalPrep RNA Amplification Kit (Ambion).
Hybridization on Illumina whole-genome HumanHT-12 v 4.0 chip (Illumina), scanning and
background subtraction were done according to the manufacturer’s specification. Fold-change
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and p-values for each probe set were calculated using a moderated t-statistic in the limma
package [63], with the variance estimate being adjusted by incorporating global variation mea-
sures for the complete set of probes on the array. The p-value data were then corrected for
multiple hypotheses testing using the Benjamini and Hochberg.
Datasets were retrieved from GEO Dataset (GSE764, GSE21124, GSE21050, GSE39262)
and analyzed as previously described [28]. For the expression levels and Kaplan–Meier analysis
of TCGA sarcoma samples (265 sarcomas, 106 LMS), data were retrieved from CBio Portal
[64] and expressed as z-score. Z-scores > |2| were selected as cut-off. Kaplan–Meier analysis
was based on the expression levels of the four MEF2 and the four class IIa HDACs. GSEA and
Gene Ontology-terms enrichment analysis were performed as described previously [28, 65].
Tissue array construction and immunohistochemistry
Paraffin-embedded samples from leiomyosarcomas were available from 57 patients. All cases
were histologically and immunohistochemically validated. Immunohistochemistry for
HDAC4 (1:100), MEF2C an SKP2 was performed by an automated immunostainer (Dako
Autostainer). Antigen retrieval was performed with cytrate buffer at pH 6 for HDAC4 and at
pH 9 with EnVision FLEX Target Retrieval Solution (Dako) for MEF2C and SKP2. All tumors
were scored for the intensity of signal (range from 0 = no expression, to 4 = strong expression).
Mean of intensity and percentage of duplicate cores were used for the final analysis.
Generation of KO SK-UT-1 cells
CRISPR/Cas9 technology was applied to obtain HDAC4 and HDAC9 clones. The KO clones
were screened by PCR, immunoblot and validated by Sanger sequencing. SpCas9 and D10A
mutant of spCas9 [39] were used to obtain respectively HDAC4 and HDAC9 KO clones.
Paired-end RNA-sequencing and isoform abundancy quantification
Total RNA was extracted from FFPE sections of 26 LMS samples using the Ambion RecoverAll
Total Nucleic Acid Isolation Kit (Life Technology).
RNA-sequencing libraries were prepared as previously described [66] and sequenced on a
Illumina HiSeq 1000 apparatus (Illumina) to a depth of 50–80 million paired-end reads per
sample. The QoRts package was used to evaluate data quality and STAR2.5.2a for reads map-
ping to the GRCh37.74 genome assembly. RSEM was used for quantifying gene and isoform
abundances [67]. Here we provide the list of class IIa HDACs isoforms analyzed: HDAC4
(ENST00000345617, ENST00000430200, ENST00000543185), HDAC5 (ENST00000225983,
ENST00000336057, ENST00000393622, ENST00000586802), HDAC7 (ENST00000080059,
ENST00000380610, ENST00000427332, ENST00000552960, ENST00000354334), HDAC9
(ENST00000401921, ENST00000406451, ENST00000432645, ENST00000441542), MITR
(ENST00000405010, ENST00000406072, ENST00000417496, ENST00000428307, ENST0
0000456174, ENST00000524023).
Statistic
For experimental data Student t-test was employed. Mann-Whitney test was applied when
normality could not be assumed. p< 0.05 was chosen as statistical limit of significance. For
comparisons between samples >2 Anova test was applied, coupled to Krustal-Wallis and
Dunn’s Multiple Comparison Test. We mark with  p< 0.05,  p < 0.01,  p< 0.001.
Unless otherwise indicated, all the data in the figures were represented as arithmetic mean +
SD of at least three independent experiments.
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Supporting information
S1 Table. Genes comprised in the MEF2 signature.
(XLSX)
S2 Table. Immunohistochemistry analysis.
(XLSX)
S3 Table. The 85 common MEF2-target genes. The list of the genes significantly regulated
by MEF2A e MEF2D silencing in both SK-LMS-1 and SK-UT-1 cells. Values are indicated as
mean fold change relative to the control. A prediction of the binding of MEF2 TFs on chroma-
tin was done by scrutinizing all published BED files of ChIP-seq data: ENCFF148PLM, ENCF
F001TXJ, GSE1499534, ENCFF139PSX, GSE1499535, ENCF001UPO, ENCFF001TXL, GSE7
3453, GSE61391, GSE43223. Pavis software was used for the annotation of the peaks [Huang
W, Loganantharaj R, Schroeder B, Fargo D, Li L. PAVIS: A tool for Peak Annotation and Visu-
alization. Bioinformatics. 2013;29: 3097–3099. doi:10.1093/bioinformatics/btt520].
(XLSX)
S4 Table. Characteristics of the selected atypical and classical MEF2-target genes.
(XLSX)
S1 Fig. Roles of MEF2A and of MEF2D in tumor cells invasion. Fluorescence analysis of
Matrigel invading SK-LMS-1 and SK-UT-1 cells expressing the indicated shRNAs and stained
with Hoechst 33342. Bar = 100μM.
(TIF)
S2 Fig. Silencing of MEF2D isoforms in SK-LMS-1. A) qRT-PCR analysis of the mRNAs
expression levels of two alternative isoforms of MEF2D (α1 and α2) in SK-LMS-1 cells
expressing the indicated isoform-specific shRNAs. mRNA levels are relative to control shRNA.
Data are presented as mean ± SD; n = 3.
B) Immunoblot analysis of the MEF2D isoforms levels in SK-LMS-1 cells expressing the indi-
cated shRNAs. Actin was used as loading control.
C) qRT-PCR analysis of the mRNAs expression levels of some MEF2-target genes (KLF2,
RHOB, IRS1) in SK-LMS-1 cells expressing the indicated isoform specific shRNAs. mRNA lev-
els are relative to control shRNA. Data are presented as mean ± SD; n = 3.
D) Growth in soft agar of SK-LMS-1 cells expressing the indicated shRNAs. Foci were stained
with MTT and counted. Data are presented as mean ± SD; n = 4.
(TIF)
S3 Fig. MEF2A silencing causes opposite effects in SK-LMS-1 and SK-UT-1 cells. A)
MEF2A expression was silenced by lentiviral infection using two different shRNA (#4 and #5).
Immunoblot analysis of MEF2D and CDKN1A levels in SK-LMS-1 cells expressing the control
shRNA or two different shRNAs against MEF2A. Actin was used as loading control.
B) qRT-PCR analysis of the mRNA expression levels of MEF2A and of MEF2-target genes
(KLF2, RHOB, CDKN1A, JUN, CNN1, IRS1) in SK-LMS-1 cells expressing the different shRNAs.
mRNA levels are relative to control shRNA. Data are presented as mean ± SD; n = 4.
C) Analysis of the cells synthetizing DNA as scored after BrdU staining. Data are presented as
mean ± SD; n = 3.
D) SK-LMS-1 cells expressing the indicated shRNAs were subjected to time-lapse analysis for 6
hours. Results represent the individual migration rate and the average (bar) from at least 140 cells
from three independent experiments. Cell movements were quantified using MetaMorph soft-
ware (Molecular Devices, Sunnyvale, CA).
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E) Invasion properties of the SK-LMS-1 cells expressing the shRNA4 against MEF2A or the con-
trol. Data are presented as mean ± SD; n = 4.
F) Growth in soft agar of SK-LMS-1 cells expressing the indicated shRNAs, foci were stained
with MTT and counted. Data are presented as mean ± SD; n = 4.
G) MEF2A expression was silenced by lentiviral infection using two different shRNA (#4 and
#5). Immunoblot analysis of MEF2D and CDKN1A levels in SK-UT-1 cells expressing the con-
trol shRNA or two different shRNAs against MEF2A. Actin was used as loading control.
H) qRT-PCR analysis of the mRNA expression levels of MEF2A and of MEF2-target genes
(KLF2, RHOB, CDKN1A, JUN, CNN1, IRS1) in SK-UT-1 cells expressing the different shRNAs.
mRNA levels are relative to control shRNA. Data are presented as mean ± SD; n = 4.
I) Analysis of the cells synthetizing DNA as scored after BrdU staining. Data are presented as
mean ± SD; n = 3.
J) SK-UT-1 cells expressing the indicated shRNAs were subjected to time-lapse analysis for 6
hours. Results represent the individual migration rate and the average (bar) from at least 140 cells
from three independent experiments. Cell movements were quantified using MetaMorph soft-
ware (Molecular Devices, Sunnyvale, CA).
K) Invasion properties of the SK-UT-1 cells expressing the shRNA4 against MEF2A or the con-
trol. Data are presented as mean ± SD; n = 4.
L) Growth in soft agar of SK-UT-1 cells expressing the indicated shRNAs, foci were stained with
MTT and counted. Data are presented as mean ± SD; n = 4.
(TIF)
S4 Fig. MEF2D and HDAC4 co-occupancy. 6x106 cells were employed. First immunoprecipi-
tations were conducted ON with 2μg of anti-MEF2D or anti-FLAG antibodies. Protein-DNA
complexes were collected with 8μl of protein A magnetic beads (ZymoMag, Zymo research)
and washed twice with RIPA and TE. Beads were incubated for 30’ at 37˚C in Re-Chip elution
buffer (1×TE, 2%SDS, 15mM DTT), diluted 15 times into RIPA buffer and subjected to the
second immunoprecipitation using 3μg of anti-HDAC4 or USP33 IgG as control. TK pro-
moter was used as negative control. Data are presented as mean fold enrichment relatively to
the first input
(TIF)
S5 Fig. Characterization of the new MEF2-target genes. A) qRT-PCR analysis of the mRNA
expression levels of the identified atypical and classical MEF2-target genes in SK-LMS-1 cells
expressing the shRNAs against MEF2D. mRNA levels are relative to control shRNA. GAPDH
was used as control. Data are presented as mean ± SD; n = 3.
B) qRT-PCR analysis of the mRNA expression levels of the identified atypical and classical
MEF2-target genes in SK-UT-1 cells expressing the shRNAs against MEF2D. mRNA levels are
relative to control shRNA. GAPDH was used as control. Data are presented as mean ± SD;
n = 3.
C) qRT-PCR analysis of the mRNA expression levels of the identified atypical and classical
MEF2-target genes in SK-LMS-1 cells expressing the shRNAs against MEF2A. mRNA levels
are relative to control shRNA. GAPDH was used as control. Data are presented as mean ± SD;
n = 3.
D) qRT-PCR analysis of the mRNA expression levels of the identified atypical and classical
MEF2-target genes in SK-UT-1 cells expressing the shRNAs against MEF2A. mRNA levels are
relative to control shRNA. GAPDH was used as control. Data are presented as mean ± SD;
n = 3.
E) Chromatin was immunoprecipitated from SK-LMS-1 or SK-UT-1 cells using the anti-
MEF2D antibody. Anti-FLAG antibody was used as control. Cells KD for MEF2D are indicated.
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TK promoter was used as negative control. The MEF2 binding site (arrowheads), the amplified
region and the TSS (arrows) are indicated for each tested gene.
Atypical MEF2-target genes are in orange whereas classical ones are in blue. Data are presented
as mean ± SD; n = 3.
(TIF)
S6 Fig. Role of MEF2 in controlling histone H3K27 acetylation. A) Chromatin was immu-
noprecipitated from SK-LMS-1 or SK-UT-1 cells WT or KD for MEF2D, using the anti-
H3K27ac antibody. Normal rabbit IgGs were used as control. The MEF2 binding site (arrow-
heads), the amplified region and the TSS (arrows) are indicated for each tested atypical gene.
Data are presented as mean ± SD; n = 3.
B) Chromatin was immunoprecipitated from SK-LMS-1 or SK-UT-1 cells WT or KD for MEF2D,
using the anti-H3K27ac antibody. Normal rabbit IgGs were used as control. TK promoter was
used as negative control. The MEF2 binding site (arrowheads), the amplified region and the TSS
(arrows) are indicated for each tested classical gene. Data are presented as mean ± SD; n = 3. Atypi-
cal MEF2-target genes are in orange whereas classical ones are in blue.
(TIF)
S7 Fig. Role of MEF2 in controlling histone H3K4 methylation. A) Chromatin was immu-
noprecipitated from SK-LMS-1 or SK-UT-1 cells WT or KD for MEF2D, using the anti-
H3K4me3 antibody. Normal rabbit IgGs were used as control. The MEF2 binding site (arrow-
heads), the amplified region and the TSS (arrows) are indicated for each tested atypical gene.
Data are presented as mean ± SD; n = 3.
B) Chromatin was immunoprecipitated from SK-LMS-1 or SK-UT-1 cells WT or KD for
MEF2D, using the anti-H3K4me3 antibody. Normal rabbit IgGs were used as control. TK
promoter was used as negative control. The MEF2 binding site (arrowheads), the amplified
region and the TSS (arrows) are indicated for each tested classical gene. Data are presented as
mean ± SD; n = 3. Atypical MEF2-target genes are in orange whereas classical ones are in blue.
(TIF)
S8 Fig. CRISPR/Cas9 mediated KO of HDAC4 and HDAC9. A) Schematic representation of
HDAC9 genomic organization with indicated: the exons (vertical bars), the introns (junctions
between the bars) and the PAM sequences utilized for the CRISPR approach.
B) Genomic sequences of the HDAC9-/- SK-UT-1 cells used in this study. The sequence of
HDAC9 genomic region targeted by the CRISPR/Cas9D10A is included. The PAMs and the
two gRNAs are underlined. SKUT-1 HDAC9 KO clones were obtained through the delivery of
the D10A mutant of SpCas9. Two sgRNAs designed on the second coding exon of HDAC9
were co-delivered to obtain two close cleavages on the genome to simulate a DSB (sgRNA1:
CTGCTATCAGAAGCTGCTTC; sgRNA2: GAACTTGACACGGCAGCACC). Five clones
were selected for the presence of deletions or insertion and among them the indicated two
were selected for the analysis.
C) Schematic representation of HDAC4 genomic organization with indicated: the exons (verti-
cal bars), the introns (junctions between the bars) and the PAM sequences utilized for the
CRISPR approach.
D) Genomic sequences of the HDAC4-/- SK-UT-1 cells used in this study. The sequence of
HDAC4 genomic region targeted by the CRISPR/Cas9 is included. The PAMs and the two
gRNAs are underlined. SKUT-1 HDAC4 KO clones were obtained through the delivery of
wild-type spCas9 (pLENTI-CRISPRv2). Two sgRNAs designed on the second coding exon
were used (sgRNA1: GCAGGATTCAGCAGCTCCAC; sgRNA2: CGTGAACCACATGCC-
CAGCA). One and three KO clones were obtained respectively with sgRNA1 and 2. The two
MEF2 activities in leiomyosarcomas
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006752 April 18, 2017 24 / 29
representative clones indicated here were selected for the analysis.
(TIF)
S9 Fig. MEF2D-HDAC9 complex. The MEF2D-HDAC9 complexes were immunoprecipi-
tated from the different cell lines using 1μg of anti-MEF2D, or anti-FLAG antibodies, as a con-
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